Home Blog Page 3

Afreximbank signs project preparation financing with UTM Offshore

0

The African Export-Import Bank (Afreximbank) has announced the execution of a Project Preparation Facility Financing Terms and Conditions with UTM Offshore Limited (UTM), under which the bank will part-finance activities to advance a floating liquefied natural gas (FNLG) project in Nigeria to bankability.

The agreement marks Afreximbank’s continued support in leading UTM’s fundraising efforts to secure the investments needed to implement the projects. This project is of historical significance as it is the first FNLG project developed by an African company on the continent, Afreximbank said in a statement yesterday.

UTM is undertaking the development, design and construction of an FLNG facility with a nominal liquefied natural gas (LNG) production capacity of 1.2 million metric tons per year and a storage capacity of 200,000 cubic meters, as well ancillary facilities located 60 km from the shore in Akwa Ibom State, Nigeria.

Afreximbank said the project aligns with Afreximbank’s strategic objective to advance businesses that have strong climate finance credentials. The project would pave the way for a just energy transition in line with the reduction of carbon emissions prescribed by COP26.

Afreximbank said the project has the potential for economic transformation – by establishing trade-enabling infrastructure that will enable Nigeria to transition from a crude oil export-based economy to a gas-based transformational industrial economy. that will unlock significant development impacts.

To drive forward the timely implementation of the project, Afreximbank leverages its diverse product line to provide end-to-end solutions. During the pre-investment phase, the project preparation facility will be deployed to de-risk the project and move it rapidly towards bankability.

In addition, under the PPF, the Bank will be appointed Mandated Lead Arranger (MLA) and responsible for syndicating the debt raising – with the ability to incorporate credit enhancements, if required. Through its financial advisory mandate, Afreximbank was instrumental in structuring the transaction to ensure optimal returns and debt sizing, as well as in identifying equity investors to invest in the project. on favorable terms.

Afreximbank’s Executive Chairman for Business Development and Corporate Banking, Mr. Amr Kamel, said, “Afreximbank’s intervention will help Nigeria, one of its member states, to invest in the natural gas as part of its path towards a just energy transition and to achieve more sustainable and climate-resilient economic development.

“The holistic approach deployed by the Bank in the UTM project is a model that Afreximbank aims to replicate in its member countries. It is through such interventions that we can trigger transformative actions that will boost industrialization and export development activities across the continent.”

Tampa General Hospital launches TGH at Home, an innovative program offering personalized care and improved patient access

0

TGH at Home is a program that allows Tampa General to treat less serious patients in the comfort of their own home rather than in a hospital setting.

TAMPA, Florida., July 7, 2022 /PRNewswire/ — Patients at Tampa General Hospital now have a new care option that combines the expertise of a world-class facility with the comforts of their own home. Tampa General Hospital’s (TGH) Hospital at Home program combines expert care and innovative technology with a focus on patient needs. TGH at Home gives eligible patients the opportunity to stay at home, while receiving the best clinical hospital care from healthcare providers, including physicians, physician assistants, nurse practitioners and certified nursing assistants. . Based on the same standards used inside the hospital, patients receive daily home visits from healthcare providers, virtual visits, and 24-hour remote patient monitoring.

Tampa General Hospital logo. (PRNewsFoto/Tampa General Hospital)

“TGH at Home is a true model of innovation – integrating high-tech applications such as remote patient monitoring and telehealth visits with in-person care by trained healthcare providers,” said Jean Couris, president and CEO of Tampa General. “We can give patients what they really want – world-class care in their own environment. In addition to improving the patient experience, hospital care at home has been shown to improve quality and service. .”

To be enrolled in TGH at Home, patients must be seen in the emergency department or admitted to the hospital so that they can be assessed and transferred to the TGH at Home program (subject to patient consent). Patients must meet certain criteria to be cared for safely at home.

During their home treatment, patients receive at least two in-person visits per day by a dedicated member of the TGH home clinical team.

In addition to in-person care, TGH relies on innovative technology to provide optimal care outside of the hospital. TGH is delighted to be associated with the Israelbased on the Biobeat Remote Patient Monitoring (RPM) platform to provide each patient with a wireless device that continuously transmits vital signs. The device doubles as a blood pressure cuff, pulse oximeter and thermometer. In addition to ongoing patient monitoring, TGH is proud to work with US-based telehealth provider TytoCare to offer the TGH Virtual Health Kit powered by TytoCare. This virtual health platform provides patients with a cellular tablet to transfer information about a patient’s vital signs and can also be used to conduct telehealth visits with providers. Equipment is provided at no additional cost and is constantly monitored by the care team.

Using this technology, TGH’s home care team of doctors and nurses stays in close contact with each patient to monitor their condition and make any necessary treatment changes for optimal recovery. Patients have 24-hour access to healthcare professionals if they have a question or concern. In order for the healthcare team to respond in a timely manner, patients must live within a 30 minute drive of Tampa General. In the unlikely event of an emergency, the care team will facilitate transportation to hospital or other emergency care, as needed.

Initially, TGH at home will be limited to patients with certain conditions, including:

  • Congestive heart failure (CHF)

  • Urinary tract infection (UTI)

  • Cellulite

  • Chronic Obstructive Pulmonary Disease (COPD)

  • Diabetes

Benefits for patients include:

  • Patient-centered care

  • Intimacy of being at home

  • Comfort of family, friends and pets

  • Reduction of the risk of nosocomial infections

  • Equivalent or better results compared to traditional hospital care

“TGH at Home aims to improve access to care and the patient experience,” said Dr. Peggy Dugan, executive vice president and chief medical officer of Tampa General. “Patients are carefully assessed to determine if their condition makes them a candidate for TGH at home. They receive elements of world-class hospital care in their homes with supportive nursing care and most importantly, their families. We know that patients recover better when surrounded by the familiar.”

According to The Journal of the American Medical Association, a systematic review of nine studies found that people receiving hospital care at home had a 26% lower risk of hospital readmission and a lower risk of admission to nursing home. longer duration than traditionally hospitalized patients. Patients who received hospital care at home also had lower depression and anxiety scores than patients receiving hospital care.

“TGH at home is the future of medicine happening now, thanks to technological innovations and advanced models of care,” said Dr. peter chang, Vice President of Healthcare Design, Tampa General. “These programs are gaining momentum across the country and the benefits are tangible: improved patient experience, shorter hospital stay, reduced risk of hospital readmission and more cost-effective care.” For more information about TGH At Home, call 813-844-8705 or visit TGH At Home.

ON TAMPA GENERAL HOSPITAL
Tampa General Hospital, a 1,041-bed nonprofit academic medical center, is one of America’s largest hospitals and provides world-class care as the region’s only trauma center. level I and comprehensive burn care. Tampa General Hospital is the highest-ranked hospital in the market in U.S. News & World Report’s 2021-22 Best Hospitals, and one of the top four hospitals in Floridawith five specialties ranked among the best programs in United States. Tampa General Hospital was named a Model of Excellence by the 2022 Fortune/Merative list of Top 100 Hospitals. The University Medical Center’s commitment to growing and developing its team members is recognized by two prestigious 2021 Forbes magazine rankings – America’s Best Employers by State, Third out of Florida’s 100 Companies and First Among Healthcare Organizations and and 13th nationally among America’s Top Employers. for women. Tampa General is the safety net hospital for the region, caring for everyone regardless of ability to pay, and in fiscal year 2020 provided net community benefit worth more than $182.5 million in the form of health care for underinsured patients, community education and financial support to community health organizations in Tampa Bay. It is one of the nation’s busiest adult solid organ transplant centers and the primary teaching hospital for USF Health Morsani College of Medicine. With six medical helicopters, Tampa General Hospital transports critically injured or ill patients from 23 surrounding counties to receive the advanced care they need. Tampa General is home to a nationally accredited comprehensive stroke center, and its 32-bed neuroscience and critical care unit is the largest on the west coast of Florida. It also houses the 82-bed Jennifer Leigh Muma Level IV Neonatal Intensive Care Unit and a nationally accredited rehabilitation center. Tampa General Hospital’s footprint includes 17 Tampa General Medical Group primary care offices, TGH Family Care Center Kennedy, TGH Brandon Healthplex, TGH Virtual Health, and 19 outpatient radiology centers. Tampa Bay Area residents also receive world-class care from the TGH Urgent Care network of clinics powered by Fast Track, and they can even receive home visits in select areas through TGH Urgent Care at Home, powered by Fast Track. As one of the largest hospitals in the nation, Tampa General Hospital is the first in Florida to partner with GE Healthcare and open a clinical command center that uses artificial intelligence and predictive analytics to improve and better coordinate patient care at lower cost. For more information, visit www.tgh.org.

Media Contact: Karen Barrera
Deputy Director of Communications and Partnerships
(813) 928-1603 (cell) | [email protected]

Quote

Quote

View original content to download multimedia: https://www.prnewswire.com/news-releases/tampa-general-hospital-is-launching-tgh-at-home-an-innovative-program-providing-personalized-care -and -improving-patient-access-301582594.html

SOURCE Tampa General Hospital

Notable thermal and mechanical properties of novel hybrid nanostructures

Carbon-based nanomaterials such as carbon nanotubes (CNTs), fullerenes and graphene are receiving great attention today due to their unique physical properties. A new study explores the potential of hybrid nanostructures and introduces a new porous graphene CNT hybrid structure with remarkable thermal and mechanical properties.

Image Credit: Orange Deer Studio/Shutterstock.com

The study shows how the remarkable characteristics of the new CNT graphene hybrid structures could be modified by slightly modifying the inherent geometric arrangement of CNTs and graphene, as well as various fillers.

The ability to precisely control the thermal conductivity and mechanical strength of graphene CNT hybrid structures makes it a potentially suitable candidate for various application areas, especially in advanced aerospace manufacturing where weight and strength are critical.

Carbon Nanostructures: CNTs, Graphene, Fullerenes

Carbon nanostructures and hybrids of multiple carbon nanostructures have recently been investigated as potential candidates for numerous sensing, photovoltaic, antibacterial, energy storage, fuel cell, and environmental improvement applications. .

The most important carbon-based nanostructures in research seem to be CNTs, graphene and fullerene. These structures exhibit unique thermal, mechanical, electronic and biological properties due to their extremely small size.

Structures that measure in the sub-nanometer range behave according to the particular laws of quantum physics, and therefore can be used to exploit non-intuitive phenomena such as quantum tunneling, quantum superposition, and quantum entanglement.

CNTs are carbon tubes that measure only a few nanometers in diameter. CNTs display notable electrical conductivity and some are semiconductor materials.

CNTs also have high tensile strength and thermal conductivity due to their nanostructure and the strength of covalent bonds formed between carbon atoms.

CNTs are potentially valuable materials for electronics, optics and composite materials, where they could replace carbon fibers in the next few years. Nanotechnology and materials science also use CNTs in research.

Graphene is an allotrope of carbon that is shaped into a single layer of carbon atoms arranged in a two-dimensional lattice structure composed of hexagonal shapes. Graphene was first isolated in a series of groundbreaking experiments by University of Manchester, UK, scientists Andrew Geim and Konstantin Novoselov in 2004, which won them the Nobel Prize in Physics in 2010 .

Over the next several decades, graphene has evolved into a useful nanomaterial with exceptionally high tensile strength, transparency, and electrical conductivity, leading to many and varied applications in electronics, sensing and other advanced technologies.

A fullerene is another allotrope of carbon that has been known for some time. Its molecule consists of carbon atoms connected by single and double bonds to form a mesh, which can be closed or partially closed. The mesh is fused with rings of five, six or seven atoms.

Fullerene molecules can be hollow spheres, ellipsoids, tubes, or a number of other shapes and sizes. Graphene could be considered an extreme member of the fullerene family, although it is considered a member of its own class of materials.

Hybrid nanostructures

Along with a lot of research invested in understanding and characterizing these carbon nanostructures in isolation, scientists are also exploring the properties of hybrid nanostructures that combine two or more nanostructure elements into a single material.

For example, foam materials have tunable properties that make them suitable for practical applications such as the design of sandwich structures, the design of biocompatibility, and the design of high-strength, low-weight structures.

Carbon-based nanofoams have also been used in medicine, examining bone damage and serving as the basis for replacement bone tissue.

Carbon-based cellular structures are produced by both chemical vapor deposition (CVD) and solution processing. Spark Plasma Sintering (SPS) methods are also being implemented to utilize graphene for biological and medical applications.

As a result, scientists have looked for ways to make three-dimensional carbon foams structurally stable. Research suggests that stable junctions between different types of structures (CNTs, fullerene and graphene) must be formed for this material to be stable enough for widespread application.

New research on hybrid nanostructures

New research from mechanical engineers at Istanbul Technical University in Turkey shows a new hybrid nanostructure formed by chemical bonding.

The porous structures of graphene CNTs have been made by arranging graphene around CNTs in nanoribbons. The different geometric arrangement of the graphene nanoribbon layers around the CNTs (square, hexagonal and diamond patterns) led to the observation of different physical properties in the material, suggesting that this geometric rearrangement could be used to refine the new structure.

The study was published in the journal Physica E: Low-dimensional systems and nanostructures in 2022.

The researchers found that structures with inserted fullerenes, for example, exhibited significant stability and compressive strength without sacrificing tensile strength. The geometric arrangement of the carbon nanostructures also had a significant effect on their thermal properties.

The researchers said that these new hybrid nanostructures have significant advantages, especially for the aerospace industry. Nanoarchitectures with these hybrid structures can also be used in hydrogen storage and nanoelectronics.

References and further reading

Belkin, A., A. Hubler and A. Bezryadin (2015). Self-assembled oscillating nano-structures and the principle of maximum entropy production. Scientific reports. doi.org/10.1038/srep08323

Degirmenci, U., and M. Kirca (2022). Carbon-based nano-lattice hybrid structures: Mechanical and thermal properties. Physica E: Low-dimensional systems and nanostructures. doi.org/10.1016/j.physe.2022.115392

Geim, AK (2009). Graphene: status and prospects. Science. /doi.org/10.1126/science.1158877

Geim, AK and KS Novoselov (2007). The rise of graphene. Natural materials. doi.org/10.1038/nmat1849

Monthioux, M., and VL Kuznetsov (2006). Who should take credit for the discovery of carbon nanotubes? Carbon. doi.org/10.1016/j.carbon.2006.03.019

Disclaimer: The views expressed herein are those of the author expressed privately and do not necessarily represent the views of AZoM.com Limited T/A AZoNetwork, the owner and operator of this website. This disclaimer forms part of the terms of use of this website.

Global Pet Conditioners Market Trend Research Report 2022

The in-depth study on Global Pet Conditioners Market from 2022 to 2028 that market segmentation, comprehensive, properly formed and projected that results in sustainable economic development individual decision opportunities for both MarketsandResearch.biz.

Further price adjustments are based on advertising results, technological advancements and/or budgetary constraints when reviewing the situation.

This same part of the survey is Environmental Pet Conditioners. Companies were selected and assessed to determine their relative strengths and weaknesses. Such a study examined the financial situation of large companies as well as the external opportunities and challenges they faced, among others.

DOWNLOAD A FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/306266

Key Players Covered in the Global Market Report:

  • Spectrum Marks
  • hartz
  • Central Garden & Pet Company
  • Wahl Clipper Corporation
  • Rolf C. Hagen
  • Beaphar
  • Earth bath
  • Bio-Groom
  • TropiClean
  • Cardinal Laboratories
  • 4 legs
  • Lambert Kay (PBI-Gordon)
  • Davis Manufacturing
  • Synergy Labs
  • Miracle treatment
  • Burt’s Bees
  • Logical product

Product types covered in the report include:

The countries covered in the market report are:

  • North America (United States, Canada and Mexico)
  • Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
  • Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
  • South America (Brazil, Argentina, Colombia and rest of South America)
  • Middle East and Africa (Saudi Arabia, United Arab Emirates, Egypt, South Africa and Rest of Middle East and Africa)

Studies on purchase decision making, browsing attitude towards the product and external factors are also conducted in each hemisphere. Organizational performance has therefore been addressed throughout the document.

Application types covered in the report include:

  • Home
  • Commercial app

ACCESS THE FULL REPORT: https://www.marketsandresearch.biz/report/306266/global-pet-conditioners-market-2022-by-manufacturers-regions-type-and-application-forecast-to-2028

Changes in manufacturers along with many other major market variables have been thoroughly analyzed in combination with these business categories. Your business introduction also contains information on how to reach potential customers, including information on the organization’s primary goal of providing better quality of service. Advertising for consumer products and government services is included in this category.

Report customization:

This report can be customized to meet customer requirements. Please contact our sales team ([email protected]), who will ensure that you get a report tailored to your needs. You can also get in touch with our executives at 1-201-465-4211 to share your research needs.

Contact us
mark the stone
Business Development Manager
Call: 1-201-465-4211
E-mail: [email protected]

How Tumors Convince Cells to ‘Go Bad’

0

Researchers have found that tumors can “recruit” immune cells, switching them from tumor attack to tumor promotion.

Soft tissue sarcomas alter the biology of immune cells around tumors, promoting tumor development

Researchers at Cedars-Sinai Medical Center have found that cancerous tumors known as soft tissue sarcomas release a protein that causes immune cells to change their behavior from tumor attack to tumor promotion. The work, which was recently published in the peer-reviewed journal Cell Reports, may help treat soft tissue sarcomas more effectively.

Jlenia Guarnerio

Jlenia Guarnerio, Ph.D., lead author of the study.

The study focused on the ecosystem of blood vessels and other cells that tumors attract to provide them with nutrients and support their survival.

“Tumors also recruit immune cells,” said Jlenia Guarnerio, Ph.D., research scientist at Cedars-Sinai Cancer, assistant professor of radiation oncology and biomedical sciences, and lead author of the study. “These immune cells should be able to recognize and attack tumor cells, but we found that tumor cells secrete a protein that changes their biology, so instead of killing tumor cells, they actually do the opposite.”

Soft tissue sarcoma is a rare cancer that develops in muscle, fat, blood vessels, nerves, tendons, and joint lining. The American Cancer Society estimates that it kills more than 5,000 Americans each year and most often affects the arms, legs and abdomen.

Guarnerio and his colleagues found that the majority of these tumors contain an overabundance of immune cells called myeloid cells in their microenvironment when comparing samples of various soft tissue sarcomas from laboratory mice and humans.

“It was striking that such a large percentage of immune cells were myeloid cells, and we thought that since they obviously weren’t killing tumor cells, they must be doing something to promote tumor growth,” said Stephen Shiao. , MD, Ph.D., Division Director of the Division of Radiobiology, Co-Lead of the Translational Oncology Program, and Study Co-Author. “And indeed, our analysis of tumor samples showed that many myeloid cells had adopted a tumor-promoting function.”

Stephen Shiao

Co-author Stephen Shiao, MD, Ph.D.

To find out what caused this change, the researchers looked at proteins secreted by tumor cells and receptors on the surface of myeloid cells, the things cells use to communicate. “We looked at the crosstalk between these two cell populations,” Guarnerio said. “We found that tumor cells expressed high levels of a protein called macrophage migration inhibitory factor. [MIF] and that myeloid cells had receptors to detect MIF proteins. This forces them to change their biology and promote, rather than block, tumor growth.

When researchers generated tumors from cancer cells that did not express MIF, myeloid cells were able to enter the tumors and tumor growth was reduced.

“This means that the myeloid cells could have directly attacked the tumors or activated other immune cells, for example T cells, to attack the tumors,” Guarnerio said.

Researchers believe this information could be used to create new therapies for soft tissue sarcoma. A drug designed to prevent cancer cells from expressing MIF could be tested in combination with existing therapies, for example, to see if it improves patient outcomes.

“Recurrent and aggressive soft tissue sarcoma has proven resistant to our existing therapies,” said Dan Theodorescu, MD, Ph.D., director of Cedars-Sinai Cancer. “Yet interventions to target components of the tumor microenvironment, which have shown promise against many solid tumors, have only been marginally tested in soft tissue sarcoma. This work could pave the way for much more effective interventions.

Guarnerio plans to continue these investigations and begin answering many more unanswered questions about soft tissue sarcoma.

“The majority of studies in cancer biology and immunotherapy have been done on carcinoma, the most common type of cancer,” Guarnerio said. “A lot of work has been done to describe what types of immune cells infiltrate these tumors and how carcinoma cells interact with immune cells, but there is almost no research on sarcomas. We need to investigate further to understand the roles of many other cells – T cells and B cells, for example – and how all the players work together.

The research was supported by National Institutes of Health grant numbers K99/R00, CA212200, and R01 CA258265; Sarcoma Foundation of America Grant Number 2019 SFA 15-19; and by Cedars-Sinai Cancer.

Reference: “Single cell RNA-seq of a soft tissue sarcoma model reveals the critical role of tumor-expressed MIF in the formation of macrophage heterogeneity” by Fernando HG Tessaro, Emily Y. Ko, Marco De Simone, Roberta Piras, Marina T Broz, Helen S. Goodridge, Bonnie Balzer, Stephen L. Shiao, and Jlenia Guarnerio, June 21, 2022, Cell reports.
DOI: 10.1016/j.celrep.2022.110977

Barakah nuclear power plant provides clean electricity, a solution to climate change while meeting peak electricity demand in summer

0

ABU DHABI – Energy security has quickly become the number one priority for nations around the world in light of current geopolitical issues resulting in rapidly rising energy prices. These increases, coupled with runaway inflation, are adding pressure to many national energy systems around the world and the impact on consumers’ cost of living is clear.

However, it is essential that we do not lose sight of our longer term challenge: climate change. The dangers of climate change are evident in many reports, and we know we have a limited window, until 2030, to take the bold steps we need to put us on the path to Net Zero by 2050. and a 1.5 degree global temperature rise. The question now is how do we stay on course with climate goals while ensuring energy security in the meantime?

The UAE has made a significant leap in supporting economic growth and addressing these two challenges through the Emirates Nuclear Energy Corporation (ENEC) Barakah Nuclear Power Plant, located in the Al Dhafra region of Abu Dhabi. The plant currently has two nuclear reactors in commercial operation, each generating up to 1,400 MW of carbon-free electricity 24 hours a day, 7 days a week, all year round. Barakah is one of the world’s largest nuclear power plants by installed capacity, with four APR-1400 units capable of generating up to 25% of the UAE’s electricity when fully operational, and so not only does it bolster the UAE National Energy Safety as a continuous source of electricity in the country, but it does so without generating carbon emissions, making it an optimal solution.

Indeed, the Intergovernmental Panel on Climate Change (IPCC) has identified several pathways to limit global warming to 1.5C in the coming decades and sees nuclear generation as playing an important role in decarbonization. of the energy sector. He expects that by mid-century the majority of primary energy will come from renewables and nuclear power in most scenarios. Additionally, the International Energy Agency (IEA) states that to reach Net Zero by 2050, the world must double existing nuclear power capacity from around 400 GW to over 800 GW2.

Being clean isn’t the only advantage. The latest data shows that the UAE’s electricity demand peaks at over 15,000 MW 3 and Barakah’s four units can generate up to 5,600 MW of clean electricity around the clock, equivalent to almost 40% of this demand. With two units already operating at maximum capacity today, the UAE is making significant progress in meeting peak demand with clean and plentiful electricity from the nuclear power plant, currently the largest source of clean electricity in the Arab region today.

The Barakah plant is accelerating the UAE’s trajectory towards the Net Zero strategic initiative by 2050 through the rapid decarbonization of the electricity sector. A proven solution to climate change, the plant provides abundant and reliable clean electricity to power homes and businesses across the country. Once fully operational, the four units will generate up to 5,600 MW of clean electricity and avoid 22.4 million tonnes of carbon emissions per year, while bridging other clean energy technologies, such as clean hydrogen.

This clean power generation is particularly important in this region, where temperature degrees rise steadily to around 40 degrees Celsius in the summer, when air conditioning use and water desalination demand peak to ensure that people stay cool and water is available for personal use. , watering, etc.

The UAE recognized the need for clean and plentiful electricity as early as 2008, and the UAE has remained committed to developing its nuclear energy program ever since. Fast forward to today and the benefits of nuclear power are clear. In a recent milestone, Unit 1 completed a full year of commercial operation which began in April 2021 and generated over 10.5 terawatt hours of clean electricity. Unit 2 was commissioned on March 24, 2022, less than a year after Unit 1, to double the benefits nuclear energy brings to the nation. This amount will be further increased with the planned start of the operation process of Unit 3 in 2022.

After a year of successful operations, Unit 1 has undergone a successful refueling and maintenance shutdown – a planned activity that occurs approximately every 12 months. The process involved shutting down the reactor, implementing more than 8,000 planned maintenance activities, and replacing approximately one-third of the fuel assemblies in the reactor core, with the remaining fuel reconfigured for optimal operation. Unit 1 has now restarted and restarted to run at full power for another carbon free year. Unit 2 continued to operate normally throughout this period, providing clean electricity to the nation.

Barakah crews have completed the fuel loading of Unit 3, after receiving the operating license from the UAE’s independent nuclear regulator, the Federal Nuclear Regulatory Authority (FANR), which will authorize the subsidiary to operation and maintenance of ENEC, Nawah Energy Company, to begin operation. Unity phase for the next 60 years. After completion of the fuel load, the operations team will begin preparations for the start-up of Unit 3, using lessons learned from the same process on Unit 1 in 2020 and Unit 2 in 2021 Meanwhile, major construction activities are complete at Unit 4.

By 2030, the Barakah plant will contribute 25% of the UAE’s international emission reduction commitments, making it a critical part of the national Net Zero strategy by 2050.

Dedicated doctor invents RestoreYourHealth.online to help people recover and stay well at home

0

A unique app-based system that puts the power of a personal nutritionist, personal trainer, therapist, and functional medicine practitioner in the palm of your hand

A life-changing event convinced Dr. Michael Wild that significant change was needed to enable people to truly help themselves recover and stay healthy. After losing his wife to cancer in his 40s, Dr. Wild devoted himself to studying the fundamental underlying reasons why people usually get sick in the first place, and discovered a common thread among the 5 leading causes of disease-related death in America.

He discovered that chronic inflammation at the cellular level plays a key role in the development of diseases such as heart attacks and strokes, diabetes, cancer of all kinds, dementia and even hundreds of self-defeating diseases. immune systems such as hypothyroidism. Surprisingly, he also discovered that each of these life-threatening conditions were thought to be lifestyle-related or often caused by one’s own lifestyle choices. In fact, according to the CDC, 7 out of 10 deaths in America fall into this category. Hearing of this, Dr. Wild swore at the time that he would commit to doing everything in his power to help as many people as possible make better life choices, so that they would not become un one more sad statistic.

Dr. Wild knew that most people did not recognize what they were doing to contribute to the cause of these diseases, nor did they realize the power they held to prevent and often even reverse these conditions. He realized that most people would benefit greatly from a simple, all-in-one tool to provide step-by-step nutritional guidance, personalized exercise programs, stress management strategies, and even stress tests. advanced lab and consultations as needed to identify root causes of developing or existing chronic health conditions. More importantly, this same tool could also be used to finally correct these hidden causes, and even provide the technology to do so from the comfort and ease of their own home.

He has made it his mission to create such a valuable tool in a form that is affordable, easy to understand and use, and able to meet the needs of customers at different stages of supporting health improvement. Finally, Dr. Wild’s dream came true this month with the launch of his unique new app-based system called RestoreYourHealth.online.

RestoreYourHealth.online offers 3 levels of service to meet each person where they are and help guide them where they want to be. Each service level provides Dr. Wild’s health metrics tracking app completely free of charge, with several included and add-on options available so each person can get the right amount of support for their individual needs.

Learn more at www.restoreyourhealth.online and join Dr. Wild in his mission to help people stop disease where it starts, at the cellular level.

About Dr. Wild

Dr. Michael Wild is a seasoned holistic physician with over 30 years of experience, author of the Holistic Handbook for Optimal Health and creator of the RestoreYourHealth.online system. Learn more about Dr. Wild and his unique approach to cellular healing at www.drwildcanhelp.com

Media Contact
Company Name: Restore your health online
Contact person: Dr Michael Wild
E-mail: Send an email
Call: 8043175063
Country: United States
Website: http://www.restoreyourhealth.online/

Molecular transport applied to signal phase 2 of the first line

SOUTH SAN FRANCISCO, Calif., July 05 10, 2022 (GLOBE NEWSWIRE) — Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT) today announced that the company plans to release the first results of data from its combined Phase 2 MARKET trial of AMT-101. (GI-selective, oral fusion of IL-10) with an anti-TNFα in biologic-naïve patients with moderate to severe ulcerative colitis. The Company will issue a pre-market press release and host a live web conference call on Wednesday, July 6, 2022 at 8:30 a.m. ET (5:30 a.m. PT).

Conference Call and Webcast Information
To join the conference call by phone and participate in the live Q&A session, please pre-register online here to receive a phone number and unique access code required to participate in the call. A live webcast will be available on the Events page of the Applied Molecular Transport website at https://ir.appliedmt.com/news-events/events. An archived replay will be available for 30 days after the event.

About Applied Molecular Transport Inc.
AMT is a clinical-stage biopharmaceutical company developing novel oral biologic product candidates, leveraging its technology platform to engineer biologic product candidates into patient-tailored oral dosage forms. AMT’s product candidates are designed to precisely target relevant disease pathophysiology. AMT’s proprietary technology platform is integrated into its product candidates, leveraging existing natural cellular trafficking pathways to drive the active transport of various therapeutic modalities across the IE barrier. Active transport is an efficient mechanism that uses the cell’s own machinery to transport materials across the IE barrier.

AMT’s corporate headquarters, in-house GMP manufacturing and laboratory facilities are located in South San Francisco, CA. For more information about AMT, please visit www.appliedmt.com.

Contact with Investor Relations:
Andrew Chang
Head, Investor Relations and Corporate Communications
[email protected]

Media contacts:
Alexandra Santos
Wheelhouse Life Science Advisors
[email protected]

Aljanae Reynolds
Wheelhouse Life Science Advisors
[email protected]

Global Radar Detector Market 2022 to 2028 – Growth, Opportunities and Key Players are Cobra Electronics, Valentine Research, Inc., Escort

Global Radar Detectors Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028 is the title of a corporate market line published by MarketsandResearch.biz which examines the opportunities and growth potential of the market. By utilizing numerous educational methodologies, the research on the Global Radar Detectors Market has comprehensively examined and collected essential industry specialist knowledge and their coverage in the industry. The rise of the dominant manufacturer was studied using Porter’s five forces approach, risk assessment and net benefit analysis. Key findings from the survey are featured in the research, including the top reasons organizations will increase supply chain visibility in the coming decades.

Here are the critical apps that have been highlighted in the news:

  • car owners
  • Transport departments

DOWNLOAD A FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/262655

This document focuses on several core regions:

  • North America (United States, Canada and Mexico)
  • Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
  • Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
  • South America (Brazil, Argentina, Colombia and rest of South America)
  • Middle East and Africa (Saudi Arabia, United Arab Emirates, Egypt, South Africa and Rest of Middle East and Africa)

The study also examines vital market characteristics and current trends, as well as relevant customer segments and sub-segments.

The following companies are heavily featured in the published report:

  • Cobra Electronic
  • Valentine Research, Inc.
  • Escort
  • Uniden
  • Beltronics
  • Whistler Group
  • Shenzhen Lutu Technology
  • K40
  • Browser
  • Quinte
  • Radenso
  • rocky mountain

The study examines the level of price competition among major suppliers, as well as the company profile, before moving on to complex business research and supply chain management.

The following product types are highlighted in the report:

  • full band radar detector
  • GPS radar detector
  • GPS Full Band Radar Detector
  • Ordinary radar detector

ACCESS THE FULL REPORT: https://www.marketsandresearch.biz/report/262655/global-radar-detector-market-2022-by-manufacturers-regions-type-and-application-forecast-to-2028

The Radar Detector report offers the following key highlights:

  • It covers assessments at national and regional levels.
  • Recommendations and methods for newcomers
  • Industry Drivers, Constraints, Opportunities, Risks, Challenges, Asset Management and Insights.
  • It displays information in a written and graphical format that is easy to interpret and compare.
  • Market changes are dynamic, such as market expansions, partnerships, market penetration, and mergers.

Report customization:

This report can be customized to meet customer requirements. Please contact our sales team ([email protected]), who will ensure that you get a report tailored to your needs. You can also get in touch with our executives at 1-201-465-4211 to share your research needs.

Contact us
mark the stone
Business Development Manager
Call: 1-201-465-4211
E-mail: [email protected]
The Web: www.marketsandresearch.biz

Expansion of the nurturGROW offer with a new range of vertical trusses

0

Light Science Technologies has expanded its nurturGROW lighting product portfolio with the launch of its “slimline” Vertical Farm range, characterized by its sustainable design.

Specifically for use in a closed, climate-controlled growing facility such as a vertical/urban farm, container or research facility, the Vertical Farm range can be used in a variety of multi-layered growing applications. Offering optimum growing space, the range is ideal for growing but not limited to leafy greens, strawberries, microgreens, herbs, violas and other small flowers.

nurturGROW is designed to maximize space in a vertical farm environment with its lower profile and tailored length while providing efficiency up to 2.8 umol, which helps reduce energy requirements and reduce operating costs without compromising performance. It has also been designed to provide the best possible uniformity to ensure even growth on all grow trays. At the same time, its IP67 rating ensures better protection against the harmful effects of dirt and moisture. Additionally, by connecting eight fixtures per driver, growers can control light intensity remotely and connect directly to their control system.

Providing up to nine independent light spectra, growers can choose the right grow recipe, including UVC, to give the flexibility of a bespoke option to create the perfect light spectrum for crops throughout the full grow cycle cultures.

Simon Deacon, CEO and Founder of Light Science Technologies, said, “At a time of soaring energy prices, indoor farmers are under increasing pressure to find more energy-efficient ways to grow their crops to reduce long-term costs. nurturGROW is a solution that builds on a 25-year product lifecycle, ensuring growers maximize the use of every element over a longer lifespan to generate maximum yields and save them a third on future costs.

“We have created a sustainable and scalable design so that 90% of the product is recyclable and 85% is reusable, allowing for simple component upgrades, cost effectively and without downtime, making nurturGROW easy to maintain. It also means that growers can benefit from new technology and more efficient LEDs, which can be added as they are developed, instead of having to buy new lighting from scratch, which is an additional expense. What indoor growers are also looking for is durability and reliability while optimizing crop performance, which is exactly what nurturGROW delivers. There is also the element of durability; this does not only apply to indoor farming methods, but must also cover products, which is why nurturGROW significantly reduces landfill waste and reduces carbon footprint by minimizing the number of materials used.

“Our new range of vertical farms allows more growers in the market to enjoy the benefits of nurturGROW, whether in a vertical or urban farm or in a research center where space may be more limited. In short, it helps them grow more with less.

For more information:
Light science technologies
[email protected]
www.lightsciencetech.com

Health News | Scientists develop thermogel that helps prevent retinal scarring

0

Washington [US]Jul 4 (ANI): According to a new study, a group of scientists from Singapore have found that a biofunctional thermogel, a type of synthetic polymer, helps prevent retinal scarring caused by failed detachment repair surgery of the retina.

Research has found that proliferative vitreoretinopathy occurs when retinal scarring prevents the retina from healing and growing back into place. And it is said to account for more than 75% of failed retinal detachment surgeries and could lead to vision loss or blindness if left untreated.

Read also | New N95 face mask that can kill the COVID-19 virus developed by researchers.

The results of the study have been published in the journal Nature.

Current treatment options for PVR are limited to surgical removal of these scar membranes with protected visual recovery.[1] This work highlights the potential of using synthetic polymers alone to modulate cellular behavior and, for the first time, provides a new thermogel-based therapy to prevent retinal scarring. The team behind the development is drawn from the Institute of Molecular and Cellular Biology (IMCB) and the Institute of Materials Research and Engineering (IMRE) of A*STAR, National University of Singapore (NUS) and the Singapore Eye Research Institute (SERI).

Read also | Diarrhea outbreak in Pondicherry: Public health emergency declared in Karaikal, schools will remain closed until June 6.

The research team demonstrated that a biofunctional thermogel alone is able to prevent retinal scarring in a preclinical model that mimics human disease. Using retinal cells, the team observed that the thermogel prevented the development of scar membranes by modulating cell behaviors such as proliferation and migration. Using genome-wide transcriptomic analysis to profile cellular gene expression, they revealed that the thermogel activated a protein called erythroid-related nuclear factor 2 (NRF2), to trigger a series of chemical reactions to prevent scarring.

“Our study offers insight into how synthetic polymers no longer simply function as inert drug carriers. It challenges the conventional belief that the use of a small molecule drug is always necessary to achieve an effect. Beyond ophthalmology, this unique bio-functionality of the thermogel can also be applied to other diseases such as orthopedics where intra-articular joint scarring could be an issue,” said Dr. Su Xinyi, Senior Principal Investigator and Division Director at A*STAR’s IMCB, and Assistant Professor in the Department of Ophthalmology at NUS Yong Loo Lin School of Medicine.

“When we first developed this biofunctional thermogel at IMRE, we realized that it was a significant step forward in the development of next-generation biodegradable polymers. Its ability to mimic and replace vitreous given the biocompatibility of the material, makes it useful for many other biomedical applications,” said Prof. Loh Xian Jun, IMRE Executive Director of A*STAR.

The thermogel is currently commercialized by Vitreogel Innovations Inc, an A*STAR spin-off that focuses on the development of polymer-based therapies for ophthalmology indications. Vitreogel Innovations Inc is an ISO 13485 (Medical Device Quality Systems) accredited company that generates a clinical-grade version of the polymer for first-in-man clinical trials.

Building on this work, the team will continue to test the safety and efficacy of this polymer for repairing retinal detachment and preventing PVR using additional preclinical disease models. Through their work, the team aims to design the next generation of polymers with targeted chemical modifications to elicit specific cellular behaviors and to identify alternative applications of the thermogel beyond ophthalmology. (ANI)

(This is an unedited and auto-generated story from syndicated newsfeed, LatestLY staff may not have edited or edited the body of the content)

Heat and handle, one cell at a time

KANAZAWA, Japan, July 4, 2022 /PRNewswire/ — Researchers from Kanazawa University report in ACS Nano the development of a nanoparticle that acts as a heating element and a thermometer. The insertion of the nanoparticle into living cells creates a heat point which, by switching it on and off, allows the controlled modulation of local cellular activities.

Being able to heat nanoscale regions in biological tissues is key to several biomedical applications. Indeed, many biological processes are temperature sensitive, and the ability to locally alter temperature provides a means to manipulate cellular activity. A notable goal is the destruction of cancer cells by heating them. In addition to the need for a local heating mechanism in the tissues, it is also important to be able to instantly measure the temperature generated. Satoshi Arai from Kanazawa University and his colleagues have now designed a nanoparticle that is both a nanoheater and a nanothermometer. They have successfully shown that inserting a single point of controllable heat into tissues can be very effective in altering cell function.

The nanoparticle, called “nanoHT” by scientists – short for “nanoheater-thermometer” – is essentially a polymer matrix incorporating a dye molecule (called EuDT) used to sense temperature, and another dye molecule (called V- Nc) to release Heat. The latter occurs through the conversion of light into thermal energy (the photothermal effect, also exploited in solar cells): shining a near-infrared laser (with a wavelength of 808 nanometers) on V-Nc results in a rapid heating, with greater temperature rise for higher laser power.

Temperature sensing is based on the thermal fluorescence effect of EuDT. When irradiated with light of one wavelength, the molecule emits light at another wavelength – fluorescence. The higher the temperature, the less intense the fluorescence becomes. This inverse relationship can be used to measure temperature. Arai and his colleagues tested the performance of the nanoHT as a thermometer and found that it can determine temperatures with a resolution of 0.8°C and less.

The researchers then performed experiments with a type of human cell called HeLa cells. They examined the effect of nanoHT heating and found that at a temperature increase of about 11.4°C, heated HeLa cells died after only a few seconds. This finding suggests that nanoHT could be used to induce cell death in cancer cells.

Arai and his colleagues also investigated how nanoHT can be used to affect muscle behavior. They introduced the nanoparticle into the myotube, a type of fiber found in muscle tissue. Upon heating the myotube by approximately 10.5°C, the muscle tissue contracted. The procedure worked reversibly; allowing the myotube to cool again resulted in muscle relaxation.

Work by Arai and colleagues shows that local heating at a subcellular scale using nanoHT enables the controlled manipulation of single cell activity. Regarding applications, the scientists believe that “targeted application of nanoHT has a diverse and versatile range of abilities to regulate cellular activities that would facilitate the development of thermodynamic cellular engineering.”

Background

Fluorescence

Fluorescence refers to the emission of light by a substance after which it has absorbed light (or another type of electromagnetic radiation). Typically, the emitted light has a longer wavelength, and therefore lower photon energy, than the absorbed radiation. A well-known case of fluorescence occurs when the absorbed radiation is in the ultraviolet region of the spectrum, invisible to the human eye, while the emitted light is in the visible region.

Fluorescent thermometry is a technique for measuring temperatures through the use of fluorescent dye molecules, the fluorescence intensity of which is strongly dependent on temperature. Dye molecules are inserted into a material of interest; a detailed knowledge of the fluorescence intensity as a function of temperature dependence allows the temperature of the material to be inferred. (Dye molecules are excited to fluoresce by incident light; its intensity provides a measure of local temperature.)

Satoshi Arai from Kanazawa University and his colleagues used fluorescent dye molecules to develop nanoHT, a nanoparticle that acts as both a heater and a thermometer for nano-bio applications.

Reference

Ferdinand, madoka suzukiCong Quang Vu, Yoshie Harada, Satya Ranjan SarkerShinichi Ishiwata, Tetsuya Kitaguchiand Satoshi Arai. Modulation of local cellular activities using a photothermal dye-based subcellular-sized heat spot, ACS Nano 169004–9018 (2022).

DOI: 10.1021/acsnano.2c00285

URL: https://pubs.acs.org/doi/10.1021/acsnano.2c00285

Pictures

https://nanolsi.kanazawa-u.ac.jp/wp-content/uploads/2022/07/fig1.jpg

Figure 1. Thermodynamic cellular engineering: creating a tiny point of heat helps regulate cellular functions

https://nanolsi.kanazawa-u.ac.jp/wp-content/uploads/2022/07/fig2.jpg

Figure 2. Microscopic system for nanoheating. A) Schematic and microscopic images of nanoheater (nanoHT) (transmission electron microscopy). B) A system for warming a localized region at the single cellular level (upper panel). A single nanoHT dot was located in a single cell (lower left panel). The microscale temperature gradient was generated at the subcellular level (lower right panel).

https://nanolsi.kanazawa-u.ac.jp/wp-content/uploads/2022/07/fig3.jpg

Figure 3. A nanoparticle combining photothermal heating and fluorescence thermometry functions as a localized heat point and is able to induce cell death or muscle contraction.

Contact

Hiroe Yoneda
Deputy Director of Public Affairs
WPI Nano Life Sciences Institute (WPI-NanoLSI)
Kanazawa University
Kakuma-machi, Kanazawa 920-1192, Japan
E-mail: [email protected]
Tel: +81 (76) 234-4550

About the Nano Life Science Institute (WPI-NanoLSI)

https://nanolsi.kanazawa-u.ac.jp/en/

The Nano Life Science Institute (NanoLSI) at Kanazawa University is a research center established in 2017 under the World Premier International Research Center Initiative of the Ministry of Education, Culture, Sports, Science and Technology. The objective of this initiative is to create world-class research centres. NanoLSI combines the most advanced knowledge of biological probe microscopy to establish “nano-endoscopic techniques” to directly image, analyze and manipulate biomolecules to better understand the mechanisms governing life phenomena such as diseases.

About Kanazawa University

http://www.kanazawa-u.ac.jp/e/

As the leading comprehensive university in the sea of Japan coast, Kanazawa University has contributed greatly to higher education and academic research in Japan since its inception in 1949. The University has three colleges and 17 schools offering courses in subjects including medicine, computer engineering, and humanities.

The University is located on the sea coast of Japan in Kanazawa – a city rich in history and culture. The city of Kanazawa has had a highly respected intellectual profile since the time of the feud (1598-1867). The University of Kanazawa is divided into two main campuses: Kakuma and Takaramachi for its approximately 10,200 students, including 600 foreigners.

SOURCE Kanazawa University

Judge puts Biden in the hot seat over Saudi crown prince’s immunity | Mohammad bin Salman

0

A US judge has asked the Biden administration to rule on whether Mohammed bin Salman, the crown prince of Saudi Arabia, should enjoy sovereign immunity in a civil case brought against him in the United States by Hatice Cengiz, the fiancée of Jamal Khashoggi, the journalist killed by Saudi agents in 2018.

John Bates, a district court judge, gave the US government until August 1 to declare its interests in the civil case or notify the court that it had no opinion on the matter.

The administration’s decision could have a profound effect on the civil case and comes as Joe Biden faces criticism for abandoning a campaign promise to turn Saudi Arabia into an “outcast”.

The US president is due to meet the heir to the Saudi throne later this month on his first trip to Riyadh since entering the White House.

The civil complaint against Prince Mohammed, which was filed by Cengiz in Washington DC Federal District Court in October 2020, alleges that he and other Saudi officials acted in a “conspiracy and with premeditation” when Saudi agents abducted, tied up, drugged, tortured and killed Khashoggi inside the Saudi consulate in Istanbul in 2018.

Khashoggi, a former Saudi insider who had fled the kingdom and resided in Virginia, was an outspoken critic of the young crown prince and was actively seeking to counter Saudi propaganda online at the time he was killed.

After years of inaction against Prince Mohammed by Donald Trump, who was president when Khashoggi was killed, the Biden administration decided to release an unclassified US intelligence report in 2021, shortly after Biden entered. at the White House, which concluded that Prince Mohammed was likely to have ordered Khashoggi’s murder.

At the time of the report’s release, the Saudi Foreign Ministry said the kingdom’s government “categorically rejects what is stated in the report provided to Congress.”

While Saudi Arabia says it held a trial against the commando responsible for the grisly murder, the proceedings have been widely condemned as a sham, and some of the team’s most senior members have been spotted inside a security compound of the state in Riyadh.

Other possible avenues of justice have been blocked for political reasons. A Turkish prosecutor ended a long trial in absentia against Khashoggi’s killers in March, in a move seen as part of Turkish President Recep Tayyip Erdoğan’s attempts to improve relations with Prince Mohammed.

The Saudi prince took responsibility for the murder on behalf of the Saudi government but denied any personal involvement in planning the assassination.

For supporters of Cengiz, who has been a strong advocate for justice for Khashoggi’s murder, any decision by the US government to call on the crown prince to be granted sovereign immunity in the case would represent a betrayal of the promise of Biden to hold Saudi Arabia accountable.

“It would be absurd and unprecedented for the administration to protect him. It would be the final nail in the coffin of attempts to hold Khashoggi’s killers accountable,” said Abdullah Alaoudh, research director of Dawn, a nonprofit that promotes democracy in the Middle East and was founded by Khashoggi and a co-plaintiff on the case against the Crown Prince.

Judge Bates said in an order released Friday that he would hold a hearing on August 31 after motions to dismiss the civil case by Prince Mohammed and others.

The motions to dismiss the civil case hinge on claims by Prince Mohammed’s lawyers that the DC court does not have jurisdiction over the crown prince.

“In the opinion of the court, some of the grounds for dismissal advanced by the defendants could jeopardize the interests of the United States; moreover, the court’s resolution of defendants’ motions could be facilitated by knowing the views of the United States,” Bates said.

The judge said he was specifically inviting the US government to submit a statement of interest regarding the applicability of the so-called act of state doctrine, which states that the US should refrain from review the actions of another foreign government in its courts; the interplay of this doctrine with a 1991 law that gives Americans and non-citizens the right to file complaints in the United States for torture and extrajudicial executions committed in foreign countries; the applicability of head of state immunity in this case; and the United States’ view of whether Saudi Arabia’s sovereign interests could be compromised if the case were to proceed.

Agnes Callamard, the head of Amnesty International, which investigated Khashoggi’s murder in her previous role as UN special rapporteur on extrajudicial executions, said it was “laughable” that Prince Mohammed, who she called a “quasi-sovereign” head of state immunity after the United States itself publicly concluded that it most likely approved the operation to kill Khashoggi.

Noting that Prince Mohammed was not king, she added: “MBS [as the crown prince is known] is not the ruler of Saudi Arabia and the United States should not recognize him as head of state. This would grant him authority and legitimacy that he certainly does not deserve and hopefully will never receive.

Cengiz could not immediately be reached for comment. The Saudi Embassy in Washington was unavailable for comment.

Eat protein to improve your health and build muscle, not to store extra body fat

0

When, what type and how much protein should you eat per day? How do you build and maintain healthy bones and muscles, repair your body, regulate hormones, improve metabolism and manage your weight?

Forget about fad diets limiting the intake of other nutrients (protein, carbohydrates or fats) which can lead to health deficiencies, hormonal imbalance and weight problems. Prioritize balancing your food intake with your goals and activity level to improve your health and energy and achieve long-term weight control.

Spread your protein intake throughout the day

Make sure I eat a balanced diet, including protein with every meal and snack to stave off hunger pangs, to recover enough after every workout, and to keep my energy levels up until the evening.

Try eating fruit or a piece of toast just for easy grabbing snacks in the past, but a lack of protein would always make me crave more food during the day which might even reach late at night. I realized the importance of eating the right amount and type of protein for every snack or meal I consume.

Protein is the key to weight management. Studies show that it promotes satiety better than other macronutrients. You also burn more calories digesting and metabolizing food – this is called the thermic food effect (TEF). Protein has a lot of TEF (20-30%) compared to carbohydrates (5-10%) and fats (0-3%).

Instead of including all of your protein sources in one to two meals a day, spread your protein intake strategically throughout the day to effectively regulate your appetite, cravings, and energy levels. A 2015 study from the University of Missouri-Columbia shows that eating a high-protein breakfast can shed body mass and reduce daily food intake by 400 calories.

To gain muscle effectively (or avoid muscle loss) while losing body fat, consume 20-30 grams (the equivalent of a serving or palm size of lean meat, boneless, skinless chicken and seafood) of protein for each main meal and 10 to 15 grams for snacks.

Always aim for healthy carbs, good fats, and enough protein for your main meals and snacks. Eat your post-workout meal/snack 15-60 minutes after your workout for your muscles to recover effectively and re-energize.

Here’s how you can still incorporate protein with your healthy carbs and good fats.

BREAKFAST

  • Instead of eating a high-carb breakfast of a croissant or bagel with jam or cream cheese, choose whole-grain bread with eggs, avocado, and low-fat milk in bold.
  • Add chia seeds and nuts to your oats and milk
  • Make a Salmon and Spinach Omelet with Sweet Potato and Cheese
  • Eat a full meal of sardines, brown rice, eggs, and fresh fruit on the side

LUNCH AND DINNER

  • Consume 1/2 to 1 cup of healthy grains (brown rice, millet, couscous, quinoa, whole wheat pasta or adlai) and cooked vegetables with a serving of 90% lean beef, pork, salmon, chicken, prawns or white fish
  • Have a baked or boiled sweet potato and a vegetable omelet with chicken or shrimp
  • Create your favorite salad and sandwich using whole wheat bread, cottage cheese, lettuce, onion, tomato and chicken breast
  • Make your healthy wrap – lettuce, whole wheat tortilla, 1/4 cup beans, 1/2 cup lean ground beef, 1 tbsp cheese, and yogurt dressing

TO TASTE

  • Have a slice of whole wheat bread with a tablespoon of peanut butter
  • Mix chopped fresh fruit with 1/2 cup Greek yogurt and 1 tbsp almonds or cashews
  • Prepare a protein smoothie consisting of 1/2 cup fresh or frozen fruit, 1 cup milk (skim or nut milk), 1 cup vegetables (kale, cucumber, celery), 1 tablespoon chia seeds, and /or 1 tbsp Almond Butter.
  • Mix 1 tbsp nuts with, 1 tbsp seeds, 2-4 tbsp oats or granola, and 1/2 cup milk or yogurt

Your Protein Intake Should Match Your Unique Profile

Match your needs with the right amount of nutrients to achieve your desired goals. As with carbohydrate and fat intake, you should consume the recommended amount of protein based on your body weight, fitness goals, age, gender, and current health status.

Eating more than the required amount of protein can lead to fat gain, especially if you are sedentary. You need to use the extra protein by moving and building muscle and getting enough rest. In fact, your body has a limit when it comes to absorbing protein daily and at every meal.

On the other hand, exercising more and eating less protein can also affect your body composition – you may lose muscle, you will feel weaker, your metabolism will slow down and you will gain body fat.

For optimal health and weight management, you need to exercise to lose body fat and build or maintain muscle mass. Prolonged and intense workouts require eating the right amount of nutrients at the right time to avoid muscle wasting.

The Recommended Dietary Allowance (RDA) based on various nutritional organizations around the world differs for each individual. 10-35% of daily intake should come from protein to avoid deficiencies, function well efficiently, and achieve your fitness goals.

Sedentary to average adults – should consume 0.8 to 1.2 grams of protein per kilogram of body weight to achieve satiety and effective weight control.

Active and athletic people should consume at least 1.2 to 2 grams of protein per kilogram of body weight. You need more if you’re trying to build more muscle mass and are currently doing prolonged, high-intensity endurance activities.

Older people should consume at least 1 gram of protein per kilogram of body weight to prevent loss of lean body mass from occurring naturally with age.

Always choose quality foods rich in protein, fiber and good fats to avoid weight gain while improving your physical performance and muscle recovery. Avoid protein foods high in saturated fat and refined carbohydrates:

  • Pizza
  • A bacon cheeseburger
  • Savory pastry and pie
  • Fried chicken sandwich
  • Fried chicken with skin
  • Meat with visible fat
  • Processed meats like bacon, salami, hot dog, sausage, and ham
    cheesecake
  • Fried seafood such as tempura, fish and chips, breaded calamari or calamari

Insider Selling: FactSet Research Systems Inc. (NYSE: FDS) CEO Sells 2,500 Shares

FactSet Research Systems Inc. (NYSE: MSDS – Get a rating) CEO Frederick Philippe Snow sold 2,500 shares of the company in a transaction dated Friday, July 1. The shares were sold at an average price of $384.54, for a total transaction of $961,350.00. As a result of the transaction, the CEO now owns 3,988 shares of the company, valued at approximately $1,533,545.52. The transaction was disclosed in an SEC filing, available at this link.

Frederick Philip Snow also recently made the following trade(s):

  • On Wednesday, June 1, Frederick Philip Snow sold 2,500 shares of FactSet Research Systems. The stock was sold at an average price of $370.95, for a total transaction of $927,375.00.
  • On Monday, May 2, Frederick Philip Snow sold 2,500 shares of FactSet Research Systems. The stock was sold at an average price of $404.37, for a total transaction of $1,010,925.00.

Shares of FDS traded at $9.63 during Friday’s trading, hitting $394.20. 312,778 shares of the company were traded, against an average volume of 293,990. The company has a debt ratio of 1.63, a quick ratio of 3.72 and a current ratio of 1.99. The company has a market capitalization of $14.94 billion, a price/earnings ratio of 37.74, a P/E/G ratio of 2.95 and a beta of 0.83. The company’s 50-day simple moving average is $378.56 and its 200-day simple moving average is $413.49. FactSet Research Systems Inc. has a 12-month low of $332.67 and a 12-month high of $495.39.

FactSet Research Systems (NYSE: FDS – Get a rating) last reported results on Thursday, June 23. The business services provider reported earnings per share (EPS) of $3.76 for the quarter, beating analyst consensus estimates of $3.18 by $0.58. FactSet Research Systems posted a net margin of 22.41% and a return on equity of 44.24%. In the same period a year earlier, the company earned earnings per share of $2.72. On average, stock analysts expect FactSet Research Systems Inc. to post earnings per share of 13.29 for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Thursday, June 16. Shareholders of record on Tuesday, May 31 received a dividend of $0.89. The ex-dividend date was Friday, May 27. This is a boost from FactSet Research Systems’ previous quarterly dividend of $0.82. This represents a dividend of $3.56 on an annualized basis and a yield of 0.90%. FactSet Research Systems payout ratio is 34.94%.

A number of hedge funds and other institutional investors have recently bought and sold shares of FDS. State Street Corp increased its stake in FactSet Research Systems by 27.5% in the fourth quarter. State Street Corp now owns 1,955,530 shares of the business services provider valued at $950,407,000 after acquiring an additional 421,362 shares in the last quarter. Geode Capital Management LLC raised its position in shares of FactSet Research Systems by 40.1% in the fourth quarter. Geode Capital Management LLC now owns 827,816 shares of the business services provider valued at $401,813,000 after purchasing an additional 236,744 shares during the period. Sumitomo Mitsui Trust Holdings Inc. raised its position in FactSet Research Systems shares by 98.3% in the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 284,262 shares of the business services provider valued at $138,154,000 after purchasing an additional 140,946 shares during the period. Invesco Ltd. raised its position in shares of FactSet Research Systems by 103.6% in the fourth quarter. Invesco Ltd. now owns 240,740 shares of the business services provider valued at $117,002,000 after purchasing an additional 122,485 shares during the period. Finally, AustralianSuper Pty Ltd increased its position in shares of FactSet Research Systems by 179.4% in the first quarter. AustralianSuper Pty Ltd now owns 178,785 shares of the business services provider valued at $77,620,000 after buying an additional 114,793 shares during the period. Hedge funds and other institutional investors own 89.99% of the company’s shares.

FDS has been the subject of several recent research reports. Credit Suisse Group lowered its price target on shares of FactSet Research Systems from $475.00 to $390.00 and set a “neutral” rating on the stock in a Friday, June 24 research note. Barclays cut its price target on shares of FactSet Research Systems from $550.00 to $440.00 and set an “overweight” rating for the company in a Friday, June 24 report. Morgan Stanley lowered its price target on shares of FactSet Research Systems from $362.00 to $338.00 and set an “underweight” rating for the company in a Tuesday, June 21 report. Royal Bank of Canada lowered its target price on shares of FactSet Research Systems from $525.00 to $475.00 and set an “outperform” rating for the company in a Friday, June 24 report. Finally, Redburn Partners assumed stock coverage for FactSet Research Systems in a report on Tuesday, May 17. They issued a “sell” rating for the company. Three research analysts rated the stock with a sell rating, seven gave the company’s stock a hold rating and two gave the company’s stock a buy rating. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $407.50.

FactSet Research Systems Company Profile (Get a rating)

FactSet Research Systems Inc, a financial data and analytics company, provides integrated financial information and analytical applications to the investment community in the Americas, Europe, Middle East, Africa and Asia-Pacific. The Company provides insights and insights through the Research, Analytics & Trading, Content & Technology and Wealth Solutions Workflow Solutions.

Recommended Stories

Insider buying and selling by quarter for FactSet Research Systems (NYSE:FDS)

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in FactSet Research Systems right now?

Before you consider FactSet Research Systems, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes over… and FactSet Research Systems was not on the list.

While FactSet Research Systems currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here

A bloated gene promoter prevents heat from undermining plant defenses

0

Summary

Plant immune defenses weaken during heat waves, making them more vulnerable to insects and pathogens under climate change. HHMI scientists have now understood why high temperatures knock out a key defense system and they have developed a strategy that boosts plant immunity.

The immune system of plants relies on the hormone salicylic acid, which helps to fine-tune their defenses against infections and insect infestations. But in warm temperatures, plants stop producing salicylic acid. New research from HHMI investigators reveals why and uses genetic engineering to boost immune function during hot spells. Credit: Lesley Warren Design Group, Ontario, Canada

Plants that sense heat face risks beyond wilting. During heat waves, plant defenses falter, making them more vulnerable to infections and infestations. This is all the more worrying as climate change makes heat waves more frequent and intense.

“Plants actually have a very strong innate immune system which is why they have survived on Earth for so long,” says plant scientist Sheng Yang He, who is a Howard Hughes Medical Institute (HHMI) researcher at Duke University. “But now we know that this immune system may not work as well in a hot climate, especially for many crops in cool weather. Continued climate warming could exacerbate this reduction in innate immunity and increase disease and insect infestations in the future.

His team has uncovered new clues as to why heat saps plant immunity. This allowed them to find a genetic solution to keep a key plant defense system online during periods of heat, the researchers report on June 29, 2022, at Nature.

Plant immune function requires the hormone salicylic acid, which helps coordinate the defenses that plants raise or lower. But smothering plants slow their production of salicylic acid, and researchers aren’t sure why.

He and his colleagues grew up Arabidopsis, a model plant and cousin of cruciferous vegetables, allowing plants to thrive in pleasant temperatures for four weeks before turning up the heat for a few days. Then they infected the plants with a pathogenic bacterium and observed that the hot plants had much lower levels of salicylic acid than the infected plants that had escaped the heat wave. Expression of plant genes allowed the team to discover regulatory genes that could be responsible for the lackluster production of salicylic acid in plants.

To determine which gene was the kingpin of salicylic acid, the team spent many years growing various transgenic or mutant plants. Each expressed a hijacked candidate gene to retain it during high temperatures. Eventually, He’s team landed on a gene called CBP60g, which was surprisingly far upstream of salicylic acid production. But the team still didn’t know why he collapsed in the heat.

“Plants actually have a very powerful innate immune system which explains why they have survived so long on Earth.”

Sheng Yang He, HHMI Investigator at Duke University

So he and his colleagues sifted through the gene’s known transcription factors and coactivators, exhausting all possibilities. None were found to be involved in the temperature sensitivity of CBP60g expression. “We were about to give up,” he says. But then immunologist John MacMicking published an article last year in Nature which provided a new clue to the puzzle. MacMicking, an HHMI researcher at Yale University, and colleagues have reported a new protein condensate, a bead of concentrated proteins formed by a process called phase separation, involved in the regulation CBP60gis expressed and produces salicylic acid upon infection. Therefore, he and MacMicking began a collaboration to investigate CBP60g’s role in loss of immunity under hot temperatures.

This protein bubble is located at CBP60gand appears to be essential for transcription, perhaps because it concentrates the molecules needed to start the process, he says. Such phase-separated structures, which resemble organelles yet self-assemble without a lipid bilayer membrane, have been studied in animals for more than a decade. But they have only been examined more closely in plants in recent years, MacMicking says. “It will be a very exciting time for plant biologists,” notes MacMicking. Protein condensates can be involved in germination, flowering and growth. And it seems that they can form, perform their tasks, and then disassemble. We must now revise our notion of the composition of a cell, he says.

His team found that their infected plants developed fewer protein bubbles at high temperatures. It’s still unclear exactly how heat-sensitive these condensates are during transcription, so He’s team found a workaround to jump-start salicylic acid production.

The researchers grew more transgenic plants, this time replacing CBP60g‘s promoter with a switch that was not temperature sensitive. This left the salicylic acid system still activated. And they discovered that the elevated immune response came with a trade-off: These plants sacrificed growth and produced smaller leaves.

Farmers don’t want stunted plants, so the team then turned to a promoter developed in 2017 by Duke University plant scientist Xinnian Dong, who is also an HHMI researcher. Dong’s swollen switch only turns on when infected. This allowed the Arabidopsis to have her salicylic acid defense at the ready, but only deploy it when attacked. This strategy also worked with rapeseed cultivation.

“There is great promise that plants can be engineered to preserve immunity in warmer conditions,” says Jian Hua, a plant biologist at Cornell University who was not part of this work. Understanding how other environmental factors affect plant immunity can help researchers develop more resilient plants, she says. “This work is a great example of fundamental research translating into an impactful solution to address climate change.”

His collaborators are currently testing the plants with the modified genes in the field. All plants have CBP60gso he and his colleagues want to figure out how to edit plant genes with CRISPR to alter the endogenous of plants CBP60g Genoa. Ultimately, the goal, which will take on a community of plant scientists, is to give plants an edge as new threats, from increasing droughts to new pathogens, arise.

###

Quote

Jong Hum Kim et al. “Increasing the resilience of plant immunity to global warming.” Nature. Published online June 29, 2022. doi: 10.1038/s41586-022-04902-y

Forsee joins EDF Store & Forcast on second life batteries

0

French battery manufacturer Forsee Power is cooperating with EDF Store & Forecast, a subsidiary of French energy group Électricité de France (EDF), to give a “second life” to batteries in electric vehicles.

Forsee Power will supply battery packs for heavy vehicles such as electric buses, and EDF Store & Forecast will integrate them into its storage solutions. Second-life batteries will be used, among other things, to power micro-grids or charging stations.

Forsee Power also wants to use stationary battery storage at its own sites. This allows the company to avoid overloading the grid and/or to be able to temporarily store PV electricity. A mobile battery storage application is planned this year for a grid operator wishing to replace diesel generators with such a solution.

“This partnership with EDF Store & Forecast is an important step for the commercialization of our second life battery systems. Designed for use in stationary applications, our high energy density battery packs dedicated to heavy transport will support the growth of the market for stationary mobile storage solutions necessary for the decarbonization of maintenance operations and the adoption of renewable energies that can be used at all times”, declares Vincent Gauthier, director of the Forsee Power Services activity.

This is not the first cooperation in this field for Forsee Power since the French company is also collaborating with the British company Connected Energy, which also builds stationary energy storage systems based on disused electric vehicle batteries (second life ). A first joint project with a volume of approximately 3.5 MWh is planned for the second half of 2023. A second much larger energy storage system of approximately 40 MWh is also expected to come into service in the United Kingdom from of the third quarter of 2024.

Forsee Power has an extraordinary diversity of businesses in the sustainable transportation sector, ranging from batteries for micromobility electric vehicles, to electric off-road vehicles, large public transport and utility vehicles, and batteries for the marine sector. The company claims to be the leading supplier of electric bus battery systems in Europe. Forsee not only provides batteries for pure electric vehicles, but also for hydrogen fuel cell electric vehicles for public transport, marine and commercial vehicles with fuel cell technology in partnership with Ballard.

Forsee Power already supplies a wide range of vehicles that require batteries (fuel cell vehicles also require batteries, just smaller ones). These vehicle sectors covered by Forsee are mainly focused on applications where operators manage fleets, i.e. more easily recoverable batteries for second life applications – this is optimal for the battery manufacturer enters the dynamic second-life battery market. This market is set to explode in the next few years as the batteries currently used in the growing electric vehicle market will all get a lucrative second life in other applications before being recycled.

forseepower.com

Going forward, 5G cellular units will be co-located with streetlights, city says | Policy

0

After months of pushback by a small but persistent group of Tulsans, the city is removing four 5G wireless hubs from the Walnut Creek neighborhood, it announced Wednesday.

Going forward, the city will make every effort to have small cell units installed on streetlights instead, she said in a prepared statement.

“After lengthy discussions between city officials, small cellular companies, neighborhood leaders and some members of the Tulsa City Council, we were able to produce a remedy in the Walnut Creek neighborhood that involved the removal of four small poles cellular while allowing the co-location of these small cells on new poles in existing street light pole locations in the area,” the statement read.

Shelli Landon, who led the effort to have the 5G poles removed, joined residents of Walnut Creek on Wednesday for a press conference celebrating the news. Walnut Creek is in the neighborhood of 85th Place and Harvard Avenue.

“Our main focus today was to thank the city officials, (Councillor) Jeannie (Cue), the mayor, the folks out there at stormwater, utilities, whoever ultimately made the decision to us finally listening collectively, the whole team working together,” Landon said. “Thank you.”

People also read…

Cue said she was grateful to Mayor GT Bynum and Streets and Stormwater Director Terry Ball for their efforts to address residents’ concerns.

“It just takes a team,” Cue said. “We can get things done by working together.”

But Landon stressed that the city’s action, while appreciated, is not enough.

“We also got together to tell them that now that we have 5G out of here, we don’t want a switcheroo if they’re just going to put it on streetlights that already exist, because 5G signals are dangerous” , says Landon.

Landon, who said she is a cancer survivor, worries about the potential health risks that 5G cells could pose and their potential to decrease property values.

Cue shares Landon’s concerns about the potential effect on property values, and she said she was frustrated that residents weren’t given advance notice from telecom companies before the poles were installed.

Landon said she wanted fiber optic technology to be used instead.

“Fiber has no adverse effects of radiation factors, and it doesn’t disrupt property value, and it’s a faster delivery technology for the internet,” she said. “We therefore ask everyone to upload this form on petition5g.org; fill it; write it down if you can.

According to the American Cancer Society, there is no solid evidence that radio frequency waves from cell phone towers cause cancer.

“However, this does not mean that RF waves from cell phone towers have proven to be absolutely safe,” the organization’s website states. “Most expert organizations agree that more research is needed to help clarify this, particularly for possible long-term effects.”

The city of Tulsa has limited authority over where telcos install 5G towers, but it issues permits before the devices are installed.

As of February, the city had authorized 350 small cell device locations, with 25 more on hold. At that time, AT&T, Verizon, Mobilitie and US Cellular had applied for permits to install poles.

The city has no plans to remove any other existing 5G poles. City officials say the plan moving forward is to co-locate 5G cells where streetlights already exist.

Councilman Phil Lakin visited the site of a 5G tower in his neighborhood on Wednesday and said he was troubled by the size of the poles and where they were installed.

“I know there are benefits to this new technology and there are federal and state laws largely regulating 5G service, but I have to say that very few people in Tulsa would want this pole standing in their front yard.” , did he declare. “It’s the size of a telephone pole and sits almost 8 feet from the sidewalk.

“I will continue to push the city and state to find ways to prevent new utilities like this from being added to above-ground neighborhoods.”

Mysterious viruses infecting the archaea of ​​Asgard discovered

0

Asgard archaea are globally distributed microorganisms related to eukaryotes – complex organisms including animals, plants, fungi, and amoebas. However, the viruses that infect these organisms were unknown until now. In new research, biologists have characterized six relatively large double-stranded DNA viruses that infect two groups of Asgard archaea: Lokiarchaeota and Helarchaeota. This discovery offers tantalizing clues to the origins of complex life and suggests new directions for exploring the hypothesis that viruses were essential for the evolution of complex life.

Model of Asgard virus infection mechanisms and protein similarity to other viruses: (a) Identified genes in Asgard viruses involved in infection (i), replication (ii), transcription (iii) and translation (iv); Asgard viruses are represented by differently colored hexagons, Asgard hosts by differently colored circles, and the host’s transcription machinery is labeled with ovals color-coded by function (see legend); (b) gene distribution (lower x-axis) among Asgard viruses (y-axis); filled circles indicate annotated orthologs, while open circles indicate that an ortholog has not been identified. Image credit: Rambo et al., doi: 10.1038/s41564-022-01150-8.

“Our study opens the door to a better resolution of the origin of eukaryotes and to understanding the role of viruses in the ecology and evolution of archaea in Asgard,” said Dr Ian Rambo, a researcher at the Department of marine sciences from the University of Texas at Austin.

“There is a hypothesis that viruses may have contributed to the emergence of complex cellular life.”

“We are referring to a very controversial hypothesis called viral eukaryogenesis. This suggests that in addition to bacteria and archaea, viruses may have contributed a genetic component to eukaryotic development.

“This latest finding doesn’t settle that debate, but it does offer some interesting clues.”

Archaea of ​​Asgard, which likely evolved over 2 billion years ago, have been found in deep sea sediments and hot springs around the world.

To identify them, scientists take their genetic material from the environment and then reconstitute their genomes.

In the new study, Dr. Rambo and his colleagues analyzed sediments associated with hydrothermal vents from Guaymas Basin2000 m water depth, Gulf of California.

They scanned the genomes of the archaea of ​​Asgard to look for repeating regions of DNA known as CRISPR chips, which contain small pieces of viral DNA that can be precisely matched to viruses that previously infected these microbes.

These DNA fingerprints allowed the team to identify six viral invaders that currently infect the archaea Asgard, Lokiarchaeota, and Helarchaeota.

Genomic analysis of these Asgard viruses revealed that they contain features of both prokaryotic and eukaryotic viruses.

“The most exciting thing is that these are completely new types of viruses, different from those we’ve seen before in archaea and eukaryotes, infecting our microbial relatives,” said researcher Dr Brett Baker. at the Department of Marine Science and the Department of Integrative Biology at the University of Texas at Austin.

“We are now beginning to understand the involvement and role that viruses might have had in the eukaryogenesis puzzle,” added Dr. Valerie De Anda, a researcher in the Department of Marine Science at the University of Texas at Austin.

The paper was published in the journal Natural microbiology.

_____

IM Rambo et al. 2022. Genomes of six viruses that infect Asgard archaea from deep sea sediments. Nat Microbiol 7, 953-961; doi: 10.1038/s41564-022-01150-8

RAIN RESEARCH GROUP – AI AND DEFENSE STARTUP LAUNCHES NEW REPORTS

0

ALEXANDRIAGo. , June 30, 2022 /PRNewswire/ — RAIN Research Group, an international research firm, has published expert research and analysis into the defense and artificial intelligence sector. Norine MacDonald QCFounding Chairman of the company: “We have launched reports that offer unprecedented insights to startups, venture capitalists, analysts and national security officials interested in AI and defense .”

Based at Virginiathe company’s advisory board includes retired senior officers.

The RAIN 500: Who’s Who of AI and Defense in the United States

The rain 500 maps, tracks, and analyzes the institutions and 500 people shaping the future of AI and defense in the United States. dr. Jorrit Kammingathe report’s lead author: “This is the first comprehensive report that maps individuals, institutions and the connections between them.”

The RAIN VC: a directory of venture capital and defense in the United States

The RAIN VC is the first comprehensive report on the involvement of venture capital in the US defense industry. George Howelllead author: “The report covers all critical emerging technology industries, highlighting the top 40 defense venture capital firms and the top 150 defense and dual-use companies backed by venture capital.”

The RAIN drone: high-altitude platforms and artificial intelligence

RAIN presents two series of reports providing in-depth analysis of the new frontier of defense in the stratosphere: High altitude platform systems (HAPS) and Long endurance at high altitude Systems (TAN). Analyst Rutger Veltman: ‘The high altitude segment is of crucial importance in the future battlefield. We map, track and assess platforms, technologies, investments, policies, military requirements and more. Analyst Larein Zhang: “Through our comprehensive data analysis, as well as trends and forecasts, we provide an entry point to the complex HAPS and HALE sectors.”

RAIN Ethics

The RAIN research group includes a dedicated ethics division covering the debate on AI in the defense sector. Rains 60 second videos and intros highlight the main issues. Jorrit KammingaDirector of RAIN+ Ethics: “The revolutionary impact of AI in defense compels a re-examination of the ethics of war.”

RAIN Data

Peter WilcoxDirector of RAIN Data: “Our data shows granular relationships that provide new insights into AI developments affecting the defense industry.”

Download the report summaries

The RAIN 500
The RAIN VC
HAPS
TAN

Please contact us using [email protected]
Or visit our website at: www.rainresearchgroup.ai

Follow RAIN on LinkedIn and Twitter

RAIN Research Group
[email protected]

SOURCE RAIN Research Group

Industry Trends, Share, Size and Research Report – Designer Women

0

According to IMARC Group’s latest report, titled “Immunity Enhancement Products Market: Global Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2021-2026”, the global immune enhancement products market Immunity is expected to show moderate growth over the period 2021-2026.

Immunity boosting products refer to a range of health consumables used to boost immunity. Some of the common product variants include probiotics, dietary supplements, prebiotics, and food and beverage products. These products are a rich source of several micro and macronutrients, fibers, minerals, enzymes, amino acids and vitamins. Immunity enhancing products have immunomodulatory properties, provide non-specific immune responses and help minimize nutritional deficiencies in the body. Apart from that, they are considered an essential part of preventive health care as their consumption helps the body to fight many infections and viruses.

As the novel coronavirus (COVID-19) crisis engulfs the world, we continuously monitor changes in markets, as well as consumer behaviors in the industry around the world and our estimates on the latest market trends and forecasts are made. after considering the impact of this pandemic.

Global Immunity Enhancement Products Market Trends:

Rising awareness of personal health and fitness along with increasing prevalence of chronic diseases due to hectic and sedentary lifestyles are mainly driving the growth of the immunity enhancing products market. With this in mind, the outbreak of the coronavirus disease (COVID-19) has led to a significant increase in demand for supplements and other immunity-boosting products to improve individual response against the virus, which is supporting growth. of the market. Additionally, increasing healthcare expenditures and the introduction of organic healthcare consumables and non-genetically modified organisms (GMOs) in the form of flavored gummies, pills and soft gels act as other growth inducing factors. .

Request Free Sample Report: https://www.imarcgroup.com/immunity-boosting-products-market/requestsample

2021-2026 Global Immunity Enhancement Products Market Analysis and Segmentation:

Competitive Landscape:

The competitive landscape of the market has been studied in the report along with the detailed profiles of key players operating in the market.

Associated British Foods Plc, Danone SA, Diamond Foods (Snyder’s-Lance Inc.), Dole Food Company, Fonterra group Cooperative Limited, Hines Nut Company, Nestle SA, Olam International and Pinnacle Foods (Conagra Brands Inc.).

The report has segmented the market based on region, type and distribution channel.

Breakdown by type:

Supplements
Beverages
Food
Nuts and seeds
Fruits and vegetables
Dairy products
Probiotics and prebiotics
Others

Breakdown by distribution channel:

convenience stores
Medical stores
Supermarkets and Hypermarkets
Online stores
Others

Breakdown by region:

North America: (United States, Canada)
Asia-Pacific: (China, Japan, India, South Korea, Australia, Indonesia, Others)
Europe: (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
Latin America: (Brazil, Mexico, Others)
Middle East and Africa

Ask before you buy – https://www.imarcgroup.com/request?type=report&id=2771&flag=F

If you want the latest primary and secondary data (2021-2026) with cost module, business strategy, distribution channel, etc. Click request a free sample report, the published report will be emailed to you in PDF format within 24-48 hours of receipt. full payment.

Main highlights of the report:

  • Market performance (2015-2020)
  • Market Outlook (2021-2026)
  • Porter’s Five Forces Analysis
  • Market drivers and success factors
  • SWOT analysis
  • Value chain
  • Complete mapping of the competitive landscape

If you need specific information that is not currently within the scope of the report, we can provide it to you as part of the customization.

Other reports:

https://www.einpresswire.com/article/564058754/oilfield-equipment-rental-market-2021-26-global-industry-trends-share-size-growth-opportunity-and-forecast
https://www.einnews.com/pr_news/564059508/fractional-flow-reserve-market-report-2021-industry-size-share-growth-trends-and-forecast-2026
https://www.einnews.com/pr_news/564060473/biochips-market-report-2021-2026-industry-trends-share-size-growth-opportunity-and-forecast
https://www.einnews.com/pr_news/564061855/faucet-market-report-2022-industry-share-size-trends-demand-and-future-scope-2027
https://www.einnews.com/pr_news/564063025/automotive-climate-control-system-market-research-report-2021-size-share-trends-and-forecast-to-2026

About Us

The IMARC Group is a leading market research firm providing management strategies and market research worldwide. We partner with clients across all industries and geographies to identify their most important opportunities, address their most critical challenges and transform their businesses.

IMARC’s information products include major business, scientific, economic and technological developments for business leaders in pharmaceutical, industrial and high-tech organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverages, travel and tourism, nanotechnology and new processing methods are at the top of the list. company expertise.

Contact us

30 N Gould St
St R
Sheridan, WY 82801
UNITED STATES
Email: [email protected]
Website: https://www.imarcgroup.com

Nigeria and Japan sign $2.78m bills of exchange on high-speed boat – The Sun Nigeria

0

By Steve Agbota

The The Federal Republic of Nigeria has signed an Exchange of Notes (E/N) with the Government of Japan for an economic and social development program involving the acquisition of high-speed vessels to strengthen coastal security services in Nigeria, with the Nigerian Maritime Administration and Safety Agency, (NIMASA), as an implementing partner.

Federal Minister of State for Budget and National Planning, Prince Clem Agba, signed on behalf of Nigeria, while Japan’s Ambassador Extraordinary and Plenipotentiary to Nigeria, Kazuyoshi Matsunaga, signed on behalf of the Japanese government, with NIMASA Managing Director Dr. Bashir Jamoh present.

Prince Agba noted that the purchase of the high-speed vessels worth $2.78 million would significantly improve the operations of the Deep Blue project. He commended the Japanese government for its interest and interventions in Nigeria for economic development. “This NIMASA Operations Enhancement Project will definitely strengthen the partnership between the Government of Japan and the Federal Republic of Nigeria.”

“Nigeria also appreciates the recent exchange of notes we signed for the emergency upgrade of electricity supply facilities in Abuja, and the role Japan has played in developing the national development master plan for energy designed to guide the government on the optimal energy mix and efficiency for Nigeria,” the minister said.

For his part, NIMASA Director General Dr. Bashir Jamoh assured the Japanese government that the Agency working with relevant stakeholders will ensure the sustainability of the recent success in the war against piracy in Nigerian waters and the Gulf. from Guinea. “This high-speed vessel is a welcome addition to our growing arsenal of rigs and assets to bolster coastal security service, not only in Nigeria but also in the Gulf of Guinea, as over 60% of maritime activity in the region pass through Nigerian waters.

“This ship will be integrated into the Deep Blue project which already has 2 special mission ships; 2 special mission aircraft; 3 special mission helicopters; 10 unmanned aerial systems and vehicles; 17 fast interceptor boats; 16 armored vehicles and the C4i center,” he said.

Ambassador Matsunaga Kazuyoshi noted that the project aims to support the measures adopted by the Nigerian government to address the threat of the blue economy, to prevent and suppress piracy, armed robbery and any other illegal acts against ships in Nigerian waters.

Single gene previously linked to the rare syndrome of epilepsy, autism and developmental disabilities

0

A single gene previously shown to be the driving force behind a rare syndrome linked to epilepsy, autism and developmental disabilities has been identified as central to the formation of healthy neurons.

Duke researchers say the gene, DDX3X, forms a cellular machine called helicase, whose job is to open the hairpins and dead ends of RNA so that its code can be read by the machinery of production of cell proteins. This gene is carried on the X chromosome, so females have two copies of the gene and males have only one.

“If you delete both copies of the gene in a female mouse, it results in massive microcephaly where brain size is dramatically reduced,” said Debra Silver, PhD, associate professor of molecular genetics and microbiology at Duke School of Medicine. . who led the research team. “But the deletion of a single copy probably more closely mimics what happens in human patients,” Silver said.

In other words, the defects caused by defective DDX3X are dose-dependent – ​​the syndrome can vary depending on how severe the helicase production affected by the mutations is. The results appear June 28 in the open-access journal eLife.

When DDX3X is altered by a mutation early in development, “you don’t get as many neurons over time because this gene is necessary for the production of neurons from progenitor cells,” Silver said. “And it also helps the progenitors divide properly.”

While it normally takes about 15 hours for a nerve precursor cell to divide, mutated DDX3X can make that process even longer, Silver said. “And what that means over time, if those neural precursors take too long to divide, you’re falling behind and the brain isn’t developing properly.”

In a previous study published by the team in March 2020, using genetic samples from 107 children with developmental disabilities from around the world, researchers found that half of DDX3X mutations completely disrupt the gene, but the other half only made it work worse.

DDX3X mutations are now thought to cause 1-3% of intellectual disabilities in women, but the mutations are almost always “de novo”, meaning they occurred spontaneously during some developmental phase. , rather than being inherited from parents.

The children in the previous study were almost all female, leading researchers to speculate that loss of DDX3X in males would be fatal, as they carry only one copy of the gene. But in this work, Silver’s team discovered that a companion gene carried by the male Y chromosome, DDX3Y, may perform part of the gene’s function.

To do this work, Silver’s lab, led by Mariah Hoye, developed a novel approach to profiling all newly made proteins from progenitor cells in the brain of a living animal, a technique that could lead to an important understanding of the protein synthesis in the brain, she said.

Some of the RNAs whose translation is reduced by damage to DDX3X also play a role in brain development, Silver said. “So that’s helping us uncover what I would call an RNA network that depends on this gene for translation. And that’s starting to give us clues as to how, at the molecular level, DDX3X can disrupt brain development. “

DDX3X has also been implicated in neurodegeneration, the progression of certain cancers, and innate immune responses. Silver said understanding the cellular processes and molecular targets of DDX3X in the developing brain could help shed light on the basis of many disorders.

“We know of over 800 families worldwide who have been diagnosed with DDX3X syndrome,” Silver said. “It’s definitely an important gene, with probably hundreds of mutations. There really is a lot to learn about how DDX3X controls brain development.”

“We hope this research can improve understanding of the basis of DDX3X syndrome and associated disorders,” Silver said. “In the longer term, this may contribute to the development of therapies.”

Funding for this study was received from the DDX3X Foundation, the Holland-Trice Foundation, the Pew Charitable Trusts and the National Institutes of Health (R21-ND104514, R01-NS120667, F32-NS112566)

Source of the story:

Material provided by duke university. Original written by Karl Leif Bates. Note: Content may be edited for style and length.

Researchers develop a new method based on magneto-active polymers to study cellular behavior

0

Scientists from 4D-BIOMAP, an ERC research project at Carlos III University of Madrid (UC3M), have developed a new experimental method, based on magneto-active polymers, to study cell behavior.

These compounds, consisting of a polymeric matrix (for example, an elastomer) containing magnetic particles (for example, iron), react mechanically by modifying their shape and their rigidity. This system could be used to study complex scenarios (such as brain trauma, wound healing, etc.) or to influence cellular responses, guiding their functions.

We succeeded in reproducing the local deformations that occur in the brain when subjected to a shock. This would make it possible to reproduce these cases in the laboratory, analyzing what happens to cells and how they are damaged in real time. In addition, we validated the system by demonstrating its ability to transmit forces to cells and to act on them..”


Daniel García González, Researcher in charge of 4D-BIOMAP, Department of Continuum Mechanics and Structural Analysis, Universidad Carlos III de Madrid – Officina de Informacion Cientifica

The idea of ​​this project is to be able to carry out studies reproducing complex biological processes thanks to a new virtually assisted experimental system, which allows non-invasive and real-time control of the mechanical environment. Cells and biological tissues are continuously subjected to mechanical stresses from their surrounding substrate. The analysis and control of the forces that influence their behavior would therefore be an important step for the “mechanobiology” community.

The system proposed by 4D-BIOMAP is based on the use of extremely soft magneto-active polymers which mimic the rigidity of biological materials. Thanks to their qualities, magneto-active materials allow researchers to carry out unlimited monitoring of biological substrates, since the mechanical modifications applied during experimentation can be reversible.

“Supported by the computer model, we used all this basic science to design an intelligent actuation system which, coupled with a microscope developed within the ERC, allows us to visualize the cellular response in situ. We have thus consolidated a global framework vision to stimulate cellular systems with magneto-active smart materials”, explains Daniel García González. This proposed framework paves the way for understanding the complex “mechanobiological” processes that occur during states of dynamic deformation, such as traumatic brain injury, pathological skin scarring, or fibrotic remodeling of the heart during heart infarction. myocardium, for example.

Tapping into the Million-Year-Old Power Source Beneath Our Feet | MIT News

0

There’s an abandoned coal-fired power plant in upstate New York that most people consider a useless relic. But Paul Woskov of MIT sees things differently.

Woskov, a research engineer at MIT’s Plasma Science and Fusion Center, notes that the plant’s power turbine is still intact and the transmission lines are still connected to the grid. Using an approach he’s been working on for 14 years, he hopes it’ll be back online, completely carbon-free, within a decade.

In fact, Quaise Energy, the company marketing Woskov’s work, believes that if it can retrofit a power plant, the same process will work on virtually every coal and gas-fired power plant in the world.

Quaise hopes to achieve these lofty goals by tapping into the power source beneath our feet. The company plans to vaporize enough rock to create the world’s deepest holes and harvest geothermal energy on a scale that could satisfy human energy consumption for millions of years. They haven’t solved all the related engineering challenges yet, but the Quaise founders have set an ambitious timeline to start harvesting energy from a pilot well by 2026.

The plan would be easier to dismiss as unrealistic if it were based on new and unproven technology. But Quaise’s drilling systems revolve around a microwave-emitting device called a gyrotron that’s been used in research and manufacturing for decades.

“That will happen quickly once we resolve the immediate engineering issues of transmitting a clean beam and operating it at high energy density without failure,” says Woskov, who is not officially affiliated. in Quaise but serves as an adviser. “It will go fast because the underlying technology, gyrotrons, is commercially available. You can place an order with a company and have a system delivered to you immediately. Admittedly, these beam sources have never been used 24/7, but they are designed to be operational for long periods of time. In five or six years, I think we will have a plant running if we solve these engineering problems. I am very optimistic.

Woskov and many other researchers have been using gyrotrons to heat materials in nuclear fusion experiments for decades. It was not until 2008, however, after the publication of the MIT Energy Initiative (MITEI) a request for proposals on new geothermal drilling technologies, that Woskov thought of using gyrotrons for a new application.

“[Gyrotrons] haven’t been well publicized in the general science community, but those of us in fusion research have come to realize that these are very powerful beam sources – like lasers, but in a range of frequencies different,” says Woskov. “I thought, why not direct these high power beams, instead of into the fusion plasma, into the rock and vaporize the hole?”

While power from other renewable energy sources has exploded in recent decades, geothermal power has plateaued, primarily because geothermal power plants only exist in places where natural conditions allow extraction. energy at relatively shallow depths of up to 400 feet below the Earth’s surface. At a certain point, conventional drilling becomes impractical because the deeper crust is both hotter and harder, which wears down mechanical drill bits.

Woskov’s idea of ​​using gyrotron beams to vaporize rock sent him on a research journey that never really ended. With funding from MITEI, he began performing tests, quickly filling his office with small rock formations he had projected with millimeter waves from a small gyrotron at MIT’s Plasma Science and Fusion Center.

Around 2018, the Woskov rocks caught the eye of Carlos Araque ’01, SM ’02, who had spent his career in the oil and gas industry and was at the time technical director of the MIT investment fund, TheEngine.

That year, Araque and Matt Houde, who were working with geothermal company AltaRock Energy, founded Quaise. Quaise soon received a grant from the Department of Energy to expand Woskov’s experiments using a larger gyrotron.

With the larger machine, the team hopes to vaporize a hole 10 times deeper than Woskov’s lab experiments. This should be accomplished by the end of this year. After that, the team will vaporize a hole 10 times deeper than the previous one – what Houde calls a 100 to 1 hole.

“It’s something [the DOE] is particularly interested, as they want to address the challenges of material removal over these longer lengths – in other words, can we show that we completely eliminate rock fumes? Houde explains. “We believe the 100-to-1 test also gives us the confidence to go out and mobilize a prototype gyrotron drill into the field for initial field demonstrations.”

Testing on the 100-to-1 hole is expected to be completed within the next year. Quaise also hopes to start vaporizing rock in field trials late next year. The short timeline reflects the progress Woskov has already made in his lab.

Although more engineering research is needed, the team expects to be able to drill and operate these geothermal wells safely. “We believe, through Paul’s work at MIT over the past decade, that most, if not all, of the fundamental questions in physics have been answered and resolved,” Houde says. “These are really engineering challenges that we have to meet, which doesn’t mean they’re easy to solve, but we’re not working against the laws of physics, to which there are no answers. It’s more about overcoming some of the more technical and cost considerations to make it work at scale.

The company plans to start harvesting energy from pilot geothermal wells that reach rock temperatures of up to 500°C by 2026. From there, the team hopes to start repurposing the plants coal and natural gas using his system.

“We believe that if we can dig down to 20 kilometers, we can access these extremely hot temperatures in over 90% of places around the world,” Houde said.

Quaise’s work with the DOE addresses what he sees as the biggest remaining questions about drilling holes of unprecedented depth and pressure, such as material removal and determining the best casing for keep the hole stable and open. For this final well stability issue, Houde believes additional computer modeling is needed and expects to complete this modeling by the end of 2024.

By drilling the holes in existing power plants, Quaise will be able to move faster than if it had to obtain permits to build new power plants and transmission lines. And by making their millimeter wave drilling equipment compatible with the existing global fleet of drilling rigs, it will also allow the company to tap into the global oil and gas industry workforce.

“At these high temperatures [we’re accessing], we produce steam that is very close to, if not better than, the temperature at which today’s coal and gas-fired power plants operate,” says Houde. “So we can go into existing power plants and say, ‘We can replace 95% to 100% of your coal consumption by developing a geothermal field and producing steam from the Earth at the same temperature as you burn coal to run your turbine, directly replacing carbon emissions.

Transforming the world’s energy systems in such a short time is something the Founders consider essential to help avoid the most catastrophic global warming scenarios.

“There have been huge gains in renewable energy over the past decade, but the big picture today is that we are not moving fast enough to meet the milestones we need to limit the worst impacts. of climate change,” says Houde. “[Deep geothermal] is an energy resource that can scale anywhere and has the ability to tap into a large energy industry workforce to easily retrain their skills for a completely carbon-free energy source.

New antibody analysis predicts serious outcomes for COVID-19

0

Most research on SARS-CoV-2 virus immunity and COVID-19 vaccine development has focused on antibody responses to the spike protein and other viral surface proteins. But antibodies that recognize internal proteins of the virus could also be important for immunity and disease outcomes, according to a new study led by researchers from the University of Pittsburgh, the Georgia Institute of Technology and the University Emory.

In the study, online now in Cell reports, the team performed the most comprehensive analysis to date of COVID-19 antibodies in a small group of patients with severe disease. They found that antibody profiles of internal viral proteins, including those conserved across coronaviruses, predicted which patients survived or died just as well as corresponding profiles for surface proteins, suggesting that targeting other parts of the virus beyond the spike protein could be important for improving COVID -19 vaccines and therapies.

“The novel aspect of this study is that we did a very thorough profiling of SARS-CoV-2 antibodies and looked at many different aspects of these antibodies,” said co-lead author Jishnu Das, Ph.D. , assistant professor of immunology and computational and systems biology at Pitt’s School of Medicine. “The whole world has focused on the spike protein and the receptor binding domain, but this study is the first concrete evidence that specific antibodies against internal proteins are also positively associated with survival in severe COVID-19. .

When the immune system encounters a virus, it produces antibodies that help neutralize and eliminate the infection. Each antibody specifically recognizes a single antigen, often a viral protein. Most research on COVID-19 immunity has focused on the spike and other surface proteins, which form the outer envelope of the virus, but beyond these so-called “canonical antigens”, the SARS-CoV-2 has about 25 other internal proteins.

To see if immune responses to these non-canonical antigens could predict survival outcomes in patients with severe COVID-19, Das teamed up with co-lead authors Aniruddh Sarkar, Ph.D., assistant professor at the Wallace H Coulter Department of Biomedical Engineering at Georgia Tech and Emory University, and Harinder Singh, Ph.D., professor of immunology and director of the Center for Systems Immunology at Pitt.

The researchers analyzed blood samples that had been taken from 21 patients hospitalized with severe COVID-19 in 2020 – before the vaccines were approved. Seven of these patients died of the disease and the other 14 survived. Using a microscale antibody profiling platform developed by Sarkar, the team extensively analyzed antibodies to three canonical antigens and four non-canonical antigens.

According to Sarkar, the platform analyzes three key characteristics of antibodies. One is the specificity of the antigen, or what the antibody binds to. The second is effector function, which relates to the role of the antibody in the immune response. The third feature is glycosylation, or the addition of carbohydrate molecules to the antibody, which dramatically impacts antibody function.

“By profiling these three characteristics simultaneously, we can get a much deeper understanding of a given antibody than just looking at antibody titers,” Sarkar explained.

The researchers found that no single antibody characteristic could differentiate patient survival outcomes. But when they analyzed the overall antibody profiles – canonical or non-canonical – they noticed clear differences between survivors and non-survivors.

“We were surprised to find such compelling evidence that antibodies against canonical and non-canonical antigens were equally predictive of survival outcomes,” Singh said. “Our results suggest that non-canonical antibodies may play a role in recovery from severe disease, although further research is needed to prove causation and identify mechanisms.”

Most COVID-19 vaccines and monoclonal antibodies — artificial antibodies used to treat COVID-19 — have become less effective with the emergence of delta and omicron variants because mutations in the spike help the virus avoid detection. Far fewer mutations have accumulated in the virus’s internal proteins, Singh says, suggesting that increasing vaccines or therapies to target these non-canonical antigens could elicit more robust immunity against emerging variants of concern.

When the team limited their analysis to antibodies against noncanonical antigens conserved across coronaviruses — including those that cause the common cold and other respiratory infections — in COVID-19 patients, they could still distinguish between survivors and non-survivors. These antibodies were also found in nine pre-pandemic healthy control subjects, suggesting that exposure to coronaviruses in addition to SARS-CoV-2 may induce antibody responses linked to favorable outcomes in severe cases of COVID- 19.

According to Das, these findings could inform the development of pan-coronavirus vaccines.

In ongoing work, the team is using its platform to look at antibodies in vaccinated people with breakthrough infections compared to unvaccinated people. They also want to understand whether different antibodies play different roles in protecting against COVID-19 over time.

They also plan to expand the platform to understand antibodies in other settings, including organ transplant rejection and other infectious diseases.

Other contributing authors to this study were co-first authors Sai Preetham Peddireddy, Georgia Institute of Technology, and Syed A. Rahman, Ph.D., Pitt, and Anthony R. Cillo, Ph.D. ., Godhev Manakkat Vijay, Ph.D., Ashwin Somasundaram, MD, Creg J. Workman, Ph.D., William Bain, MD, Bryan J. McVerry, MD, Barbara Methe, Ph.D., Janet S. Lee , MD , Prabir Ray, Ph.D., Anuradha Ray, Ph.D., Tullia C. Bruno, Ph.D., Dario AA Vignali, Ph.D., Georgios D. Kitsios, MD, Ph.D., and Alison Morris, MD, all of Pitt.

This research was supported by the National Institutes of Health (DP2AI164325 and U01AI141990) and the UPMC Immune Transplant and Therapy Center.

New approach cuts EV battery testing time by 75%

0

Testing the longevity of new electric vehicle battery designs could be four times faster with a streamlined approach, researchers at the University of Michigan have shown.

Their optimization framework could significantly reduce the cost of evaluating the performance of battery configurations over the long term.

“The goal is to design a better battery, and traditionally the industry has tried to do that using trial and error testing,” said Wei Lu, professor of mechanical engineering at UM and chief from the research team behind the framework, published in Patterns- Cell Press. “It takes so long to assess.”

As electric vehicle (EV) battery makers grapple with range anxiety and concerns about charging availability, the optimization system developed by Lu’s team could reduce approximately 75% the simulation and physical test time of new and better batteries. This speed could give a major boost to battery developers looking for the right mix of materials and configurations to ensure consumers always have enough capacity to reach their destinations.

Parameters involved in battery design include everything from the materials used to the thickness of the electrodes to the size of the particles in the electrode and more. Testing each configuration typically means several months of fully charging and then fully discharging (or cycling the battery) 1,000 times to mimic a decade of use. It is extremely time-consuming to repeat this test through the large number of possible battery models to discover the best ones.

“Our approach not only reduces test time, it automatically generates better designs,” said Lu. end. This is not a simple task as a battery configuration that performs poorly in the first cycles may perform well later on, or vice versa.

“We systematically formulated the early termination process and allowed the system to learn from accumulated data to produce promising new configurations.”

To achieve a dramatic reduction in time and cost, UM engineers leveraged the latest advances in machine learning to create a system that knows both when to stop and how to improve over time.

The framework stops cycle tests that do not start promisingly in order to save resources by using the mathematical techniques known as the asynchronous successive halving and hyperband algorithm. During this time, it takes data from previous tests and suggests promising new sets of parameters to study using Tree of Parzen estimators.

In addition to cutting out tests that lack promise, a key time-saving element in the UM system is the way it generates multiple battery configurations to test at the same time, known as asynchronous parallelization. If a configuration ends the test or is rejected, the algorithm immediately calculates a new configuration to test without having to wait for the results of the other tests.

UM’s framework is effective at testing designs for all types of batteries, from those used for decades to power internal combustion automobiles, to the smaller products that power our watches and cell phones. But EV batteries may represent the technology’s most urgent use.

“This framework can be tuned to be more efficient when a performance prediction model is incorporated,” said Changyu Deng, a UM doctoral student in mechanical engineering and first author of the paper. “We expect this work to inspire improved methods that lead us to optimal batteries to make better electric vehicles and other life-enhancing devices.”

A recent survey conducted by Mobility Consumer Index showed that 52% of consumers are now considering an electric vehicle for their next vehicle purchase. Despite the evolution of mentalities, concerns remain about the autonomy of vehicles (battery capacity) and the number of charging stations available to drivers.

Battery performance therefore plays a central role in making electric vehicles available to the masses to offset the impacts of climate change.

“By dramatically reducing test time, we hope our system can help accelerate the development of better batteries, accelerate the adoption or certification of batteries for various applications, and accelerate the quantification of model parameters for battery management systems. battery,” Lu said.

The research was funded by LG Energy Solution.

Hologram Unveils Improved IoT Dashboard Analytics for Fleet Management

0

Hologram, a global cellular platform for Internet of Things (IoT) connectivity, unveiled its enhanced IoT dashboard analytics, the first in the industry to provide teams with both at-a-glance views of fleet health data and device usage and tools to take real-time action.

In industries from transportation and logistics to healthcare and agriculture, businesses have quickly adopted IoT technology, but lack the transparency and control to proactively manage costs, time and Shutdown and Security Issues. Now, with the addition of dashboard analytics on the homepage, fleet managers have a quick and easy way to keep tabs on their fleets and take action.

While Hologram provides Global IoT SIM cards that allow IoT devices to securely access a transparent global cellular network through its Hologram Hyper platform, the Hologram IoT Dashboard provides the information needed to manage IoT fleets.

The new dashboard homepage offers a clear and intuitive 360° visualization of IoT operations, serving as an instant check on the status of the fleet. Automatically generated alerts and usage trend information allow fleet managers and non-technical users to find cost savings and catch device anomalies before they become issues, causing downtime and disturbances.

In addition to device health and location information metrics, fleet managers have the ability to reduce expenses and manage total cost of ownership, right from the dashboard home page. Beyond the home page, the Hologram IoT dashboard gives users unique levels of control, including tools to change data limits or even change device-level connectivity plans, whether managing ten or ten thousand devices.are.

Mike Georgoff, Product Manager for Hologram
Not all providers show customers where they are spending too much on connectivity. By setting new standards of transparency and control, Hologram drives the industry forward and helps customers direct the same resources to launching new, larger IoT fleets. And this is just the first phase of our investment and commitment to creating the best analytics to optimize IoT device performance on multiple fronts – cost, availability, fraud mitigation.

Indian scientists study long-term memory of covid-19 vaccination

0

NEW DELHI : Scientists at the Department of Biotechnology (DBT) are studying the long-term memory of covid-19 vaccination in the human body, including the quality and durability of bites.

The research results will impact future vaccine dosing strategies, including for booster doses.

DBT Secretary Rajesh Gokhale said: “Given the widespread vaccination against covid-19 in the country, the study aims to understand the long-term immune responses of the population. Memory studies are relatively complex studies unlike antibody studies and involve cell therapies that require isolating cells, tracking cells, antigens, and then examining the cells, which is called the cellular response. These require standardization of assays, virus isolation, and examination of the infected and uninfected population. Response of one vaccine versus another vaccine.”

This study should also help the government design public health responses to future pandemics and viruses.

“We need to understand the long-term importance of our vaccination. Before the covid-19 vaccination, all the vaccines we took were studied for 4-5 years and then decided. Therefore, we need to do a good study about it to know the long term memory of vaccination in our body. It is necessary to know if there is superinfection; So how does it work ? How good is the memory and how good is the quality and durability? We are taking vaccination data for this and several labs in the Department of Biotechnology are conducting the study,” Gokhale said.

India’s covid-19 vaccination coverage has exceeded 1.97 billion doses.

However, only 7% of 18-60 year olds and 40% of over 60s have received the booster shot so far.

“Never before in this world has such a large amount of vaccine been given in such a short time. So it’s a fantastic way to study how to assess the immune response occurring in the population. And this study can provide data for several other viruses and vaccination strategies. This has very big implications in terms of understanding vaccination than what is being done right now,” Gokhale said.

Speaking about the recent increase in covid-19 cases, the scientist said: “At the moment no new variants are coming and small recombinant variants are also very few. All variants have a very similar pattern.”

India recorded 11,739 new cases and 25 deaths in the past 24 hours.

The number of active cases soared to more than 92,576, bringing the total number of cases to 43 million and deaths to 524,999, the government said. Unofficial estimates are much higher.

Asked about the reasons for the increase, the DBT chief said: “These are sporadic events and they keep happening. Because then only endemicity will occur. Endemicity will occur when you have a very robust T-cell response in the nasal airways.”

“The nasal airway response is slowly growing in our country and continues to do so. He will eventually take the flu pattern. People should continue to wear masks and follow covid-19 appropriate behavior.”

To subscribe to Mint Bulletins

* Enter a valid email

* Thank you for subscribing to our newsletter.

Carbon Nanomaterials Market Research Report, Market Growth Prospects, Company Profiles, Future Demand, Regional Analysis with Business Share, Opportunities and Forecast 2022- – Instant Interview

0

Global “Carbon Nanomaterials Market” report helps determine the shortages and problems faced by dominant or new companies. It also provides insight into the implied impact of being COVID-19 on the request script. The application report also includes all the essential profitability, tax and social elements applicable to the application and provides the actors with the data necessary to form an informed opinion. The Carbon Nanomaterials Market report is a combination of actual information, quantitative and qualitative assessments delivered by the application judges, and contributions from diligent players and experts across the value chain . This demand report also examines the impact of qualitative demand factors on the market land and coins.

Nanodiamonds (ND), also called detonation diamonds (DND) or ultradisperse diamonds (UDD), are relatively easy and inexpensive to produce, and have been developed on a large scale.
This report contains Carbon Nano Materials market size and forecast globally, including the following market insights:
Global Carbon Nanomaterials Market Revenue, 2017-2022, 2023-2028, (Million USD)
Global Carbon Nanomaterials Market Sales, 2017-2022, 2023-2028, (K MT)
Top five global carbon nanomaterials companies in 2021 (%)
Global Carbon Nanomaterials Market was valued at Million in 2021 and is projected to reach Million US$ by 2028, at a CAGR of % during the forecast period.

Get sample PDF report @

https://trouve360reports.com/carbon-nano-materials-market-28348/?ff_landing=3&form=request-sample

Key Manufacturers of the Carbon Nanomaterials Market in 2022-2028:

  • Nano-C
  • Frontier Carbon Corporation
  • Solenne B.V.
  • MTR
  • BuckyUSA
  • EMFUTUR Technologies
  • MER Assets
  • OCSiAl
  • Hanwa
  • Raymor
  • Thomas Swan
  • Timesnano
  • Meijo Nano Carbon Co.Ltd.
  • Zeon Nano Technology Co. Ltd.
  • NeoTech product
  • American Nanomaterials Research, Inc.
  • XiamenFunano
  • CCOC
  • Suzhou Dade

Percentages of the global carbon nanomaterials market segment, by type2022 (%)

  • fullerene
  • graphene
  • Carbon nanotubes
  • Others

Percentages of the global carbon nanomaterials market segment, per app2022 (%)

  • Beauty products
  • Pharmaceutical
  • Semiconductor and electronics
  • Renewable energy
  • Others

If you have any special requirements for this report, please let us know and we can provide you with a customized report.

Exploring the size of the global demand for carbon nanomaterials 2022-2028 includes insights into demand dynamics, which parts of the demand are growing, who are the major players, and what are their demand strategies and their share in attendance. The growth in demand is largely explained by the vital factors described in this Carbon Nanomaterials Market report. The overall demand in terms of profit and size is going to be enormous.

Contents:

1 Introduction to research and analysis reports

2 Global Global Carbon Nanomaterials Market Size

3 Business landscape

4 curiosities per product

5 curiosities per application

6 curiosities per region

7 manufacturer and brand profiles

8 Global Carbon Nanomaterials Production Capacity, Analysis

9 Key Market Trends, Opportunities, Drivers and Restraints

10 Carbon Nanomaterials Supply Chain Analysis

11 Conclusion

12 Appendix

Get the Carbon Nanomaterials Market Report Price $3250 for a 114-page single-user license copy.

Inquire for a copy of the Carbon Nanomaterials Market Business License @

https://find360reports.com/carbon-nano-materials-market-28348/?ff_landing=6&form=corporate-license

About Find 360 reports:

The growth of your organization largely depends on your grip on your market. An essential part of it is market research. With end-to-end industry reports that cover a plethora of factors, your search ends here at Find360reports.

Contact us

Email us: [email protected]

Call us: +1 (415) 655-1709

Website: https://find360reports.com/




‘Greater ability to evade immunity’: warning as cases of Omicron subvariants rise in eastern states

0

An Omicron subvariant of COVID0-19 that can evade vaccine immunity is on the rise in Victoria, with health officials warning it is set to be the state’s main strain in line with the spread of the virus in NSW and Queensland.

Traces of the BA.4/BA.5 strain in Victoria’s underground and regional sewage “have increased significantly in recent weeks, indicating increasing transmission of this sub-lineage in the community”, the director of Victoria’s health, Brett Sutton, in a statement. .

Mr Sutton said the BA.4/BA.5 sublineage – first identified in catchments in April – accounted for 17% of Victorian infections and is expected in coming weeks to surpass BA.2 to become the dominant strain of the state.

Watch the latest news on Channel 7 or stream for free on 7plus >>

He said the stump’s lifting figures in Victoria followed similar patterns in New South Wales and Queensland.

“The Department of Health anticipates that the prevalence of BA.4/BA.5 in Victoria is likely to lead to an increase in cases, including re-infections and hospital admissions,” he said.

“This is because the strain has a greater ability than BA.2 to evade immunity provided by vaccination and prior COVID-19 infection.”

There was no evidence at this point that the subvariant causes more severe illness, but authorities were “monitoring the situation closely.”

Medical experts this week renewed calls for people to get their boosters following rising infections and hospitalizations as new subvariants emerge over the winter.

On Saturday, more than 28,000 new cases and 56 deaths were recorded across the country during the last reporting period. There were nearly 225,000 active cases across the country, with 3,046 hospitalized patients.

As the number of cases rises, doctors have urged people with symptoms to stay home and get tested, especially following the relaxation of vaccination and mask mandates in some parts of the country.

Several states have begun to lift restrictions, including allowing unvaccinated school personnel to return to work, lifting bans on unvaccinated visitors to nursing homes or easing mask requirements at airports.

“We’ve seen too many people with symptoms walking around the community who may have had a negative (rapid antigen test) saying, ‘Oh, that’s not COVID, that’s not the flu. I’m okay with being with people,” Australian Medical Association Queensland president Maria Boultan said on Saturday.

Can F1 get back on its heavyweight path?

0

I once read that airplanes are like people, they get bigger and bigger over time. And the same could be said of racing cars.

This year’s Formula 1 cars are the heaviest ever at 798kg, which is a big increase from when I raced in F1 12 years ago. At the time, the Virgin VR-01 weighed 620 kg with the pilot and even lighter before that. Now, several teams are still working to achieve this minimum weight limit. This trend has everything to do with the way technical regulations have been written by motorsport’s governing body.

MORE: The overlooked flaws of the 2022 F1 cars that Baku will exhibit

It’s not a natural route to go bigger and heavier like F1 has. If the choice was left to the F1 teams, I’m sure they would go for a lighter car with the most powerful engines available, unlike what they have now. The lighter the car, the better, for many reasons.

To explain this, first remember that weight and mass are not the same. While mass is the sum of the atoms that make up an entity, or its inertia, which remains the same regardless of the force acting on it, weight is the product of the gravitational force acting on a mass. Why is this important?

Common sense tends to think that a vehicle mass will act the most on the car in linear acceleration, the heavier the car, the slower it accelerates. But in fact, at high g, the turns are where the mass really kicks in: a high-speed 4G turn will have four times the inertia of its normal vertical force.

In a nutshell, the more g-force a race car can generate in a turn, the more mass has a negative effect. Of course, this is oversimplified because the center of gravity, weight distribution and other factors must also be taken into consideration.

Another extremely negative effect of a heavier car is an accident. The total energy of the car to be dissipated is a function of the mass and the square of the speed. The heavier the car, the more serious the accident.

Today’s F1 cars are easily the heaviest ever

Photo by: Andy Hone / Motorsport Images

The effect of weight is most clearly demonstrated by the difference in lap times between qualifying and the opening laps of a fully fueled race, when the same car is several seconds per lap slower. As soon as you have less weight, the car turns better, accelerates better and brakes better. He comes to life. The difference for the driver is very clear.

If you have understeer, it only increases with more weight. It’s the same with oversteer. When you add weight, it’s always a negative thing. This is why you want the car to be as light as possible and why teams design their cars to be under the minimum weight limit so they can position the ballast most strategically.

This principle does not only apply to F1, weight is important in all categories. I remember Alex Wurz and I put a lot of pressure on the Automobile Club de l’Ouest to incorporate driver weight into the minimum weight of an LMP1 car, so that from 2015, any team whose average weight was less than 80 kg had to carry ballast.

Base LMP1 weight at the time was 870kg without driver or fuel, and by having a driver 20kg lighter you could go a second faster per lap at Le Mans – sometimes much more than balance performance between the cars or the talent of the driver himself. Getting very light riders was a huge plus for any sports car race.

We would have to change the whole philosophy of F1 to have performance through lightness, because an important factor in the increase in weight of F1 is the complexity of the hybrid engines.

Design legend Adrian Newey said we should aim to get cars as light as possible and not the other way around, and I agree with him. I think F1 should be the pinnacle of the most capable vehicles on the planet. They must be extreme and the technical rules must facilitate certain advantages to seek optimal lightness.

In the past, without sophisticated simulation tools and production methods or even safety rules, F1 designers focusing on it often had parts reliability issues, which led to accidents. But technology has improved to such an extent that we can absolutely reconcile having light cars without compromising safety.

In the Colin Chapman days, they had to build the part, go to the track to see if it broke, then modify it and start over. We now have sophisticated modeling and testing tools so you can ensure it has equivalent strength properties and the required safety. This is also why the cars are more reliable and suspension failures are rarely seen, even if they are made from lightweight materials, because the technology has advanced so much.

We shouldn’t just accept that cars have to get heavier as technology evolves. We have a very prominent example of this in the new Formula E Gen3 car, where the FIA ​​has done a fantastic job of making it smaller (70mm width, 160mm length) and 80kg lighter than the Gen1. It would have been easy to make the car heavier with more power as is the general trend with electric cars so I was positively surprised and happy with the decision to reverse that with Gen3 and push the durability in real and measurable terms.

The Formula E Gen3 car is smaller and lighter than its predecessors - showing that the trend of increased weight can be reversed

The Formula E Gen3 car is smaller and lighter than its predecessors – showing that the trend of increased weight can be reversed

Photo by: NIO Formula E Team

It shows that changing course is possible, but you need to create the right environment and the right rules to make it work. The question with F1 is what would a lightweight formula look like and be achievable?

We would have to change the whole philosophy of F1 to have performance through lightness, because an important factor in the increase in weight of F1 is the complexity of the hybrid engines. And clearly, it wouldn’t be cheap to make these extreme materials, so F1 would have to decide where the most value falls within its cost cap. But going a light route would surely have a greater benefit for the whole world than the F1 hybrids used today.

There isn’t a single component today in an F1 car that you’ll see in a Toyota Corolla or similar, and it’s no surprise that the MGU-H has been dropped for the new 2026 regulations. was a flaw since the inception of the rules to have such a complex powertrain to pursue efficiency, as it would never have reached normal road cars with hybrid technologies.

MORE: Explaining key aspects of Porsche and Audi’s planned F1 entries

For example, the reason airplanes aren’t electric or even hybrid today is that the extra weight of batteries doesn’t make sense to fly a long flight for the energy benefit. And I believe that if an F1 car can go as fast or faster without the heavy hybrid than it would using the hybrid to harvest and deploy power, then the idea of ​​having the hybrid has no sense.

It wouldn’t be popular with major stakeholders who have invested heavily in hybrid engines, but for me motorsport should have a very clear definition of the purpose of the best racing series so they don’t overlap. F1 should focus on maximum performance without compromise, Formula E should focus on efficiency and other series like the World Endurance Championship on road-related technologies.

It would be in my opinion much more dramatic and much more towards the right mentality of what F1 should be. Also, for real sustainability gains, having a lighter car and equipment would mean a lot less emissions from logistics, for example.

If there is no clearly marketed sustainability angle for F1, then it will be less attractive for sponsors and car manufacturers to be associated with it. Obviously, giving up durability to build the most exotic cars ever isn’t realistic. But there are arguments to argue that a renewed interest in lighter cars would meet sustainability criteria and would still be a test bed for use in road cars – if F1 was willing that it happen.

Reducing the weight would have additional advantages in logistics

Reducing the weight would have additional advantages in logistics

Photo by: Mark Sutton / Motorsport Images

Using lighter cars means fewer parts produced and less energy used to make those parts. A lighter car would require less fuel and it is also much easier to ship it around the world. Even if the actual car doesn’t matter as much, it would send the right message.

With Europe banning the sale of combustion cars by 2035, there is clear pressure to focus on more efficient hybrid powertrains if F1 is to remain relevant in the automotive market. But this is not necessarily necessary, because it is already not at all relevant for commercial cars.

Perhaps F1 should focus on the extreme technology development path that may be relevant to aerospace, lightweight construction or just pure extreme vehicles that will use the best technology for that purpose. What the future brings will be very interesting.

Would the search for lightweight technology be more relevant for the road than today's complex hybrid engines?

Would the search for lightweight technology be more relevant for the road than today’s complex hybrid engines?

Photo by: Giorgio Piola

Can certain food combinations make vitiligo worse? An expert busts some common myths

0

Vitiligo, also known as Leucoderma (white skin) or white leprosy, is an autoimmune disease in which the body immune system attacks healthy pigment cells called melanocytes, eventually affecting the whole body.

“The condition is characterized by white patches on the skin that appear as a result of the loss of melanocytes in the skin. These cells are responsible for producing skin pigment melanin, which gives your skin its color. When the melanocytes die, white spots are formed. Although Vitiligo is often considered to be one of the most common skin conditions, it is essential to dispel some popular misconceptions about it,” said Dr Rohit Batra, Dermatologist and Vitiligo Expert at Sir Ganga Hospital New Delhi rams.

So, without further ado, let’s begin the debunking process.

Myth 1: People with vitiligo have a lower level of mental or physical ability.
Fact 1: Vitiligo is a skin disease that only affects the skin. Accordingly, it has no effect or influence on other organs of the body, whether mental or physical.

Myth 2: Vitiligo is linked to cancer, albinism and leprosy.
Fact 2: Again, vitiligo is a skin disease; there is no connection between this and skin cancer, leprosy or albinism. It is an autoimmune disease in which a person’s immune system attacks and kills its own skin-staining cells, called melanocytes.

Myth 3: Eating a specific combination of foods can make vitiligo worse.
Fact 3: This statement is categorically false. There is no connection between food and vitiligo disease. In fact, it is a condition that is not affected by the foods you choose to eat.

Myth #4: Vitiligo can only affect the hands and face.
Fact 4: White or light spots caused by vitiligo are most common in sun-exposed areas such as the hands, feet, arms, lips and face. Plaques of this nature can appear in the armpits, eyes, genitals, navel and rectal areas under certain circumstances. Similarly, plaques may form on the mucous membrane as well as on the retina.

Myth 5: Vitiligo only affects people with dark complexion or dark skin.
Fact 5: Vitiligo is an independent complexion skin disease that can affect people of all skin tones, whether dark, fair or fair.

Myth 6: Vitiligo can be treated by putting different oils, using home remedies on the affected skin area and consuming particular vitamins.
Fact 6: No, applying home remedies or oils will not cure vitiligo. In fact, you are delaying the treatment process, which is not advisable at all. A certified dermatologist depending on your condition can guide you with a variety of treatments, including UV light therapy, surgical skin and cell transplants, tattooing and medication. Some people choose to conceal their skin with special cosmetics. Consult your doctor if you have vitiligo for any available or appropriate alternatives for treating skin color loss.

Myth 7: Vitiligo is transmissible and contagious.
Fact 7: Vitiligo is not an infectious or contagious disease. Therefore, there is no need to escape or avoid touching someone who is suffering from the same condition. Instead, you can use this information to help them challenge the prejudice and stigma they face on a daily basis. As vitiligo sufferers go through tremendous mental trauma, stress and the Depression.

Myth 8: Every white spot is vitiligo
Fact 8: No, a variety of factors can cause skin discoloration including: eczema, atopic dermatitis, fungal infection, Nevus Depigmentosus, Pityriasis Alba, Lichen Simplex Atrophicans, Post-burn depigmentation. Only a board-certified dermatologist can tell you if the white patch is vitiligo or another skin problem.

📣 For more lifestyle news, follow us on Instagram | Twitter | Facebook and don’t miss the latest updates!

Bruker showcases life science and materials research solutions

0

The high-value instrumentation was on display in Munich, Germany at this year’s analytics

Bruker Corporation is showcasing its high-value scientific instruments, software and integrated solutions for applications in materials and energy research, biopharma, applied markets, as well as life sciences and translational research this week. at Analytica 2022.

Frank H. Laukien, Ph.D., President and CEO of Bruker Corporation, said, “Our differentiated, high-value scientific instruments and solutions showcased at analytica 2022 demonstrate the diversity, flexibility, and high performance that Bruker brings. to the world of laboratory science. Bruker is committed to providing technology, software, chemical and biological solutions optimized to enable the success of our customers. We are very excited to introduce new solutions that now also enable single-cell spatial metabolomics, a key new capability for in situ multi-omics single-cell biology and cancer research.

Applied and industrial markets

Bruker launches the HYPERION II FT-IR/IR Laser Imaging Microscope as a flexible research platform, combining FTIR microscopy with QCL IR laser imaging. The HYPERION II is the first IR laser microscope that offers the three modes of transmission, reflection and ATR. The intuitive software allows seamless switching between FT-IR and QCL technology. With an unprecedented imaging speed of 6mm² per second, it sets the new benchmark in vibrational microscopy.

The new TGA II FT-IR module enables advanced gas analysis by hyphenation of thermogravimetry (TG) and FT-IR spectroscopy. Its new cell design allows high temperature analysis up to 370°C. Most applications can now be covered by a DTGS detector without the need for liquid nitrogen. The TGA II is prepared for adaptation to TG balances from partner Netzsch and other manufacturers.

Bruker introduces PoN mass spectrometry for accelerated measurements without chromatography to bring the power of mass spectrometry (MS) to new food, beverage, forensic, industrial, safety, environmental and pharmaceutical applications. The new DART-EVOQ Point of Need (PoN) triple quadrupole MS system was developed with the IonSense DART source to enable PoN workflows that reduce analysis time to seconds or minutes, with little or no preparation for rapid analyzes of solids, liquids or gas samples.

Food Analysis Solutions

Bruker launches the MPA II Dairy Analyzer for a new standard in quality control and analysis of liquid and solid samples in the dairy industry, as well as plant-based alternatives. It allows automated sampling and homogenization for liquid product analysis, or with an integrating sphere can also measure heterogeneous materials without sample preparation in diffuse reflection. Near-infrared (NIR) spectroscopy is a recognized method for liquid and solid sample types, described in ISO 21543 | IDF 201 guidelines published in 2020.

A new Olive Oil-Profiling 1.0™ NMR solution provides analysis of the authenticity and quality of olive oil, one of the most adulterated food products in the world. Olive Oil-Profiling 1.0 is available on the Fourier™ 80 benchtop system for olive oil bottlers, as well as the FoodScreener™ 400 MHz NMR platform for advanced testing laboratories.

New laboratory solutions for BioPharma

Bruker introduces the new Fourier 80 FT-NMR capabilities for pharmaceutical and chemical analysis. The Fourier 80 benchtop spectrometer requires no special lab infrastructure or cryogens and offers excellent 1H sensitivity of 200:1 for gradient spectroscopy proton probes, bringing FT-NMR to more research labs and analysis. The new Fourier 80 Adjustable Temperature (AT) option allows analysis up to 60°C, and the AT option is compatible with the Fourier 80 PAL autosampler option.

A new benchtop FT-NMR Reaction Monitoring Solution and GxP Prep Kit for RxnLab™ 80 Fourier Reaction Monitoring Solution has been introduced for chemical and pharmaceutical laboratories, and features temperature-controlled reaction lanes for optimize process control and reaction product monitoring of the MPA II dairy analyzer with the new Fourier 80 flow accessory. Running InsightMR software, the RxnLab brings benchtop FT-NMR to bio and chemical production for non-NMR experts. The new Fourier 80 GxP Prep Kit enables full GxP compliance for development and manufacturing labs with 21 CFR Part 11 compliance.

Integration of the timsTOF flex platform with 5-micrometer single-cell resolution and new MALDI Hiplex-IHC assays ushers in the era of unbiased single-cell spatial metabolomics (SSCM) and enables in situ multi-omics tissue research and single-cell biology to accelerate drug development. Bruker’s strategic partnership with AmberGen brings breakthrough capabilities to single-cell biology with spatial multi-omics capabilities that allow researchers to simultaneously observe how drugs affect both protein and metabolic states by combining targeted spatial protein profiling MALDI HiPLEXIHC with an unbiased bias, Cell-Resolved Small Molecule MALDI Imaging for co-localization of proteins and small molecules such as glycans, lipids, metabolites or xenobiotics

Microscopy and Nanoanalysis

The new NeuraLight 3D Ultra™ module expands neuroscience research capabilities and optogenetic applications on Bruker’s Ultima multiphoton microscopes. NeuraLight 3D Ultra provides breakthrough 3D holographic photostimulation optimized for large-scale functional and Fourier 80 Benchtop FT-NMR studies of neural networks and brain computation. Based on proprietary Spatial Light Modulator (SLM) technology, NeuraLight 3D Ultra uses a new, larger LCD chip for a wider field of view, improved targeting accuracy, and a top speed of 600 frames per second. holograms per second.

Bruker introduces XFlash® 7, the next generation of EDS detectors for elemental analysis with QUANTAX™ energy dispersive X-ray spectrometer (EDS) accessories that enable chemical analysis on electron microscopes with speed, ultimate sensitivity and reliability. Unique new features in XFlash 7 further increase performance and productivity and reduce cost of ownership. XFlash 7 detectors offer a range of detector window sizes, shapes and materials, and are designed to provide maximum collection angles for X-rays, with an optimized ratio of detector active area and sample distance -detector.

Translational and clinical research in proteomics

The new timsTOF® HT features a 4th generation TIMS-XR (Trapped Ion Mobility Separation) cell and 14-bit digitizer for even greater dynamic range in proteomics, improved peptide coverage and more accurate quantification, especially in plasma and 4D tissue unbiased proteomics and epiproteomics. Dia-PASEF acquisition on the timsTOF HT quantifies proteins over a wide dynamic range, even in challenging samples, such as heart tissue, without sacrificing throughput or sensitivity.

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>

Daily coverage of analytics 2022 by SelectScience is available by clicking here >>

Chemical Vapor Deposition Market Size, Scope and Forecast

0

New Jersey, United States – The Chemical Vapor Deposition Market The research report examines the market in detail over the predicted period. The research is divided into sections, each of which includes analysis of market trends and changes. Drivers, limitations, opportunities, and barriers, as well as the impact of numerous aspects on the industry, are all variables of market dynamics.

The report provides participants with essential information as well as specific recommendations for gaining a competitive advantage in the global business world. It studies how different players compete in the global market and shows how they compete differently. The market size for the Chemical Vapor Deposition market is calculated with the help of a projected period included in the research study. Current market status and trends, along with business growth drivers, industry share, sales volume, interesting BI dashboards, and market forces are all explored.

Get Sample Full PDF Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.verifiedmarketresearch.com/download-sample/?rid=49158

Key Players Mentioned in the Chemical Vapor Deposition Market Research Report:

ASM International NV, Adeka Corporation, Applied Materials Inc., Aixtron SE, IHI Corporation, Lam research Corporation, Plasma-Therm, Richter Precision Inc., Denton Vacuum LLC, Tokyo Electron Limited.

Our analysts have performed a qualitative and quantitative analysis of the microeconomic and macroeconomic components of the Chemical Vapor Deposition market. This study will also help to understand changes in Chemical Vapor Deposition market industrial supply chain, manufacturing processes and costs, sales scenarios and market dynamics.

This analysis highlights significant mergers and acquisitions, business expansions, differences in goods or services, market structure, competitive conditions in the Chemical Vapor Deposition market and market size by participant .

Global Chemical Vapor Deposition Market Segmentation:

Chemical Vapor Deposition Market, By Application

• Solar products
• Microelectronics
• Medical equipement
• Data storage
• Others

Chemical Vapor Deposition Market, By Category

• CVD equipment
• CVD materials
• CVD Services

Inquire for a discount on this Premium Report @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=49158

Scope of Chemical Vapor Deposition Market Report

ATTRIBUTES DETAILS
ESTIMATED YEAR 2022
YEAR OF REFERENCE 2021
FORECAST YEAR 2029
HISTORICAL YEAR 2020
UNITY Value (million USD/billion)
SECTORS COVERED Types, applications, end users, and more.
REPORT COVER Revenue Forecast, Business Ranking, Competitive Landscape, Growth Factors and Trends
BY REGION North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
CUSTOMIZATION SCOPE Free report customization (equivalent to up to 4 analyst business days) with purchase. Added or changed country, region and segment scope.

Answers to key questions in the report:

1. Who are the top five players in the Chemical Vapor Deposition market?

2. How will the chemical vapor deposition market develop in the next five years?

3. Which products and applications will occupy the lion’s share of the chemical vapor deposition market?

4. What are the drivers and restraints of Chemical Vapor Deposition Market?

5. Which regional market will show the strongest growth?

6. What will be the CAGR and size of the Chemical Vapor Deposition market throughout the forecast period?

For more information or query or customization before buying, visit @ https://www.verifiedmarketresearch.com/product/chemical-vapor-deposition-market/

Visualize the Chemical Vapor Deposition Market Using Verified Market Intelligence:-

Verified Market Intelligence is our BI platform for market narrative storytelling. VMI offers in-depth forecast trends and accurate insights on over 20,000 emerging and niche markets, helping you make critical revenue-impacting decisions for a bright future.

VMI provides a global overview and competitive landscape with respect to region, country and segment, as well as key players in your market. Present your market report and findings with an integrated presentation feature that saves you over 70% of your time and resources for presentations to investors, sales and marketing, R&D and development of products. VMI enables data delivery in Excel and interactive PDF formats with over 15+ key market indicators for your market.

Visualize the Chemical Vapor Deposition Market Using [email protected] https://www.verifiedmarketresearch.com/vmintelligence/

About Us: Verified Market Research®

Verified Market Research® is a leading global research and advisory firm that for over 10 years has provided advanced analytical research solutions, personalized advice and in-depth data analysis to individuals and businesses seeking accurate research, reliable and up to date. data and technical advice. We provide insight into strategic and growth analytics, the data needed to achieve business goals, and help make critical revenue decisions.

Our research studies help our clients make superior data-driven decisions, understand market forecasts, capitalize on future opportunities, and maximize efficiency by working as a partner to deliver accurate and valuable insights. The industries we cover span a wide spectrum, including technology, chemicals, manufacturing, energy, food and beverage, automotive, robotics, packaging, construction, mining and the gas. Etc.

At Verified Market Research, we help in understanding holistic market indicator factors and most current and future market trends. Our analysts, with their deep expertise in data collection and governance, use industry techniques to gather and review data at all stages. They are trained to combine modern data collection techniques, superior research methodology, subject matter expertise and years of collective experience to produce informative and accurate research.

Having served over 5000 clients, we have provided reliable market research services to over 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi. We have co-consulted with some of the world’s leading consulting firms such as McKinsey & Company, Boston Consulting Group, Bain and Company for custom research and consulting projects for companies around the world.

Contact us:

Mr. Edwyne Fernandes

Verified Market Research®

USA: +1 (650)-781-4080
UK: +44 (753)-715-0008
APAC: +61 (488)-85-9400
US toll free: +1 (800)-782-1768

E-mail: [email protected]

Website:- https://www.verifiedmarketresearch.com/

Correlates of anamnestic humoral immunity in all SARS-CoV-2 variants of concern

0

A recent book posted on bioRxiv* The preprint server assessed indicators of anamnestic humoral immunity among variants of concern (COVs) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Study: Anamnestic humoral correlates of immunity across SARS-CoV-2 variants of concern. Image Credit: Corona Borealis Studio / Shutterstock

Background

The decrease in vaccine conferred immunity and the awakening of SARS-CoV-2 VOCs resistant to neutralizing antibodies, such as B.1.612 (Delta) and B.1.529 (Omicron), led to a rapid increase of CoV disease 2019 (COVID -19) transmission events around the world, regardless of the impressive vaccine efficacy seen in SARS-CoV-2 phase III vaccine experiments. However, the incidence of severe illness and mortality did not increase simultaneously, indicating that other post-transmission inhibitory immune responses help eliminate and manage COVID-19 once it has subsided. product.

Immune correlates may have a mechanistic role in protective immunity. Yet they may also indicate surrogates for other immune systems vital for anti-pathogen control. Immune correlates to SARS-CoV-2 are usually determined at peak immunogenicity after vaccination. Nonetheless, immune responses that specifically increase during the anamnestic response after infection can offer comprehensive and mechanistic details regarding protective immune pathways. Additionally, it is unknown whether any anamnestic correlates are shared by SARS-CoV-2 COVs, such as the more distant Delta and Omicron COVs.

About the study

In the present study, researchers carefully assessed the humoral immune response in individuals vaccinated against COVID-19 who had recently acquired Omicron or Delta VOC infections to characterize anamnestic markers of immunity among SARS-CoV-COVs. 2.

A significant association exists between non-neutralizing antibody effector patterns and the natural resolution of severe COVID-19. In light of this link, the team performed systemic serology on the sera of 37 and 23 subjects who had completed their series of SARS-CoV-2 vaccinations and had a recorded breakthrough infection of VOC Delta or Omicron, respectively. , one week and two to three weeks after infection. They sought to identify particular humoral traits linked to infection resolution.

Additionally, the authors assessed the fold increase in immunoglobulin G1 (IgG1) concentrations in all spike (S) protein subdomains of SARS-CoV-2, COVs, and common human CoVs ( HCoV). This involved comparing the degree of anamnestic expansion between S domains across breakthrough instances. They used partial least squares discriminant analysis (PLS-DA) on antibody responses obtained in breakthrough cases two to three weeks after infection to determine a minimal multivariate fingerprint of Omicron or Delta breakthrough infections in vaccinated people.

Breakthrough cases were split between people who received one of two messenger ribonucleic acid (mRNA) COVID-19 vaccines (mRNA-1273 (Moderna) or BNT162b2 (Pfizer)). It was to see if they produced an identical anamnestic reaction. Additionally, the team mapped the broadening of the breakthrough infection response among peptides spanning the S2 domain of the S antigen to determine whether S2-specific responses targeted distinct areas of S2.

Results

Study results indicated that after breakthrough infections of Omicron and Delta, limited specific immune enhancement of N-terminal domain (NTD) and receptor-binding domain (RBD) of SARS-CoV -2 was observed. On the contrary, one week after the infection breakthrough, opsonophagocyte S-specific antibody responses showed a remarkable immunodominant expansion, focusing mainly on the conserved SARS-CoV-2 S2 domain.

Conserved regions of Spike are selectively expanded in breakthrough cases.  (A) Fold changes in IgG1 binding of Spike subdomains (NTD in black, RBD in blue, and S2 in red) for Delta breakthrough cases vaccinated at <1 week or 2-3 weeks post-breakthrough.  (B) Same as A, but for vaccinated Omicron breakthrough cases.  (C) Fold changes in IgG1 binding of full-length VoC spikes in Delta breakthrough cases.  (D) Same as C, but for Omicron breakthrough cases.  (E) Fold changes in spike IgG1 binding of common CoV spikes in Delta breakthrough infections at <1 week or 2-3 weeks post-breakthrough.  The SARS-CoV-2 (N) nucleocapsid is used as an infection control.  (F) Same as C, but for Omicron breakthroughs.  * = p < 0.05, and ** = p < 0,01 pour tous les panels.Conserved regions of Spike are selectively extended in breakthrough cases. (A) Fold changes in IgG1 binding of Spike subdomains (NTD in black, RBD in blue, and S2 in red) for Delta breakthrough cases vaccinated at

This functional S2-specific humoral response, which primarily targets common CoVs and many SARS-CoV-2 COVs, continued to develop for two to three weeks after the breakthroughs of Omicron and Delta. These reactions focused drastically on fusion peptide 2 (FP2) and repeat heptad 1 (HR1), and FP2 and HR1 were linked to faster viral clearance rates.

A distinct anamnestic increase in early S2-specific IgM antibodies FP2 and HR1 exploiting monocyte phagocytosis was responsible for most of the S-specific expansion. Recruitment of neutrophils attached to the crystallizable receptor (FcR) to the S2-specific IgG fraction HR1 and more mature FP2 was observed. These data suggest an unexpected and crucial role for S2-specific functional humoral immunity as important anamnestic markers of immunity across SARS-CoV-2 COVs. This inference was contrary to the reaction elicited by the immunodominant RBD vaccine.

The authors noted deviations in the anamnestic reflex post-Pfizer and Moderna vaccination. They found a large-scale improvement in anamnestic immunity in Pfizer vaccinees and a functional increase in Moderna vaccinees. Nevertheless, both breakthrough features led to an expansion of S2 domain-specific immunity.

Variations in vaccination data could be associated with differences in actual efficacy between vaccine platforms. Indeed, Moderna vaccinees demonstrated a decrease in breakthrough infections, possibly related to elevated functional humoral immunity and IgA concentrations, likely conferring a particularly robust defense against SARS-CoV-2 infection in the level of the mucous barrier. Yet, the increase in S2-specific immunity after both vaccinations targeting HR1 and FP2 might be related to their accessible sites on protein S.

conclusion

Current research assessed the post-COVID-19 immunological patterns that emerged in breakthrough infections with particular emphasis on determining whether the kinetics of breakthrough markers of immunity were consistent among SARS-CoV-2 COVs. Study results showed rapid expansion of FcR attachment and opsonophagocytic humoral immune responses in breakthrough Omicron and Delta VOC cases, with a consistent priority for expansion of the S protein S2 subdomain centered on FP2 and HR1, which followed with increased SARS. coV-2 clearance.

Taken together, the present study indicates that control of SARS-CoV-2 infection among COVs was critically dependent on highly conserved and efficient S2-specific responses. Current work implies that the humoral response linked to viral attenuation could guide next-generation COVID-19 vaccine stimulation techniques to provide broad protection against future SARS-CoV-2 COVs.

*Important Notice

bioRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be considered conclusive, guide clinical practice/health-related behaviors, or treated as established information.

Journal reference:

  • Anamnestic humoral correlates of immunity across SARS-CoV-2 variants of concern; Ryan McNamara, Jenny S Maron, Harry L Bertera, Julie Boucau, Vicky Roy, Amy K. Barczak, The Positive Study Staff, Nicholas Franko, Jonathan Z Li, Jason S McLellan, Mark Siedner, Jacob E Lemieux, Helen Chu, Galit Alter, bioRxiv preprint 2022, DOI: https://doi.org/10.1101/2022.06.19.496718, https://www.biorxiv.org/content/10.1101/2022.06.19.496718v1

Egypt expects boost from gas deal with Israel and EU

0

CAIRO — The European Union, Israel and Egypt signed an agreement on June 15 to boost the export of natural gas from Israel to Europe via Egypt.

The signing of the agreement took place during the 7th Ministerial Meeting of the Eastern Mediterranean Gas Forum (EMGF) held in Cairo.

Egyptian Minister of Petroleum and Mineral Resources Tarek el-Mulla said in a statement at the signing ceremony that the agreement is a very important step that can be built on to promote cooperation between member states. of the EMGF, including the EU.

Israeli Energy Minister Karine Elharrar said the agreement is an important message about the success of cooperation under the EMGF umbrella, which underlines its central role in securing part of the Europe’s energy supply. The fruitful cooperation would allow optimal use of the region’s resources and position Egypt and Israel as important players in the gas market, she continued.

EU Energy Commissioner Kadri Simson said the deal was an opportunity for all to cooperate, especially as the signing of the deal comes at a difficult time for the EU, which is seeking to ensure a reliable energy supply.

The tripartite agreement comes as Europe seeks to meet its gas needs from eastern Mediterranean resources as part of a plan to reduce dependence on Russian gas imports which have been affected by the Russian invasion of Ukraine.

Under the deal, the Israeli gas will be transported by pipeline to liquefaction plants at the Damietta and Edco plants on Egypt’s Mediterranean coast, before being exported to Europe.

Charles Ellinas, a nonresident senior fellow at the Atlantic Council Global Energy Center, told Al-Monitor that the EU is seeking to cut Russian gas supplies by two-thirds by the end of 2022 and end its dependence on Russian fossil fuels by 2027.

He said the recent deal is an opportunity for Eastern Mediterranean gas to fill the void for Europe.

Ellinas noted that the most optimal and fastest way to increase the volume of Eastern Mediterranean gas exports to Europe is through Israel’s new Leviathan offshore natural gas field, where production is currently in progress. ongoing, and by the existing liquefaction plants in Egypt and their operation at maximum capacity.

He explained that the gas liquefaction plants enabled Egypt to respond immediately to Europe’s needs. “It fits perfectly with Egyptian aspirations to become a hub for the export of gas from the Eastern Mediterranean to Europe. However, given Europe’s plan to massively increase green energy, the need for gas imports will decrease as we get closer to 2030,” he said.

Ellinas added: “In the long term, it is possible for Egypt to supply Europe with green hydrogen, given that Egypt is the country most capable of meeting European hydrogen needs in the Eastern Mediterranean. Additionally, the abundance of solar and wind power and a number of green hydrogen projects that are currently under development put Egypt on the right track.

He said these projects are an opportunity for Egypt to become a regional leader in the production, use and export of green hydrogen and ammonia.

Egypt is seeking to attract more foreign investment in the green hydrogen production sector. On April 20, the government approved additional incentives for investment in this area.

Maher Aziz, a member of the World Energy Council, told Al-Monitor: “Cooperation among Eastern Mediterranean countries in gas export has been on the table since the formation of the EMGF, which the Egypt sought to establish in order to strengthen its position as an energy supplier. hub of the region.

He said: “The Russian-Ukrainian war, which cast a shadow over Europe’s natural gas supply, showed the backwardness of cooperation between Eastern Mediterranean countries to supply Europe with natural gas. “.

Aziz noted: “If this cooperation had been established two years ago, gas exports to Europe would have brought huge profits to Eastern Mediterranean countries today, especially in light of the surge in world gas prices.

He added: “The opportunity always presents itself, and it is good to start implementing this cooperation on the ground. This could position the Eastern Mediterranean countries as a main hub for gas supplies to Europe, which imports more than 30% of its consumption from Russia. It would also help the Egyptian project to become a regional energy hub. »

According to Elharrar, the agreement signed between Israel, Egypt and the EU is valid for three years and will be automatically renewed for an additional two years. She added, during the signing ceremony, that the agreement amounted to a commitment to share natural gas with Europe and contribute to the energy crisis.

As part of the agreement, the EU will also encourage European companies to participate in exploration tenders in Israel and Egypt. The agreement also provides for the formulation of a plan for the optimal use of the infrastructures linked to the extraction, liquefaction and transport of natural gas.

Aziz said: “Eastern Mediterranean countries have enough natural gas to meet their domestic needs and to export abroad. According to the US Geopolitical Survey, the Eastern Mediterranean has a proven reserve of up to 345 trillion cubic feet of natural gas. This is a huge quantity capable of supplying Europe with gas for the next 20 to 25 years.

Speaking to Masrawy News on June 15, Osama Kamal, Egypt’s former oil minister, said the gas export deal would bring economic and political benefits to the Egyptian state.

He said that Egypt will benefit from gas transit fees and liquefaction fees, and that the agreement will allow Egypt to play a strong and influential political role between certain parties or countries in the Eastern Mediterranean who know gas disputes, including the dispute between Lebanon and Israel.

The correct order to apply skincare for the best results – Cleveland Clinic

0

There are so many skin care products to choose from. How do you decide which ones are best for your skin? And in what order should they be applied? It’s a lot of trying to figure it out for yourself.

Cleveland Clinic is a nonprofit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Cosmetic and surgical dermatologist Kiyanna Williams, MD, is here to help you figure out how to start a daily routine tailored to your skin’s unique needs.

Why ordering your skincare products is important

The order in which you apply each product dictates your skin’s ability to absorb it, so you should apply them according to how much each product weighs on your skin.

“Generally you want to go from light to heavy,” says Dr. Williams. “If you’re using a very thin, lightweight lotion, start there. “Then you follow with your cream, then a serum, if you’re using one.”

But it’s a little more complicated than that.

“It gets very specific as to what things can be mixed with what,” says Dr. Williams. “If you have a lot of products and a lot of questions, you should make an appointment with a dermatologist.”

The correct order for applying skin care products

First of all, you don’t need a medicine cabinet full of rows and rows of skin care products.

“I think it’s best to cut it back to the basics,” says Dr. Williams. “Most people don’t need more than two products, and there’s usually no need for multiple serums or toners or multiples of the same product.”

Still, it can be overwhelming analyzing all the many skin care products on the market and trying to figure out how to use them all. Dr. Williams walks you through a basic skincare routine for day and night and what each should include.

Your morning skincare routine

Rise and Shine! As you and your fresh face start the day, a simple and straightforward skincare routine is best. In fact, just three products should do the trick for most people.

1. Cleanser

Sorry to break it to you, but no, these cleansing wipes do not count as washing your face. If you’re traveling or in a hurry, it’s better than nothing – but as a general rule, cleanup should involve water.

To choose the best cleanser for you, consider your skin type. “If your face is prone to dryness, avoid foaming cleansers,” advises Dr. Williams, “and if your skin is sensitive, look for cleansers that say ‘mild’ or ‘for sensitive skin’.”

She recommends avoiding cleansers with physical exfoliants, like microbeads or other gritty-textured products, as they can cause irritation and inflammation. “Instead, I recommend chemical exfoliants, which contain ingredients like glycolic acid,” she says. “These provide a more gentle and even exfoliation.”

2. Sunscreen

If there is a fountain of youth for the skin, it is sunscreen. But if you think you’re ready because you’re wearing a moisturizer with SPF, think again. It’s not enough to protect your skin, says Dr. Williams.

“I recommend an SPF of 30 or more every day of the year, even in the winter,” she continues. “Then if you know you’re going to be sunbathing or golfing or the beach or whatever, put on an SPF 50 or higher.”

Try a tinted mineral sunscreen, which doesn’t have the thick, cakey consistency you might think of when considering applying sunscreen to your face.

3. Moisturizing

The older you get, the drier your skin becomes. The moisturizer is an opportunity to give back to your skin some of what it has lost.

“As you age, you want to replace some of the moisture you lose,” says Dr. Williams. “Moisturizers that contain hyaluronic acids and ceramides can be helpful in replacing some of that moisture.”

Wait, what about the toner?

These astringents are believed to help shrink pores. If you use one, apply it after cleansing, as a second step to prep your face for sunscreen and moisturizer, but you probably don’t need it.

“Unfortunately, there’s really nothing you can put on your face that’s going to shrink your pores,” notes Dr. Williams, “so I’m indifferent to toners.”

Your evening skincare routine

You can skip sunscreen at night, when for the most part, Dr. Williams still recommends minimal products. Here are her tips on how to take care of your skin before you call it a day.

wash the day

Again, makeup remover wipes won’t do the trick. Before bed, use a cleanser and water to remove dirt and grime from the day.

Moisturize again

Some people use two types of moisturizers: a lighter day cream and a thicker night cream. “Some people don’t like that heavy feeling on their face during the day, when they’re not as aware of it when they’re sleeping,” says Dr. Williams.

Night is retinol time

Products that contain retinols (vitamin A) and retinoids (which are derived from vitamin A) increase cell turnover, giving your skin that youthful glow.

But these products should only be applied in the evening. “Some of them can be turned off by the sun, so it’s important that you wear them at night,” Dr. Williams points out.

Tendency to imperfections

Trying to tackle a pimple overnight? “Products containing benzoyl peroxide are my favorite,” says Dr. Williams. “Dab some benzoyl peroxide cream or retinoid cream on it to help dry it out.”

Pimple patches — small hydrocolloid stickers that you place on a pimple overnight — can be helpful on blemishes that you’ve accidentally picked or that have popped on their own and are still healing.

Face masks: good but not so useful

Face masks (not the COVID-19 type) help rehydrate your face. “Think of your skin as a grape versus a raisin,” says Dr. Williams. “If you put a raisin in water for a while, it will start to swell. This is essentially what face masks aim to do. It’s unclear how useful they really are, but if you want to plump up your raisin after a night out, it can’t hurt.

Beware of skincare products that claim to work miracles

Some people spend a lot of money and effort on products that say they can do things like prevent wrinkles and get rid of dark circles. But Dr. Williams says don’t be fooled by the promise of a panacea.

“Generally, if it sounds too good to be true, it probably isn’t,” she says. “Products exist to solve these and other problems, but if you see a product promising to do things that don’t seem very reasonable, it probably won’t work.”

Instead, she recommends making an appointment with a dermatologist so you can determine what’s best for you. your skin. “If you’re feeling bogged down, your dermatologist can review individual products’ specific active ingredients and clinical data to support their use.”

For more from Dr. Williams on this, listen to the Health Essentials podcast episode “How to Start a Skincare Routine.” New episodes of the Health Essentials podcast are released every Wednesday.

COVID bounces back: Immune responses can be jump-started by cleaning up viral remnants

0
Enlarge / A box of Paxlovid, Pfizer’s antiviral drug.

Pfizer’s Paxlovid antiviral pill is one of the most valuable tools in hammering COVID-19; it can reduce the relative risk of hospitalization and death by 89% in unvaccinated patients at high risk of severe disease. But, as the use of this convenient drug has grown in the United States, so have the troubling reports of rebound cases – people who took the pill early in their infection, started feel better and even tested negative, but then relapsed into symptoms and tested positive again. days later.

It is still unclear how common the phenomenon is, but it certainly occurs in a certain proportion of patients treated with Paxlovid. In May, the Centers for Disease Control and Prevention even published a health alertt on rebound reports.

But, amid growing awareness, it has also become clear that patients who have not been treated with Paxlovid can also rebound. In fact, in Pfizer’s clinical trials of Paxlovid, researchers noted that about 1-2% of the treatment and placebo groups had rebounds.

Taken together, this raised a host of questions: Did the rebounds revive infections? Are people still contagious? Should they resume isolation? Are they at risk of serious illness again? Has their immune system failed to mount an effective response? Does the virus mutate to become resistant to Paxlovid? Does Omicron cause more bounce than previous variants?

Data so far is limited and mostly only anecdotal reports. But a new small pre-print study by researchers at the National Institutes of Health offers encouraging news about COVID rebounds. The study, which included data on seven rebounding patients – six of whom were treated with Paxlovid and one who was not – found no evidence of Paxlovid-resistant mutations, wild-type viral replication or responses weak immune systems.

Intact immune responses

Instead, a detailed examination of their immune responses revealed that the rebounds were associated with increased antibodies and specific cellular immune responses against SARS-CoV-2. At the same time, the rebounds were accompanied by downward trends in markers of innate (nonspecific) immune responses, as well as levels of SARS-CoV-2 nucleocapsid fragments in the blood.

Together, the findings suggest the rebounds may be partly due to a reignited immune response as the body works to clear cellular debris and viral remnants from a quickly snuffed out infection. Or, as the authors put it: “rebound symptoms may in fact be partially caused by the emerging immune response against residual viral antigens possibly excreted by dying infected cells due to cytotoxicity and tissue repair in the pathways respiratory”.

In support of this, the authors – co-led by infectious disease experts Brian Epling and Joe Rocco – note that while three of the four controls had recoverable live virus during their acute infection, only one of the seven rebounding patients had a live virus virus at the time of their rebound. And this patient also had underlying immunosuppression, which may explain the finding. Moreover, none of the rebounding patients developed serious illness.

The study is, again, very small and may not be generalizable to all cases of rebound. The authors call for rebound studies with larger cohorts. But some elements of the conclusions are already substantiated. For example, other studies have also failed to identify Paxlovid-resistant mutations. And on Tuesday, the CDC published a study of more than 5,000 patients treated with Paxlovidfinding that less than 1% of patients had emergency department visits or hospitalizations during the 5 to 15 post-treatment rebound period.

So far, the NIH researchers find their new findings “encouraging.” As Epling wrote in a tweet tuesday“The results suggest that “an appropriate immune response develops, so rebound is not caused by people not developing an immune response to COVID while on Paxlovid.”

Supreme Court rejects Roundup maker’s appeal over cancer claims

0
Placeholder while loading article actions

The Supreme Court on Tuesday handed down a multimillion-dollar verdict against the maker of popular weedkiller Roundup for failing to warn of cancer risks.

The judges’ decision not to intervene paves the way for thousands of similar lawsuits against Bayer. The Biden administration had urged the court to reject the company’s request, a departure from the Trump administration’s position.

In a statement Tuesday, the company said it disagreed with the court’s decision not to appeal and “believes that the vast body of science and the consistently supportive opinions of the world’s leading regulators entire provide a solid foundation upon which she can successfully defend Roundup in court if necessary.

The case was brought by Edwin Hardeman, who was diagnosed in 2015 with non-Hodgkin’s lymphoma. He sued the company, alleging that his use of Roundup for more than two decades caused his cancer. He said the company did not warn of the cancer risks associated with the active ingredient glyphosate.

“It has been a long and difficult journey to bring justice to Mr. Hardeman and now thousands of other cancer victims can continue to hold Monsanto accountable for its decades of corporate wrongdoing,” said Hardeman attorneys Jennifer Moore and Aimee Wagstaff, in a statement. referring to the original producer of the herbicide, which was acquired by Bayer in 2018.

The Environmental Protection Agency has repeatedly concluded that glyphosate is unlikely to cause cancer in humans. California labeling laws are stricter. After an international research group classified glyphosate as “probably carcinogenic to humans” in 2015, the state required a warning label for glyphosate-based pesticides. The classification prompted a series of lawsuits against the maker of the nation’s most widely used weed killer.

An appeals court upheld a $25 million jury verdict and found that Hardeman’s exposure to Roundup was a ‘substantial factor’ in causing his cancer and that the company failed to warn risks.

Court rejects Trump-era EPA’s conclusion that weedkiller is safe

The US Court of Appeals for the 9th Circuit said federal law does not preclude a company’s requirement to include a cancer warning on its label. The court said a pesticide can be “mislabeled” even if the EPA has approved its label and a company can comply with federal and state labeling requirements.

Lawyers for the company urged the Supreme Court to overturn and pointed to previous rulings aimed at ensuring “national uniformity in pesticide labeling.” California and potentially 49 other states should not be able to “marginalize” EPA statements that glyphosate is unlikely to cause cancer, they said.

The company noted that Hardeman stopped using Roundup in 2012, before the California label requirement.

In 2020, Bayer agreed to pay over $10 billion to settle tens of thousands of potential US claims. The company said the settlement was not an admission of wrongdoing and noted in its statement Tuesday that it had won its last four cases involving Roundup.

Additionally, the company said it is discontinuing glyphosate-based residential lawn and garden products in the United States in favor of alternative ingredients to “manage the risk of litigation in the United States and not for safety reasons. “.

Last week another 9th Circuit decision ordered the EPA to reconsider its finding in 2020 that glyphosate posed “no unreasonable risk to humans or the environment.”

In a unanimous opinion, Judge Michelle Friedland wrote that the Trump-era findings “were not supported by substantial evidence” and failed to meet the agency’s legal obligations to review the impact. environmental. The opinion noted that the national area where glyphosate is used is roughly three times the size of California.

Vaccination increases risk of COVID-19, but infection without vaccination confers immunity: study

0

Having two doses of a COVID-19 vaccine has been linked to negative protection against the disease, scientists say, while prior infection without vaccination provides about 50% immunity, according to a study analyzing the Omicron wave in Qatar.

The study, published in the New England Journal of Medicine on June 15, looked at the Omicron wave in Qatar that occurred between December 2021 and approximately February 2022, comparing vaccination rates and immunity in more than 100,000 people infected and uninfected with Omicron.

The study authors found that those with prior infection but no vaccination had 46.1 and 50% immunity against both subvariants of the Omicron variant, even at an interval of more than 300 days since previous infection.

However, people who received two doses of the Pfizer and Moderna vaccine but had no previous infections were found to have negative immunity against the BA.1 and BA.2 Omicron subvariants, indicating an increased risk of contracting the COVID-19 compared to an average person.

More than six months after receiving two doses of the Pfizer vaccine, immunity to any Omicron infection has fallen to -3.4%.

But for two doses of the Moderna vaccine, immunity against any Omicron infection fell to -10.3% after more than six months since the last injection.

Although the authors reported that three doses of the Pfizer vaccine increased immunity by more than 50%, this was measured just over 40 days after the third vaccination, which is a very short interval. In comparison, natural immunity persisted at around 50% when measured more than 300 days after the previous infection, while immunity levels fell to negative numbers 270 days after the second dose of vaccine. .

These figures indicate a risk of waning immunity for the third dose of vaccine over time.

The findings are supported by another recent study conducted in Israel which also found that natural immunity wanes much more slowly than artificial or vaccinated immunity.

The study found that both natural and artificial immunity waned over time.

People previously infected but not vaccinated had half the risk of reinfection compared to those who had been vaccinated with two doses but not infected.

“Natural immunity wins again,” Dr. Martin Adel Makary, a public policy researcher at Johns Hopkins University, wrote on Twitter, referring to the Israeli study.

“Among people who had previously been infected with SARS-CoV-2, protection against reinfection decreased as time increased,” the authors concluded, “however, this protection was higher” than the protection conferred in the same time interval by two doses of the vaccine.

Enrico Trigoso contributed to this report.

Gas export tax would help solve Australia’s energy crisis, says Dr Ken Henry

0

The dire state of Australia’s domestic electricity market and our lack of investment in renewables has been a mess of our own doing, says former Treasury Secretary Ken Henry.

Australia has also squandered the opportunity to use its huge domestic gas reserves as a transition fuel to shift our electricity system from a heavy reliance on coal to renewables, he says.

“It was wasted on politics – part ideological, part, I think, driven by personal ambition – and that put us in a really bad spot,” he told the ABC this week. .

“It’s too late to have the kind of reliance on gas power as a transitional fuel that we imagined in the last century.”

Dr Henry, who served as Australian Treasury Secretary from 2001 to 2011, argued in 2004 that Australia should adopt a national emissions trading system.

In his 2010 fiscal review, he warned that energy markets could become unstable if investors didn’t have enough certainty to make long-term renewable energy investment plans.

Now, looking back, he says no one involved in energy policymaking in the late 1990s and early 2000s could say they didn’t see Australia’s current energy crisis coming.

But a one-off tax on gas exports could help smooth things over, he said.

Space to play or pause, M to mute, left and right arrows to search, up and down arrows for volume.

Would a tax on gas exports solve Australia’s energy crisis?(Rachel Pupazzoni)

Australian decision makers have ruined everything

Dr Henry spoke to the ABC after one of the most tumultuous weeks in Australia’s energy policy experience.

Australia’s east coast power system was thrown into chaos last week as a power shortage led to spikes in demand as people increased their energy use during a cold spell intense.

Some fossil fuel producers had withdrawn a huge amount of capacity from the national electricity market, which exacerbated the projected power shortage and prompted unprecedented regulatory intervention.

There were dire warnings about possible power outages, prompting politicians to ask voters to turn off devices to avoid catastrophic strain on the system.

And the crisis of soaring gas prices continued, as multinationals made extraordinary profits exporting Australian gas overseas.

Dr. Henry said that was a situation we shouldn’t be in.

“It’s weird isn’t it?” he said.

“We have a global energy price shock, energy prices around the world are skyrocketing. Australia is an energy superpower; we have an abundance of almost every energy source imaginable.

“And yet we have multinationals making windfall profits while Australian households and Australian energy-dependent manufacturers shoot in the neck.

” How did we get there ?

A gas recovery?

Dr Henry said Australia’s political leaders have missed their chance to get more control over Australia’s gas fields to help us transition our energy system to renewables.

He said the current crisis was predictable and a disaster that had been brewing for a long time.

“A lot of people will remember that 25 years ago the Kyoto Protocol was signed, in 1997. It entered into force in 2005,” he said.

“This has given Australia eight years to design an optimal policy approach to climate change.

“Senior civil servants in Canberra quickly came to the conclusion that an optimal policy response would be an economy-wide carbon price,” he said.

A coalition government, led by Prime Minister John Howard, was in power from 1996 to 2007.

Dr Henry said a price on carbon could have been introduced in different ways, either with an emissions trading scheme or with some sort of carbon tax.

But it was “very important” that a carbon price be introduced as soon as possible, before Kyoto comes into force, to help the business community make long-term investment decisions as Australia was preparing to shift to a heavy reliance on renewable energy.

“And the reason for that was that at the time, in the last century, people thought Australia’s electricity system would go through phases,” he said.

“From a heavy reliance on coal, to a transitional phase that would be heavily reliant on gas-fired power generators, until we get to the third phase, and the ultimate phase, of heavy reliance on renewables.

“But the risk was that if we failed to get the political parameters right, at the time, we would miss the opportunity to rely on our vast reserves of gas as transitional energy fuel.

“And guess what? That’s what we did.”

A Labor government, in power at federal level between 2007 and 2013, finally introduced a carbon pricing system at the end of 2012, but it was repealed by the next coalition government in 2014.

Meanwhile, gas prices on Australia’s east coast have been deliberately tied to world gas prices – with no reservation policy for Australian households – and multinationals are making extraordinary profits exporting our gas overseas .

Dr. Henry said this was a situation we shouldn’t be in, but we couldn’t go back.

However, he said that if we still wanted to have a “gas-driven recovery”, we had to do something about the domestic price of gas.

And the easiest way to do that would be through taxation, he said.

We could begin to drive down domestic gas prices for Australian consumers and manufacturers by taxing heavily the windfall profits of multinational gas companies.

“Given where we are now, I think an exceptional tax on gas exports would be the most effective way to reduce the domestic price below the world price,” he said.

“[It would] ensuring sufficient gas supplies for domestic users, both households and businesses, and this would of course have the added benefit of generating very substantial revenue for the budget.”

He said there was “no economic justification” why such windfall profits could not be taxed at a 100% rate.

Loading form…

Job , updated

Monocytes are increased in pregnancy after gestational hypertensive disease

0
  • PLEASANT. Hypertension in pregnancy: the management of hypertensive disorders in pregnancy. NICE Clinical Guideline 107 (National Institute for Health and Clinical Excellence, 2011).

    Google Scholar

  • PLEASANT. Hypertension in pregnancy: diagnosis and management. NICE directive [NG133] (National Institute for Health and Clinical Excellence, 2019).

    Google Scholar

  • Say, L… et al. Global causes of maternal death: a systematic review from WHO. Lancet Glob. Health 2, e323–e333. https://doi.org/10.1016/S2214-109X(14)70227-X (2014).

    PubMed Google Scholar article

  • Bellamy, L., Casas, JP, Hingorani, AD & Williams, DJ Pre-eclampsia and risk of cardiovascular disease and cancer later in life: a systematic review and meta-analysis. BMJ 335974. https://doi.org/10.1136/bmj.39335.385301.BE (2007).

    PubMed Article PubMed Central Google Scholar

  • Redman, CW, Sacks, GP & Sargent, IL Preeclampsia: An excessive maternal inflammatory response to pregnancy. A m. J. Obstet. Gynecol. 180499–506 (1999).

    CAS Google Scholar Article

  • Ross, R. Atherosclerosis: An Inflammatory Disease. N.Engl. J.Med. 340, 115–126. https://doi.org/10.1056/NEJM199901143400207 (1999).

    CAS PubMed Google Scholar Article

  • Weber, C. et al. Role and analysis of monocyte subsets in cardiovascular disease. Joint consensus document of the “Atherosclerosis and Vascular Biology” and “Thrombosis” working groups of the European Society of Cardiology (ESC). Thromb. Hemost. https://doi.org/10.1160/TH16-02-0091 (2016).

    PubMed Google Scholar article

  • Ghattas, A., Griffiths, HR, Devitt, A., Lip, GY & Shantsila, E. Monocytes in coronary heart disease and atherosclerosis: where do we stand?. Jam. Coll. Cardole. 62, 1541-1551. https://doi.org/10.1016/j.jacc.2013.07.043 (2013).

    CAS PubMed Google Scholar Article

  • Shantsila, E. & Lip, GY Monocytes in acute coronary syndromes. Arterioscler. Thromb. Vasc. Biol. 29, 1433–1438. https://doi.org/10.1161/ATVBAHA.108.180513 (2009).

    CAS PubMed Google Scholar Article

  • Shansila, E. et al. Immunophenotypic characterization of human monocyte subsets: possible implications for the pathophysiology of cardiovascular diseases. J. Thromb. Hemost. 9, 1056-1066. https://doi.org/10.1111/j.1538-7836.2011.04244.x (2011).

    CAS PubMed Google Scholar Article

  • Ziegler-Heitbrock, L. et al. Nomenclature of monocytes and dendritic cells in the blood. Blood 116, e74–e80. https://doi.org/10.1182/blood-2010-02-258558 (2010).

    CAS PubMed Google Scholar Article

  • Apostolakis, S., Lip, GY & Shantsila, E. Monocytes in heart failure: Relation to impaired immune overreaction or desperate attempt at tissue repair?. Cardiovascular. Res. 85, 649–660. https://doi.org/10.1093/cvr/cvp327 (2010).

    CAS PubMed Google Scholar Article

  • Yona, S. & Jung, S. Monocytes: subsets, origins, fates and functions. Running. Notice. Hematol. 17, 53–59. https://doi.org/10.1097/MOH.0b013e3283324f80 (2010).

    PubMed Google Scholar article

  • Dutta, P. & Nahrendorf, M. Monocytes in myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 35, 1066-1070. https://doi.org/10.1161/ATVBAHA.114.304652 (2015).

    CAS PubMed Article PubMed Central Google Scholar

  • Urra, X. et al. Monocyte subtypes predict the clinical course and prognosis of human stroke. J. Cereb. Blood flow Metab. 29, 994-1002. https://doi.org/10.1038/jcbfm.2009.25 (2009).

    CAS PubMed Google Scholar Article

  • Rogacev, KS et al. CD14++CD16+ Monocytes and Cardiovascular Outcomes in Patients with Chronic Kidney Disease. EUR. J-heart 32, 84–92. https://doi.org/10.1093/eurheartj/ehq371 (2011).

    CAS PubMed Google Scholar Article

  • Heine, GH et al. CD14(++)CD16+ monocytes but not total monocytes predict cardiovascular events in dialysis patients. Kidney Int. 73, 622–629. https://doi.org/10.1038/sj.ki.5002744 (2008).

    CAS PubMed Google Scholar Article

  • Wrigley, BJ, E. Shantsila, Tapp, LD, and Lip, GY Increased monocyte-platelet aggregate formation in ischemic heart failure. Circ. Cardiac failure. 6, 127–135. https://doi.org/10.1161/CIRCHEARTFAILURE.112.968073 (2013).

    CAS PubMed Google Scholar Article

  • Shantsila, E., Montoro-Garcia, S. & Lip, GY Monocytes circulate in constant reversible interaction with platelets in a [Ca2+]- dependent manner. Platelets 25, 197–201. https://doi.org/10.3109/09537104.2013.784248 (2014).

    CAS PubMed Google Scholar Article

  • Passacquale, G. et al. The monocyte-platelet interaction induces a pro-inflammatory phenotype in circulating monocytes. PLOS ONE 6, e25595. https://doi.org/10.1371/journal.pone.0025595 (2011).

    ADS CAS PubMed Article PubMed Central Google Scholar

  • Gkaliagkousi, E. et al. Decreased platelet nitric oxide contributes to increased circulating monocyte-platelet aggregates in hypertension. EUR. J-heart 30, 3048–3054. https://doi.org/10.1093/eurheartj/ehp330 (2009).

    CAS PubMed Google Scholar Article

  • Oh, ES, Na, M. & Rogers, CJ The association between monocyte subsets and cardiometabolic disorders/cardiovascular disease: a systematic review and meta-analysis. Front. Cardiovascular. Med. 8640124. https://doi.org/10.3389/fcvm.2021.640124 (2021).

    CAS PubMed Article PubMed Central Google Scholar

  • Nathan, HL, Duhig, K., Hezelgrave, NL, Chappell, LC & Shennan, AH Blood pressure measurement during pregnancy. Obstet. Gynecol. 1791–98 (2015).

    Google Scholar article

  • Shansila, E. et al. The effects of exercise and diurnal variations on monocyte subsets and monocyte-platelet aggregates. EUR. J. Clin. Invest. 42, 832–839. https://doi.org/10.1111/j.1365-2362.2012.02656.x (2012).

    CAS PubMed Google Scholar Article

  • Melgert, BN et al. Pregnancy and preeclampsia affect monocyte subsets in humans and rats. PLOS ONE seven, e45229. https://doi.org/10.1371/journal.pone.0045229 (2012).

    ADS CAS PubMed Article PubMed Central Google Scholar

  • Berg, KE et al. Elevated CD14++CD16- monocytes predict cardiovascular events. Circ. Cardiovascular. Broom. 5, 122–131. https://doi.org/10.1161/CIRCGENETICS.111.960385 (2012).

    CAS PubMed Google Scholar Article

  • Ozaki, Y. et al. Circulating CD14+CD16+ Monocyte Subsets as Biomarkers of Coronary Artery Disease Severity in Patients with Stable Angina Pectoris. Circ. J 762412-2418 (2012).

    CAS Google Scholar Article

  • Wong, KL et al. Gene expression profiling reveals the defining characteristics of classical, intermediate, and nonclassical human monocyte subsets. Blood 118, e16-31. https://doi.org/10.1182/blood-2010-12-326355 (2011).

    CAS PubMed Google Scholar Article

  • Zawada, AM et al. SuperSAGE evidence for CD14++CD16+ monocytes as the third subset of monocytes. Blood 118, e50–e61. https://doi.org/10.1182/blood-2011-01-326827 (2011).

    CAS PubMed Google Scholar Article

  • Wrigley, BJ, E. Shantsila, Tapp, LD & Lip, GY CD14++CD16+ monocytes in patients with acute ischemic heart failure. EUR. J. Clin. Invest. 43, 121–130. https://doi.org/10.1111/eci.12023 (2013).

    CAS PubMed Google Scholar Article

  • Bosco, MC et al. Monocytes and dendritic cells in a hypoxic environment: focus on chemotaxis and migration. Immunobiology 213, 733–749. https://doi.org/10.1016/j.imbio.2008.07.031 (2008).

    CAS PubMed Google Scholar Article

  • Krinninger, P. et al. Peripheral monocytes from obese women show increased expression of chemokine receptors and migration capacity. J. Clin. Endocrinol. Metab. 99, 2500–2509. https://doi.org/10.1210/jc.2013-2611 (2014).

    CAS PubMed Google Scholar Article

  • Pamukcu, B., Lip, GY, Devitt, A., Griffiths, H. & Shantsila, E. The role of monocytes in atherosclerotic coronary artery disease. Anne. Med. 42, 394–403. https://doi.org/10.3109/07853890.2010.497767 (2010).

    CAS PubMed Google Scholar Article

  • Al-ofi, E., Coffelt, SB, and Anumba, DO Monocyte subpopulations of preeclamptic patients are abnormally asymmetric and exhibit exaggerated responses to Toll-like receptor ligands. PLOS ONE seven, e42217. https://doi.org/10.1371/journal.pone.0042217 (2012).

    ADS CAS PubMed Article PubMed Central Google Scholar

  • Kim, JS et al. Distribution of CD14+ and CD68+ macrophages in the placental bed and basal plate of women with preeclampsia and preterm labor. Placenta 28, 571–576. https://doi.org/10.1016/j.placenta.2006.07.007 (2007).

    CAS PubMed Google Scholar Article

  • Brown, Ohio et al. Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease. Thromb. Hemost. 100626–633 (2008).

    CAS Google Scholar Article

  • May, AE et al. Reduction of monocyte-platelet interaction and monocyte activation in patients receiving antiplatelet therapy after coronary stent implantation. EUR. J-heart 181913-1920 (1997).

    CAS Google Scholar Article

  • Allen, N. et al. Circulating monocyte-platelet aggregates are a robust marker of platelet activity in cardiovascular disease. Atherosclerosis 282, 11–18. https://doi.org/10.1016/j.atherosclerosis.2018.12.029 (2019).

    CAS PubMed Google Scholar Article

  • Meher, S., Duley, L., Hunter, K., and Askie, L. Antiplatelet therapy before or after 16 weeks’ gestation to prevent preeclampsia: a meta-analysis of individual participant data. A m. J. Obstet. Gynecol. 216, 121–128. https://doi.org/10.1016/j.ajog.2016.10.016 (2017).

    CAS PubMed Google Scholar Article

  • Gremel, T. et al. The formation of platelet-monocyte aggregates is independent of platelet reactivity induced by residual agonists during treatment. Atherosclerosis 207, 608–613. https://doi.org/10.1016/j.atherosclerosis.2009.05.037 (2009).

    CAS PubMed Google Scholar Article

  • Broadband as a basic right will reduce poverty

    0

    The pandemic has opened up vast arenas for techpreneurs to showcase their skills. Remote work and collaboration tools have created new business models. Science became more human as larger populations understood it better. Technology is now pervading all sectors. Artificial intelligence, blockchain, cloud computing and data analytics are the buzzwords that make our lives easier every day. Remarkable changes in the way we transact, work and play would have been science fiction at some point. Pushing for greater investment in next-gen technologies is now table stakes. Technology consultancy Gartner predicts global IT spending will reach $4.5 trillion this year, a 5.1% increase from 2021.

    Cheap data plans and affordable phones have fueled a surge in internet penetration, creating unparalleled levels of convenience for end users. A study by analyst firm Nielsen found that of India’s 646 million internet users, 352 million are in rural areas. Although 60% of rural India does not have internet access, there are 20% more rural internet users than urban internet users. In 2020, India’s smartphone penetration rate reached 54% and was estimated to reach 96% in 2040, more than double from 2016 when only around 23% of the total population used smartphones.

    Technological transformations are not isolated events; it’s more like an octopus with arms dipping in various sectors complementing/feeding each other, growing along the way. Today, dazzling possibilities are emerging with 5G, the next generation of cellular technology. Location science is transforming key development sectors like health, logistics, mobility, water, agriculture, and more. The government is redefining development programs on the back of digital technologies with flagship programs like Digital India, Digital Saksharta Abhiyan, Smart cities, Study Webs of Active-Learning for Young Aspiring Minds (SWAYAM), PM e-Vidya, the rural property survey Svamiva diet, and many others. Online education, telemedicine, robotic surgeries, the rise of metaverse apps, home deliveries and many such facilities are having a huge transformational impact on our lives. AI-based diagnosis, disease surveillance and virtual health are now well understood. As the online world opens up new possibilities, broadband connectivity should become a basic right. Internet is a fundamental human right in Finland, Estonia, France, Spain, Greece and Costa Rica. Much like roads and highways, in a digital world, digital highways bring the kind of connectivity, remarkable speed and safety that only the digital world is capable of. In terms of possibilities, we’re only going to be limited by imagination (or lack thereof) now!

    India’s stack with its twin components – Aadhaar, the unique identifier for every citizen, and UPI, the digital payments infrastructure built by the National Payments Corporation of India (NPCI) – has bridged the gaps in financial inclusion and effectively provides services to citizens. According to a PwC study, UPI transactions grew at a compound annual growth rate of 785% between 2017 and 2020.

    The decade-old Bharat Net project aims to gradually deliver a minimum broadband connectivity of 100 Mbit/s to every 250,000 Gram Panchayats (GPs), covering almost 625,000 villages. Unfortunately, it has been plagued with delays resulting in a mismatch in the accessibility of Bharat India. A research paper from Ericsson points out that a 10% increase in mobile broadband adoption results in an initial 0.8% increase in GDP. This is an important consideration for policymakers to take a long-term view and usher in a new era of development growth where the entire population of 1.3 billion people is equally covered.

    Connectivity allows entrepreneurship and great ideas to thrive. The government cannot be present everywhere, to solve all the micro-problems. Such initiatives are best taken at the local level. And for that, we need connectivity. For innovation to pollinate in rural areas, among marginalized communities, for women to explore their potential, for all children to acquire greater skills, it is important to give them access first. CK Prahalad, the well-known strategist used to say, “The poor are poor because they have no information”. And therefore, broadband as a basic right will reduce the number of poor people in the country. play planning for growth is fundamental for equity In the same logic, quality broadband should be a basic right because it is crucial for economic growth.

    Dr. Ajai Chowdhry is Founder, HCL, Chairman, Epic Foundation. He is recognized as the father of hardware in India. The opinions expressed are personal.

    To subscribe to Mint Bulletins

    * Enter a valid email

    * Thank you for subscribing to our newsletter.

    Reviews | Infant formula supply shortages continue as key issues remain

    0
    Placeholder while loading article actions

    The infant formula crisis is still here, and the latest data shows an alarming sign of worsening. The powdered baby formula inventory rate was 76.5% for the week ending June 12, according to research firm IRI. It’s down from 79 percent early May, when the shortage became a major story. In another blow, Abbott Nutrition has once again had to shut down production at its infamous Michigan factory which produces special formulas after severe thunderstorms caused flood in the factory.

    The key problem at the heart of this mess remains: the United States does not have enough infant formula to meet its needs. We need to open up this market to more competition now – and for years to come.

    Three companies dominate domestic infant formula market. For decades, the United States has erected barriers that have made it virtually impossible for foreigners or domestic manufacturers to break this stronghold. The Food and Drug Administration has strict import rules. In addition to that, since 1989, Congress required that each state enter into an agreement with a company to be the provider of the state’s “WIC” (Special Supplemental Nutrition Program for Women, Infants, and Children) that serves low-income families. Since WIC purchases represent approximately half of all infant formula salesthe company that wins a state contract is almost guaranteed that its products will dominate the state’s shelves and sales.

    Our View: The FDA Must Be Held Accountable for the Infant Formula Crisis

    WIC’s state monopolies have generated substantial savings over the years, allowing the program to serve millions of other babies. But there was a dangerous side effect: a heavy reliance on three companies and seven production facilities for most US formulas. This is how we ended up in a situation where the closure of a major Abbott formula factory led to massive shortages and babies to be hospitalized.

    It is an alarm signal. Other rich countries don’t have these crises, largely because they have more competition. The FDA and the White House finally acted in May to expedite imports of foreign formulas. Congress also passed the Infant Formula Access Act to facilitate the temporary lifting of WIC monopolies. But these are short-term solutions. We should not allow a return to the old system in a few months when the emergency (hopefully) ends.

    First, we must continue to import. The FDA says its tough import controls relate to safety, but the formula could come from Europe, Australia and Singapore, which are places that have just as good, if not better, health outcomes for children. .

    Notice: Breastfeeding is not free. Here’s what it cost me

    Second, Congress should seriously consider whether it is time to abandon the WIC state monopolies, which would also require additional WIC funding, at least for a few years, to ease the transition. At a minimum, Congress could make it easier for companies to compete for WIC contracts by enacting the bipartisan WIC Act for a Healthy Start.

    Third, the FDA needs to improve its oversight of food safety, especially for domestic infant formula.

    There is blame for everyone in this crisis. Abbott’s Michigan plant was not up to standard. The FDA did not respond to the red flags in a timely manner, and the FDA and the White House should have intervened sooner. But long-standing issues have exacerbated this shortage and need to be addressed.

    A shortcut to cancer prevention

    0

    To better understand and perhaps prevent cancers caused by multiple genetic mutations, Rice University researchers are building a theoretical framework.

    New theory suggests mutations have few simple ways to establish themselves in cells and cause tumors

    For many researchers, the road to cancer prevention is long and difficult, but a recent study by scientists at Rice University suggests there may be shortcuts.

    A theoretical framework is being developed by Rice scientist Anatoly Kolomeisky, postdoctoral researcher Hamid Teimouri and research assistant Cade Spaulding that will explain how cancers caused by multiple genetic mutations could be more easily recognized and possibly prevented. .

    Cade Spaulding, Anatoly Kolomeisky and Hamid Teimouri

    A new paper from a Rice University lab shows how to increase the chances of identifying carcinogenic mutations before tumors take hold. The authors are, from left, Cade Spaulding, Anatoly Kolomeisky and Hamid Teimouri. Credit: Rice University

    It does this by detecting and ignoring transitional pathways that do not contribute significantly to fixing mutations in a cell that later becomes a tumor.

    The study, which was published on May 13, 2022 in the Biophysical Review, details their analysis of the effective energy landscapes of cellular transformation pathways linked to a number of cancers. The ability to reduce the number of pathways to those most likely to initiate cancer could aid in the development of strategies to interrupt the process before it begins.

    “In a sense, cancer is a bad luck story,” said Kolomeisky, a professor of chemistry and chemical and biomolecular engineering. “We think we can reduce the likelihood of this bad luck by looking for collections of low-probability mutations that typically lead to cancer. Depending on the type of cancer, this can vary between two mutations and 10.”

    The calculation of the effective energies which govern the interactions in the biomolecular systems can help to anticipate their behavior. The theory is widely used to predict how a protein will fold based on the sequence of its constituent atoms and how they interact.

    The Rice team applies the same idea to cancer initiation pathways that operate in cells but sometimes include mutations that go undetected by the body’s protections. When two or more of these mutations are fixed in a cell, they continue when cells divide and tumors develop.

    Rice University algorithm

    An algorithm developed at Rice University identifies and ignores transitional pathways that don’t contribute much to fixing mutations in a cell that goes on to establish a tumor. Credit: Hamid Teimouri/Rice University

    According to their calculations, the odds favor the most dominant pathways, those that transport mutations while expending the least energy, Kolomeisky said.

    “Instead of looking at all possible chemical reactions, we identify the few that we might need to look at,” he explained. “It seems to us that most of the tissues involved in the initiation of cancer try to be as homogeneous as possible. The rule is that a pathway that decreases heterogeneity will always be the fastest on the pathway to tumor formation.

    The large number of possible pathways seems to make their reduction an insoluble problem. “But it turned out that using our chemical intuition and building an effective free-energy landscape helped us by allowing us to calculate where in the process a mutation is likely to attach itself in a cell,” Kolomeisky said.

    The team simplified the calculations by initially focusing on pathways involving just two mutations that, once fixed, initiate a tumor. Kolomeisky said mechanisms involving more mutations would complicate the calculations, but the procedure remains the same.

    Much of the credit goes to Spaulding, who, under Teimouri’s guidance, created the algorithms that greatly simplify the calculations. The visiting research assistant was 12 when he first met Kolomeisky for advice. A graduate of a Houston high school two years early, he joined the Rice Lab last year at age 16 and will attend Trinity University in San Antonio this fall.

    “Cade has exceptional ability in computer programming and in implementing sophisticated algorithms despite his very young age,” Kolomeisky said. “He offered the most efficient Monte Carlo simulations to test our theory, where the system size can involve up to a billion cells.”

    Spaulding said the project brought together chemistry, physics and biology in a way that suited his interests, as well as his computer programming skills. “It was a good way to combine all branches of science and also programming, which I find most interesting,” he said.

    The study follows a 2019 paper in which the Rice lab modeled stochastic (random) processes to understand why some cancer cells overcome the body’s defenses and trigger the spread of disease.

    But understanding how these cells become cancerous in the first place could help avoid them on the cervix, Kolomeisky said. “This has implications for personalized medicine,” he said. “If a tissue test can detect mutations, our framework can tell you if you are likely to develop a tumor and if you need more frequent checkups. I think this powerful framework can be a prevention tool.

    The Welch Foundation (C-1559), the National Science Foundation (1953453, 1941106), and the NSF-supported Center for Theoretical Biological Physics (2019745) supported the research.

    Reference: “Optimal paths control fixation of multiple mutations during cancer initiation” by Hamid Teimouri, Cade Spaulding and Anatoly B. Kolomeisky, May 13, 2022, Biophysical Journal.
    DOI: 10.1016/j.bpj.2022.05.011

    Yoga, the immunity booster | Deccan Herald

    0

    Since the 5th century, yoga has benefited people by keeping the body and mind healthy. Most asanas make the body strong and flexible, and as health improves, the mind too is renewed with confidence. The practice of Pranayama regulates the purification of the internal system and organs, acting as a superior and capable complement to asanas. The energy that is generated in the body through these physical practices is then channeled into meditation or dhyan for stability, peace and calm. Yoga is known to boost our immunity and also to treat respiratory disorders. Pranayama or breathing exercises increase our oxygen consumption up to five times. Thanks to this rich oxygenation of the blood to the brain, heart, lungs and digestive systems, the functioning of our organs is greatly improved, thus improving our overall health as well. Here are some yoga asanas that help improve the immune system:

    Trikonasana or triangle pose

    This is one of the best yoga asanas to improve your immune system.

    Stand up straight with your feet wider than your hips and your hands at your sides.

    Now turn your right foot to the right and keep your left foot facing you.

    Bend your body from the waist to the right side and try to touch your right foot.

    Raise your left hand.

    Hold the position for 5 breaths and return to the starting position.

    Repeat the same on the other side.

    Advantages

    It also strengthens your arms, legs, ankles and chest and improves blood circulation in your body.

    Aids in digestion, burns fat and keeps your mind calm.

    Bhujangasana or Cobra Pose

    You can practice this asana in the morning or in the evening but leave some space after your meal.

    Lie face down on the floor with your feet together.

    Keep your palms under your shoulders and lift your upper body to resemble the raised hood of a snake.

    Tilt your head back and roll your shoulder back. Hold this position for about 30 seconds.

    Advantages

    Bhujangasana increases your metabolism and improves the digestive system.

    It also boosts your immunity and elevates your mood.

    Vrikshasana or tree pose

    When performing this pose, you should keep your eyes open if you are a beginner and maintain your balance. Try this pose with your eyes closed if you are an advanced practitioner.

    Start with your feet together.

    Now shift your body weight onto your left leg and lift your right leg. Place your right foot on the inner thigh of your left leg.

    Now join your palms in namaste in front of your chest and lift it above your head.

    Hold this position for a minute and repeat on the other side.

    Advantages

    Improves balance.

    Correct posture.

    Strengthens the lower body.

    Tadasana or mountain pose

    Practice this asana on an empty stomach. Its benefits include improving your digestion, blood circulation, and balance.

    Start with your feet together.

    Raise your hands to the sky stretching your body.

    Now slowly lift your heels and stand on your toes. Hold this position for about 30 to 60 seconds.

    Advantages

    It prepares your body and soothes your mind.

    It improves overall body posture and creates self-awareness.

    Matsyasana or fish pose

    The fish pose or matsyasana has many benefits. It can boost your immunity and digestive system. It also helps you sleep better and relieves neck and shoulder pain.

    Lie on the mat with your knees bent and your feet flat.

    Straighten your legs and place your arms on either side of your ears/shoulders.

    Exhale as you bend your elbows and push your upper body down to the floor.

    Raise your chest and tilt your head back.

    Place the crown of your head down.

    Hold this pose for 5-8 seconds and inhale as you lower your back to the floor.

    Advantages

    Strengthen the neck.

    Stimulates digestive function.

    Relieves neck and shoulder pain.

    The power of pranayama

    The breathing techniques in yoga are called pranayama, and when practiced regularly, they can have a powerful impact on your health and immune system. Bhastrika, Brahmari, Kapal Bhati and Anulom Vilom, help build your body’s defense mechanism and also aid in healing and recovery.

    (The author is a lifestyle coach and yoga entrepreneur.)

    Vitamin C levels decline with age – what you can do about it

    0

    Although science shows that older people have lower vitamin C levels, the exact cause of this unfortunate phenomenon is not completely clear.

    One theory is that our need for antioxidant activity increases with age due to higher levels of oxidative stress. Vitamin C is a dynamic, avid free radical scavenger that increases antioxidant activity in the body not only by fighting reactive oxidative species (ROS) on its own, but also regenerating other antioxidant powerhouses (e.g., glutathione and vitamin E).* Like vitamin C, our body stores of “master antioxidant” glutathione also decline with age. This decrease in antioxidant activity levels means that there is a greater need for antioxidants to fight ROS.

    While knowing vitamin C levels is important for people of all ages, increasing vitamin C intake through diet and quality supplementation can both restore glutathione and maintain healthy antioxidant levels, which is especially beneficial for the elderly. optimizing practices should ideally be a daily consideration (and effort).

    Another theory is that vitamin C absorption is less efficient in our later years (though not always effective for younger people either). Taking a bioavailable vitamin C supplement known to impact the cellular actions of vitamin C can ensure you both absorb, retain, and fully utilize the essential vitamin so it can support brain longevity. and whole body (among other amazing health benefits).*

    Latest SPAC Trends Indicate Risk of Negative Outcomes

    0
    By Adam Karageorge, Adrianna Huffman and Monet Lee (June 17, 2022, 6:03 p.m. EDT) – Calendar years 2020 and 2021 have seen a boom in special purpose acquisition companies, with an unprecedented number of IPOs. A SPAC is a shell company created by sponsors – usually private equity, venture capital or hedge fund investors – who raise money by selling shares of the SPAC through an IPO.

    Proceeds from the SPAC IPO are held in a trust and used by sponsors to identify and acquire a target company. SPACs seek to acquire or partner with an operating company through an initial business combination, and investors rely on sponsors to run the business…

    Stay one step ahead

    In the legal profession, information is the key to success. You need to know what’s going on with customers, competitors, practice areas and industries. Law360 provides the intelligence you need to stay an expert and beat the competition.

    • Access to case data in articles (numbers, filings, courts, nature of lawsuits, etc.)
    • Access to attached documents such as briefs, motions, complaints, decisions, motions, etc.
    • Create custom alerts for specific article and case topics and more!

    TRY LAW360 FREE FOR SEVEN DAYS

    Maike Sander appointed head of Max Delbrück C

    0

    image: Maike Sander has been selected to lead the Max Delbrück Center for Molecular Medicine (MDC).
    see After

    Credit: Peter Himsel/MDC

    On November 1, 2022, Prof. Maike Sander will take over as Scientific Director and Chair of the Board of Directors of the Max Delbrück Center for Molecular Medicine of the Helmholtz Association (MDC). The MDC Supervisory Board officially appointed her to this position on Thursday, June 16, 2022. The MDC, which celebrates its 30th anniversary this year, is one of five health centers of the Helmholtz Association of German Research Centers . Internationally renowned researcher and experienced science manager Maike Sander will succeed Professor Thomas Sommer, who has led the MDC on an interim basis since 2019. This will make Sander the first woman to lead one of Helmholtz’s health centers.

    “The MDC has distinguished itself as an internationally renowned center for highly innovative biomedical research,” says Maike Sander. “The work at MDC is laying the foundation for better medicine of the future. The MDC offers an exceptional environment for research and attracts talent from all over the world. I had the opportunity to experience this as a visiting professor at the MDC. As Scientific Director, my goal will be to further strengthen MDC’s role as a leading biomedical research center and to deepen partnerships with other institutions in Berlin and beyond, so that our discoveries can be rapidly transformed into medical innovations. Sander emphasizes that “medical innovation needs basic science, clinical science and strong industrial partners – components that are all part of Berlin’s vibrant biomedical ecosystem,” she points out. “The Berlin region is transforming into a thriving biotech pharma hub and I see MDC as the main driver of innovation in this landscape. I really look forward to working with all stakeholders in Berlin.

    New therapeutic approaches for diabetes

    Maike Sander’s research focuses on identifying new therapeutic approaches for diabetes. To this end, Sander is studying the molecular mechanisms that underlie the formation and function of different types of cells in the pancreas, particularly insulin-producing beta cells. Her goal is to identify strategies to replace beta cells in diabetes using beta cells derived from human pluripotent stem cells.

    Since 2012, Sander has served as Director of the Pediatric Diabetes Research Center at the University of California, San Diego (UC San Diego), where she is also a professor in the departments of Pediatrics and Cellular and Molecular Medicine. In Berlin, Maike Sander will be appointed professor at the Charité – Universitätsmedizin.

    German Minister of Research: an outstanding scientist with international experience

    “Maike Sander is an outstanding scientist with a proven track record of innovation in biomedical research,” says Bettina Stark-Watzinger, from Germany Federal Minister of Education and Research. “I am delighted that we were able to bring her back to Germany after many years in the United States and win her over as the new scientific director of the Max Delbrück Center. It demonstrates Berlin’s attractiveness as a hub for biomedical research. As a scientist and administrator, Professor Sander is a perfect fit for the MDC whose mission is to improve human health through transformative biomedical research. Also, having a female leader is an important signal. The appointment of Professor Sander represents a significant gain for German research.

    Berlin Senator for Higher Education and Research, Health, Long-Term Care and Gender Equality, Ulrike Gote, says: “In the person of Professor Maike Sander, the Max Delbrück Center has won an internationally renowned scientist as its new Scientific Director. I warmly welcome her to the science and healthcare metropolis of Berlin. Professor Sander’s expertise and experience provide the ideal context for the future development of the MDC and to increase the international visibility of the vibrant life science community at the MDC and in Berlin. As the senator responsible for higher education, research and gender equality, I am delighted to see a woman at the head of a Helmholtz health center.

    Wiestler: The Helmholtz Association will benefit enormously

    “I got to know Maike Sander as a diabetes and stem cell expert when she was a visiting professor at the MDC,” says Otmar D. Wiestler, President of the Helmholtz Association. “With her high scientific reputation and international experience, she is the ideal person to determine the future direction of the MDC as Scientific Director and Chair of the Board of Directors. With Professor Sander, we gain an excellent scientist whose expertise will be extremely beneficial to the Helmholtz Association. A critical area is the development of precision medicine approaches. The MDC is at the forefront of advancing research in this important area. I look forward to working with Professor Sander and having a lively exchange of ideas.

    About Maike Sander

    Maike Sander, from Göttingen, is 54 years old. After earning a medical degree from the University of Heidelberg Medical School in 1994, she conducted research at the University of California, San Francisco. Before joining UC San Diego in 2008, she held faculty positions at Hamburg Medical School and the University of California, Irvine. An expert in insulin-producing pancreatic beta cells, she has nearly 30 years of experience in diabetes medicine and research.

    Sander is an elected member of the German National Academy of Sciences Leopoldina, the Association of American Physicians, and the American Society of Clinical Investigation. In addition, she is a member of two NIH consortia: The Human Islet Research Network and the NIH Impact of Genomic Variation on Function Consortium, which seeks to define the basic mechanisms of gene regulation.

    She is the recipient of the Grodsky Prize from the Juvenile Diabetes Research Foundation, the 2022 Albert Renold Prize from the European Association for the Study of Diabetes, and the Alexander von Humboldt Foundation Research Prize. Since 2019, Sander has been a Visiting Einstein Scholar at the Berlin Institute of Health at Charité (BIH).

    More information

    30 years MDC

    Sander Laboratory and Publications at the University of California, San Diego

    contacts

    German Federal Ministry of Education and Research (BMBF)
    Press Division; social media; the Internet
    Kapelle-Ufer 1
    10117Berlin
    +49-(0)30-1857-5050
    [email protected]

    Jutta Kramm
    Head of the Communication Staff Unit
    Helmholtz Association (MDC) Max Delbrück Center for Molecular Medicine
    +49-(0)30-9406-2140
    [email protected] or [email protected]

    Max Delbrück Center for Molecular Medicine (MDC)

    The Helmholtz Association’s Max Delbrück Center for Molecular Medicine (MDC) is one of the world’s leading biomedical research institutions. Max Delbrück, originally from Berlin, was a Nobel laureate and one of the founders of molecular biology. At the MDC sites in Berlin-Buch and Mitte, researchers from around 60 countries analyze the human system and study the biological basis of life, from its most basic building blocks to systemic mechanisms. By understanding what regulates or disrupts the dynamic balance of a cell, an organ or the whole body, we can prevent diseases, diagnose them earlier and stop their progression thanks to appropriate therapies. Patients should benefit as soon as possible from the discoveries of basic research. The MDC thus supports the creation of spin-offs and participates in collaborative networks. It works in close partnership with Charité – Universitätsmedizin Berlin in the jointly run Center for Experimental and Clinical Research (ECRC), the Berlin Institute of Health (BIH) at Charité and the German Center for Cardiovascular Research (DZHK). Founded in 1992, the MDC today employs 1,600 people and is funded 90% by the German Federal Government and 10% by the State of Berlin.


    Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of press releases posted on EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

    Virginia’s COVID-19 quarantine rules change due to higher immunity rates

    0

    RICHMOND – “It is time to review some of our practices for groups at low risk of severe COVID-19 illness, especially those whose side effect is a significant limitation in access to daycare, school or at work,” the Virginia state health commissioner said. Colin M. Greene in a statement to the public on June 16.

    Effective immediately, the Virginia Department of Health has updated its website and revised its quarantine guidelines for COVID-19, in some cases significantly.

    These changes reflect COVID’s progression from an acute pandemic to a more endemic state, Greene said.

    To explain the changes, the commissioner provided data on adult and child immunity rates.

    COVID-19 immunity rate

    • Evidence from the Centers for Disease Control suggests that well over 75% of children have post-infection immunity to COVID-19, in addition to any vaccine-derived protection.
    • Immunity rates in adults between vaccination and post-infection probably exceed 90%.
    • There is evidence that post-infection immunity can be effective for six months or more.

    As a result, quarantine and isolation guidelines now reflect these immunity rates.

    After: Staunton’s Mill Street Grill celebrates 30 years in business

    After: Weyers Cave man charged with murder after his brother was shot and killed in a business

    COVID-19 Quarantine Guide

    No more quarantine for risk-free situations:

    • If a person is exposed to COVID-19, but has tested positive and has recovered from COVID-19 within the past six months, or is up to date on vaccines, or both, that person will no longer be recommended to quarantine.

    Instead, that person should monitor for symptoms and follow isolation protocols if they appear. This varies slightly from the CDC guidelines, which define the period of post-infection immunity at 90 days.

    “This change will apply to the general public, including but not limited to settings such as K-12 schools and early childhood education settings,” Greene said.

    Your support helps keep the lights on at The News Leader. Stay connected with our stories, corporate reports and more by by clicking “Subscribe” at the top of the page.

    Quarantine remains for high-risk situations:

    “Out of an abundance of caution, we will retain the 90-day standard for high-risk situations, including healthcare workers, staff and residents of long-term care facilities, correctional facilities and homeless shelters” , Greene said.

    This change only affects quarantine recommendations for individuals and will not impact the state’s case surveillance/classification process for the purposes of reporting probable or confirmed cases to the CDC.

    Recommendations for isolation with active disease or an asymptomatic positive test remain unchanged.

    After: Juneteenth is fast approaching. Here’s how you can celebrate in the Valley this weekend.

    After: Augusta Health reports an average COVID positivity rate. Here’s what that means.

    After: Development Updates and Fast Streets in Staunton: Where the News Takes Us

    Your support is vital for local journalism. Please register.

    How Sideshore Technology can optimize your offshore wind farm layout by applying state-of-the-art algorithms

    0

    Written by Ben de Sonneville, Director of Sideshore Technology

    Smarter offshore wind farm developments will accelerate the energy transition

    Optimizing the layout of wind farms is the art of defining the optimum locations for wind turbines, field cables and substation structures. It presents a golden opportunity to increase the value of the project.

    The academic community has done extensive research on the numerical optimization of wind farm layouts, however, in real projects it is hardly ever applied. Optimizing the location of a wind farm is complex because it is multidisciplinary. A wind farm development is usually divided into work packages (turbine, foundations, cables, substation). The location of each wind turbine influences the cost of the project in the different work packages. Although wake effects are important, other aspects must also be taken into account. For example, water depth affects the size of foundations. Turbulence levels should be limited. And cables, seabed preparation and ground conditions are often overlooked, when they too can have a substantial impact on costs. Complete optimization of turbine positions not only requires insight into wake interactions and cost factors across all work packages, but also a way to tie everything together.

    Even today, wind farm layout optimization is often still carried out as a simple iterative process. First, the layout is designed by performance specialists using a simple regular grid. Thereafter, it is improved in stages, going back and forth between the different work packages. However, Sideshore Technology has recently developed software where all cost factors are mapped and interconnected in one complete and efficient simulation. This allows the layout of the wind farm to be optimized with thousands of calculation iterations, realizing unprecedented gains in project value.

    At Sideshore Technology, we believe that data science and optimization methods will play a key role in the transition to a more sustainable world. We bring together the worlds of offshore wind project development and high performance numerical optimization to create optimal wind farm configurations.

    Together with our clients, we evaluate the variables that drive the costs of all packages, bring them together in a single model, and automatically optimize the wind farm layout using our proprietary optimization techniques and software tool, the Layout Doctor. The integration of all these variables is complex but can greatly increase the value of the project. The resulting cost savings will help accelerate the energy transition and enable more efficient use of offshore wind farm areas.

    Optimization applies parallel computing methods running on multi-core GPUs and CPUs. Our cost models include wakes, foundation cost, cable cost and seabed preparation costs. The optimization also takes into account project boundary conditions such as minimum distances, exclusion zones, installation requirements and avoidance of excessive turbulence. The resulting designs typically outperform traditional configurations with tens to hundreds of millions of dollars saved over the lifetime of a wind farm.

    Are you curious to know how your project could benefit from our optimizations? Ask for a layout check.

    This embedded content is only visible after accepting cookies.

    Note: The opinions, beliefs and views expressed in this article do not necessarily reflect the opinions of Offshore WIND.

    Science-based nonprofit funds search for chemical engineering professor for Homeland Security

    0



    Photo submitted

    Tom Spicer 3

    Battelle, a nonprofit science organization in Columbus, Ohio, has awarded Tom Spicer III, Professor of Chemical Engineering, a research fellowship to support the Science Branch’s Chemical Safety Analysis Center and technologies from the Department of Homeland Security.

    Spicer is a professor in the Department of Chemical Engineering at Ralph E. Martin whose research interests include examining the hazards of airborne contaminants and fire and explosion phenomena. The funding he received is for hazard and risk analysis of chemical and material threats. Battelle’s funding is for five years and has a contractual cap amount of just under $1.5 million.

    This funding will allow Spicer to continue to develop cutting-edge technology to assess the consequences of potential toxic or flammable cloud releases. His research team will examine how much ammonia would be removed from a toxic cloud by environmental materials. This project is made possible by the unique experimental capabilities of the Controlled Environment Reactivity Testing Facility housed and maintained at the U of A Engineering Research Center by the Chemical Hazard Research Center and the Ralph E. Martin Department of Chemical Engineering.

    This work builds on previous studies conducted at the test facility, which found that current assessment practices could significant overestimation of chlorine removal in case of accidental release. Wind tunnel experiments were used to physically model chlorine cloud releases and assess reactivity as part of the Jack Rabbit II Field Trials.

    Founded in 1929, Battle serves national security, health and life sciences; energy; and environmental industries. Battelle is the largest independent, not-for-profit research and development institute in the world.

    The Chemical Safety Analysis Center was established by the Department of Homeland Security identify and assess chemical threats and vulnerabilities in the United States and develop the best responses to potential chemical risks. The center conducted the aforementioned Jack Rabbit Project.

    Spicer earned his Ph.D. in engineering from the U of A in 1985. He earned his bachelor’s and master’s of science degrees in chemical engineering from the university in 1981 and 1983, respectively. Spicer is the director of the Chemical Hazards Research Center. The facility includes several wind tunnels and wind tunnels, including a very low speed wind tunnel.

    About the Department of Chemical Engineering: Chemical engineering has been part of the curriculum at the University of Arkansas since 1903. Today, the Ralph E. Martin Department of Chemical Engineering has an enrollment of over 300 students in its undergraduate and graduate programs and is home to five endowed chairs and eight endowed chairs to support its faculty. Faculty expertise includes cell engineering, chemical process safety, advanced materials, and membrane separations. A wide range of basic and applied research is carried out in the fields of energy, health, sustainability and computational chemical engineering. The department also houses the Chemical Hazards Research Center and is one of three national sites for membrane science, engineering and technology. (MAST) Center. The Department of Chemical Engineering is named after alumnus Ralph E. Martin (BSCh.E.’58, MSCh.E.’60) in recognition of his 2005 endowment gift.

    Houma company starts first of two ocean research vessels

    0
    to play

    A Houma company has launched the first of two ocean research vessels that will employ 300 to 400 people locally and cost nearly $200 million to build.

    Officials from the National Oceanic and Atmospheric Administration and Thoma-Sea Marine Constructors celebrated Wednesday with a keel-laying ceremony for the oceanographer at the Houma-Terrebonne Civic Center.

    “NOAA ships play a vital role in meeting the large and growing demand for ocean data, essential for protecting lives and livelihoods,” said agency administrator Rick Spinrad. “Oceanographer’s new capabilities will contribute to NOAA’s continued leadership in providing reliable, high-quality data to the nation.”

    The Oceanographer will support a variety of missions, including general ocean research and exploration to studies of marine life, climate and ecosystems. The ship, which will cost just under $100 million to build, is expected to be completed in 2025. Its homeport will be Honolulu, Hawaii.

    The local economy: The Houma region is struggling to find jobs. “It’s not a pretty picture,” says an economist

    Thoma-Sea will begin construction of the ship’s sister ship, the Discoverer, in October, with completion expected in 2026. A homeport has yet to be decided.

    The Houma company won the $178 million contract for the two US Navy ships in January. This is part of NOAA’s ongoing program to replace its aging research fleet. The first Oceanographer served from 1966 to 1996. The Discoverer served from 1967 to 1996.

    Thoma-Sea chief executive Walter Thomassie, 51, said work on the Oceanographer will involve about 700 suppliers and vendors across the United States.

    The ship, 244 1/2 feet by 51 1/4 feet, will be able to carry 48 people for 65 days at a time. It will be maintained by a crew of 20 and 28 scientists will conduct research.

    Both ships will incorporate the latest technologies, including emissions controls and high-efficiency diesel engines, officials said. The technology has the potential to save 15,000 gallons of fuel per year for each vessel, resulting in an estimated reduction of 5,700 tonnes of carbon dioxide.

    “So very similar to what you have in cars now,” Thomassie said. “So we’ve incorporated those elements into our design, so it’s a really big step forward in that regard in terms of efficiency and ecology.”

    Herd immunity and Omicron variant decrease hospitalization cases | Additional News

    0

    While Trinidad and Tobago has not shaken off the infectious spread of the Covid-19 virus, the country is recording several positive trends with regards to the number of Covid-19 cases admitted to its various health facilities.

    According to Chief Medical Officer Dr. Maryam Abdool-Richards, the current hospital occupancy rate in the parallel health system is 22%, which represents 140 patients hospitalized in the parallel health system in Trinidad and Tobago.

    “We have seen a significant drop in the use of the parallel health system from February 18. It’s a promising sign because it’s a consistent trend,” she said.

    Abdool-Richards, speaking at Wednesday’s virtual Covid-19 press conference, said the level of intensive care unit (ICU) occupancy has always been of concern as it represents the patients most at risk to have an adverse event.

    “We have low intensive care occupancy everywhere. In fact, this morning, intensive care occupancy is 14%, which represents nine patients; seven in Trinidad and two in Tobago.

    “The occupancy rate at our ward, which represents the least seriously ill patients but those still in need of medical care and with high risk factors, is 23%.

    “So overall we’ve seen some positive trends in the shadow health system.”

    She said that for the accident and emergency departments, which are the first point of contact for people in the shadow health system, there are currently ten accident and emergency patients waiting to be transferred to the parallel health system or to be stabilized and taken care of.

    She noted that these ten patients are spread across ten accident and emergency departments in Trinidad and Tobago, with the Sangre Grande A&E department hosting five and two at Mt Hope Hospital’s two.

    “Again, from February, we have noticed and identified a decrease in the number of patients who are in the accident and emergency departments.

    “We also consider the ambulance service because it is an indicator concerning the transfer of patients. As of this morning, eight percent of all ambulances in the fleet, or 37 at peak, are being used for transporting Covid-19. And that’s in stark contrast to what we would have seen from April to June of last year, and then October to January of this year, when we would have seen up to 80% of the ambulance service some days.

    Abdool-Richards said the current Covid-19 situation in the country is a far cry from the situation he would have faced between October, and especially December 23-26, and November 26.

    “On those days, the shadow health system was at 83% occupancy and our A&E had a significant number of patients and were stretched. Our ICU occupancy rate was around 85-95%.

    “We know that we had an increase in herd immunity which explains the decrease in the number of hospitalizations, and we also note the decrease in the virulence of the Omicron variant.

    She said that despite the positive trends seen, there are still caveats and warnings that people should heed.

    “Vaccination is a proven method to prevent Covid-19, and it is also a proven method to reduce the spread and transmission of Covid-19 and the severity of Covid-19. And when you get vaccinated, you protect your close and elderly relatives, and all the people who may contract Covid-19 but who cannot be vaccinated at the time, and who are at risk of being admitted to a hospital or a intensive care unit.

    She noted that people who seek medical care early are more likely to test positive and survive Covid-19 with fewer complications.

    Nuclear Waste Management Market Expected To Reach USD

    0

    New York, United States, June 15, 2022 (GLOBE NEWSWIRE) — According to a comprehensive research report by Market Research Future (MRFR), “Nuclear Waste Management Market Analysis by Waste Type, by Reactor Type (Pressurized Water Reactor, Boiling Water Reactors, Gas-Cooled Reactors, Pressurized Heavy Water Reactor), by Application (Industrial and Utility) by Region – The Global Forecast Value until 2027 is about to reach USD 6,878.9 million by 2027, registering a CAGR of 2.8% throughout the forecast period (2021-2027).

    Nuclear Waste Management Market Overview

    The global nuclear waste management market is expected to witness a significant boom. Growing awareness of the importance of nuclear waste management is a key driver.

    Scope of Nuclear Waste Management Market Report:

    Report metric Details
    Market size $6,878.9 million (2027)
    CAGR 2.8% (2021-2027)
    Year of reference 2020
    Forecast period 2021-2027
    Historical data 2019
    Forecast units Value (USD million)
    Report cover Revenue forecasts, competitive landscape, growth factors and trends
    Segments Covered Waste type, reactor type, application and region
    Geographical areas covered North America, Europe, Asia-Pacific and Rest of the World (RoW)
    Main suppliers Veolia (France), Enercon (United States), US Ecology Inc. (United States), Stericycle Inc. (United States), Posiva Oy (Finland), John Wood Group PLC (United Kingdom), Bechtel Corporation ( USA), Perma-Fix (USA), Fluor Corporation (USA), Waste Control Specialists LLC (USA), BHI Energy (USA), Augean PLC (UK), DMT ( Germany), Chase Environmental Group Inc. (USA), Westinghouse Electric Company LLC (USA), and Holtec International (USA)
    Key market opportunities High capacity required for permanent elimination
    Key Market Drivers Lack of permanent elimination alternatives

    Get a Free Sample PDF Brochure

    https://www.marketresearchfuture.com/sample_request/7226

    Strict standards and regulations introduced to control toxic nuclear emissions are having a positive impact on the market value, forcing more investment in nuclear projects. Increasing financial support from public and private sectors in an organized, consistent and timely manner to set up waste management facilities helps in the growth of the market, multiplying the total number of nuclear waste management plants.

    In the process of generating electricity using nuclear reactors, a small amount of waste results, which must be managed according to regulations. Several management strategies are practiced for direct disposal or reuse in reactors to generate more low-carbon electricity. Additionally, increasing technological advancements are increasing the size of the market, improving waste management solutions and techniques.

    Nuclear Waste Management Market Segments

    The Nuclear Waste Management Market report is segmented into Waste Types, Reactor Types, Applications, and Regions. The waste type segment includes low-level waste, intermediate-level waste and high-level waste. The reactor type segment includes pressurized water reactors, boiling water reactors, gas-cooled reactors and pressurized heavy water reactors. The application segment includes industry and utilities. The regional segment includes North America, Europe, Asia Pacific, Middle East & Africa, and others.

    Browse the in-depth market research report (143 pages) on the Nuclear Waste Management Market:

    https://www.marketresearchfuture.com/reports/nuclear-waste-management-market-7226

    Nuclear Waste Management Market Regional Analysis

    North America dominates the global nuclear waste management market. The strong presence of key technology providers, well-established waste management and infrastructure companies offers many opportunities for significant growth. With more than 104 commercial nuclear reactors in operation at 56 nuclear power plants in 28 states, the United States accounts for the major regional market share.

    In addition, industrial safety standards associations and energy regulatory commissions, such as the United States Department of Energy (DOE), the United States Nuclear Regulatory Commission (NRC), and the Agency Environmental Protection Agency (EPA), have a positive impact on market share in the region. Additionally, early adoption and widespread awareness of the benefits of advanced waste management solutions are driving the growth of the regional market.

    Europe is another lucrative market for nuclear waste management. The increase in electricity generated by the capacity of nuclear power plants due to the increase in energy demand is a key driver of growth. The region is experiencing an increase in nuclear power generation, which has increased the amount of spent fuel, leading to the adoption of nuclear waste management legislation in the EU.

    Legislation governing the responsible and safe management of spent fuel and nuclear waste is based on internationally recognized principles without imposing undue obligations on future electricity generations.

    Industry trends

    Most countries today use nuclear technology to generate electricity and radioactive materials for many other purposes. This, therefore, increases the need for an efficient process to manage the radioactive waste and spent nuclear fuel generated by these activities in a safe and efficient manner.

    However, nuclear waste must be handled properly in order for it to be disposed of safely. Waste treatment includes collecting and sorting, reducing the volume of waste and changing its chemical and physical composition, and conditioning it to make it immobilized and packaged before storage and disposal. Much research is underway to develop new waste management solutions and techniques and improve existing ones.

    Ask the expert:

    https://www.marketresearchfuture.com/ask_for_schedule_call/7226

    For example, on June 10, 2022, Delkia, a UK-based systems integrator, announced that it was working with Kawasaki, a robotics company, to develop and test software to control a robotic arm capable of protecting the staff when categorizing nuclear waste. Currently, processes, such as dismantling equipment and sorting contaminated materials, are done manually while wearing PPE suits.

    This means that operators work and are in contact with potentially dangerous nuclear substances for approximately 8 to 9 hours a day. Therefore, Delkia and Kawasaki decided to develop this innovative robotic arm to protect workers and improve plant safety, ensuring maximum protection against radioactive materials.

    In addition, manual management of nuclear waste is expensive and time-consuming, especially when many industries face labor shortage issues. The nuclear industry is increasingly looking for machines and tools to perform the tedious, repetitive and often dangerous tasks associated with waste categorization.

    The model can sort and manage different categories of nuclear waste, making it safer and more cost effective than current processes. The software will control the robot’s safety-critical movements and functions. Therefore, a robot-driven waste categorization process is certainly highly desirable in the nuclear industry.

    Nuclear Waste Management Market Competitive Analysis

    The Dominant Key Players in the Nuclear Waste Management Market Covered are:

    • Veolia (France)
    • Enercon (USA)
    • US Ecology Inc. (USA)
    • Stericycle Inc. (USA)
    • Posiva Oy (Finland)
    • John Wood Group PLC (UK)
    • Bechtel Corporation (USA)
    • Perma-Fix (USA)
    • Fluor Corporation (USA)
    • Waste Control Specialists LLC (USA)
    • BHI Energy (USA)
    • Augean PLC (UK)
    • DMT (Germany)
    • Chase Environmental Group Inc. (USA)
    • Westinghouse Electric Company LLC (USA)
    • Holtec International (USA)

    Buy this report:

    https://www.marketresearchfuture.com/checkout?currency=one_user-USD&report_id=7226

    The nuclear waste management market is witnessing several strategic partnerships, along with other strategies such as expansion, mergers and acquisitions, collaboration, and service and technology launches. Major players in the industry are investing heavily in research and development activities and promoting their expansion plans.

    For example, on March 04, 2022, on June 07, 2022, Skanska Talonrakennus Oy, a Finnish contractor responsible for the construction of the spent fuel encapsulation plant in Olkiluoto, announced that it had entered the installation phase and handed over the building to a Finnish waste management company – Posiva, for the installation of the nuclear systems and the commissioning of the encapsulation plant treatment systems.

    Related reports:

    Fixed Tilt Solar PV Market Research Report: Information by Technology, Application and Region – Forecast to 2030

    Slickline Services Marketplace Research Report: Insights by Slickline Tools, Application and Region – Forecast to 2030

    E-Load Market Research Report: Insights by Voltage, Application, Current Type and Region – Forecast to 2030

    About Market Research Future:

    Market Research Future (MRFR) is a global market research company that prides itself on its services, offering comprehensive and accurate analysis regarding various markets and consumers around the world. Market Research Future has the distinct objective of providing clients with top quality research and granular research. Our market research by products, services, technologies, applications, end users and market players for global, regional and country market segments enables our clients to see more, know more and do more , which helps answer your most important questions. questions.

    Follow us: LinkedIn | Twitter

    
    

    Mosaic Biosciences Secures Funding from Telegraph Hill Partners to Support Commercial Growth and Expand Drug Discovery Capabilities and Services

    0

    BOULDER, Colorado–(BUSINESS WIRE)–Mosaic Biosciences (“Mosaic” or “the Company”), a protein and antibody discovery company that helps partners identify next-generation therapies for the prevention and treatment of disease. announced the closing of an $11.4 million financing led by Telegraph Hill Partners (“THP”), a San Francisco, California-based life science venture and growth capital firm. Dan Mitchell, a Boulder-based venture capitalist, also participated in the financing.

    Mosaic provides its partners with experienced leadership and biopharmaceutical research teams to drive the discovery and development of therapeutic proteins, from concept to preclinical development. The Company is working with its partners to expand their research capabilities and accelerate their development programs. Mosaic’s capabilities streamline protein and antibody therapeutic programs, reduce time and cost, and successfully advance programs through the achievement of key discoveries and early development milestones.

    The growth funding will be used to expand lab facility infrastructure, develop new technologies and capabilities, strengthen the business development team, and expand Mosaic’s science team to meet changing discovery services needs. protein and antibody therapeutics.

    “We are thrilled to partner with the THP team as we work to build the preeminent company for therapeutic protein and antibody discovery,” said Marty Stanton, CEO and COO of Mosaic Biosciences. “We are committed to providing a broad spectrum of discovery capabilities to help our partners bring transformative therapies to their patients.”

    “Mosaic brings CSO-caliber expertise and experienced biopharmaceutical research teams to design, guide, execute and manage drug programs for their partners that focus on the discovery of innovative drugs,” said Jeanette Welsh, Partner at Telegraph Hill. Partners. “We look forward to working with the full team at Mosaic to address the critical need to solve challenging problems in therapeutic discovery.” Jeanette Welsh and Rob Capone of Telegraph Hill Partners will join Mosaic’s board alongside the financing, and Deval Lashkari of Telegraph Hill Partners will join the board as an observer. Dan Mitchell and Eric Furfine, Mosaic’s CEO and Scientific Director, will also serve on Mosaic’s Board of Directors.

    About Mosaic Biosciences:

    Mosaic is a protein and antibody discovery company that helps partners identify next-generation therapies for disease prevention and treatment. Mosaic teams provide comprehensive, end-to-end discovery services, including program evaluation and strategy development; program management; antibody discovery and optimization; production, purification and characterization of proteins; protein engineering; development of biochemical and cellular assays; formulation, stability and developability studies; development of bioanalytical assays (PK and PD); and validation pharmacology of clinical candidates. Mosaic’s partners include biopharmaceutical companies, start-ups, and academic venture and seed funds. For more information, please visit www.mosaicbio.com.

    About Telegraph Hill Partners:

    Telegraph Hill Partners, founded in 2001 and based in San Francisco, Calif., invests in commercial life sciences, medical technology and healthcare companies. For more information, please see www.telegraphhillpartners.com.

    According to Accenture Research, more than 60% of companies are just experimenting with AI, creating significant value opportunities on their journey to AI maturity

    0

    While the majority of organizations using artificial intelligence (AI) are still experimenting with the technology, only 12% are using it at a level of AI maturity that gives them a strong competitive advantage, according to new global research from Accenture (NYSE:ACN).

    The art of AI maturity: moving from practice to performance” uncovers strategies for AI success through a holistic framework, which includes a new index to express enterprise AI maturity on a scale of 0 to 100. According to the research, AI maturity AI is the degree to which organizations outperform their peers in a combination of AI-related core capabilities and differentiation. These capabilities include technology – data, AI, cloud – as well as organizational strategy, Responsible AI, Sponsorship of the C suite, talent and culture.

    “To remain resilient despite ongoing market disruptions, organizations must leverage the combined power of AI, data, and the cloud to address complex challenges around supply chain, sustainability, customer experience and skills shortages,” said Piyush N. Singh, Head of India Business at Accenture. “AI adoption has matured rapidly during the pandemic, but to create more value with AI and use it to reinvent the business, companies need a clear vision of leadership combined with management. effective change and the reinvention of human capital.”

    Prithvijit Roy, Managing Director – Applied Intelligence, Accenture India, said: “Our research shows that as the impact of AI on businesses across all industries rapidly increases, organizations need to champion AI as a strategic priority for the entire organization with a clear strategy. and strong executive sponsorship. To successfully scale the use of AI, they must industrialize AI tools and teams and also nurture a culture of responsible AI design. But most importantly, they must invest In addition to hiring multidisciplinary AI-related skills, it is imperative to create data and AI fluidity across the workforce through training and reskilling of a majority of employees – from product development teams to C-suite executives – to ensure that AI permeates the entire organization.”

    The research places the median AI maturity of organizations at a moderate score of 36, revealing that most companies have significant opportunities to drive greater value with AI. The research highlights a small group (12%) of organizations that are already using AI to outpace their competitors. This group is nicknamed AI developers, with a score of 64 on the maturity scale, almost double that of others and correlating with 50% higher revenue growth than their peers.

    The analysis further shows that most companies (63%) are AI experimenters, barely scratching the surface of AI’s potential with an AI maturity score of 29. AI innovators (13%), scoring 50, and AI builders (12%), at 44, are somewhat advanced in their level of AI maturity, but still leave the full value of AI untapped.

    “We believe that every part of every business should be transformed by technology, data and AI, in some cases leading to total business reinvention,” said Sanjeev Vohra, Global Head of Applied Intelligence at Accenture. “AI Achievers show their peers what’s possible when you unlock the full potential of talent and technology, working in tandem, backed by a clear vision and commitment to change. But even this most mature group has a lot room for growth.And while most industries have AI Achievers, they vary widely in their level of AI maturity and the leaps they will take.

    Automatically generated chart description

    Here are examples of the current and projected state of AI maturity by industry:

    • Technology companies already have a high AI maturity score of 54, which will increase moderately to 60 in 2024, but still positions them at the top of AI maturity across all industries.
    • In contrast, manufacturers and equipment manufacturers will rise from a modest 39 today to 57 in two years – betting on a significant increase in sales of AI-powered autonomous vehicles.
    • In the same way, retail businesses will scale in their AI maturity from 38 today to 54 in 2024. Notably, many retail companies are showing a deeper commitment to AI transformation than other industries. Walgreens Boots, as part of its efforts to create a more data-driven organization that can provide customers with highly personalized digital service, migrated from legacy databases to advanced cloud databases and analytics. The company has also created more than 100 high-value AI products that create detailed customer profiles and help it better optimize inventory and prices.

    Regardless of the industry, the impact of AI on business is growing and accelerating. The world’s largest companies that discussed AI in their 2021 earnings calls were 40% more likely to see their stock prices rise, up from 23% in 2018. Additionally, investments in AI are on the rise. In 2021, 19% of companies surveyed used more than 30% of their technology budget for AI projects. By 2024, the percentage of organizations investing more than 30% of their technology budget in AI will increase to 49%.

    Subsequently, machine learning models used for research suggest that the share of AI Achievers will rapidly increase from the current 12% to 27% by 2024. the AI ​​will go from 36 today to 50.

    “Adopting AI at scale and embedding it deeper into all aspects of business is no longer a choice, but a necessity and opportunity for every industry, organization and leader,” Vohra said. “While the science of AI is revolutionary and inspiring, harnessing it to its fullest is an art that leaders must continually practice. Our report provides practical recommendations on how to advance AI maturity to join the ranks AI Achievers.

    About Research

    The research, titled “The Art of AI Maturity: Advancing from Practice to Performance” is based on financial and non-financial data from 1,176 companies that use AI and survey data from 1,615 executives, conducted from August as of September 2021, across 16 industries (Aerospace & Defense; Automotive; Consumer Goods & Services; Chemicals; Energy; Financial Services; Healthcare; Industrial Equipment; Life Sciences; Natural Resources; Utilities; Retail; Technology; Telecommunications , Media and Entertainment; Travel and Transport; Utilities) and 15 countries (Australia, Brazil, Canada, China, France, Germany, India, Israel, Italy, Japan, Singapore, South Africa, Spain, United Kingdom, United United). The data fed into machine learning models, which determined how companies performed on a set of AI-related capabilities – mostly “core” capabilities, which companies need to compete on AI, and mainly “differentiation” capabilities, which give businesses a competitive edge with AI. The results of the two models were combined into a single index that measures the maturity of AI on a scale of 0 to 100. A detailed description of the methodology and the sample can be found in the appendix of the research report (available in download here).

    About Accenture

    Accenture is a global professional services company with industry-leading digital, cloud and security capabilities. Combining unparalleled experience and specialist skills in more than 40 industries, we offer strategy and advisory, technology and operations, and Accenture Song services, all powered by the world’s largest network of advanced technology centers and smart operations. Our 699,000 people deliver on the promise of technology and human ingenuity every day, serving customers in more than 120 countries. We embrace the power of change to create value and shared success for our customers, our people, our shareholders, our partners and our communities. Visit us ataccenture.com.

    USPTO officials say High Court helps decide immunity claim

    0
    By Britain Eakin (June 13, 2022, 9:10 p.m. EDT) – Former and current officials of the U.S. Patent and Trademark Office told a federal judge in Tennessee on Monday that a recent US Supreme Court decision- United reinforces their claim that they are immune to allegations that they ‘rigged the inter partes review system against patentees.

    Officials, including former USPTO director Michelle Lee and current and former administrative patent judges, cited the Supreme Court’s June 8 decision in Erik Egbert v. Robert Boule in an additional authoritative opinion while that they are trying to fend off a lawsuit from computer programmer Martin David. Hoyle and his company, BE Technology LLC. The notice said the Egbert decision,…

    Stay one step ahead

    In the legal profession, information is the key to success. You need to know what’s going on with customers, competitors, practice areas and industries. Law360 provides the intelligence you need to stay an expert and beat the competition.

    • Access to case data in articles (numbers, filings, courts, nature of lawsuits, etc.)
    • Access to attached documents such as briefs, motions, complaints, decisions, motions, etc.
    • Create custom alerts for specific article and case topics and more!

    TRY LAW360 FREE FOR SEVEN DAYS

    Up more than 250% in 2022, is the stock still a buy?

    0

    Energy transition company Vertex Energy, Inc. (VTNR) is a specialized refiner of alternative raw materials or replacement fuel for industrial burners and a distributor of high purity petroleum products. As VTNR’s Refined Products margins on conventional fuels reach multi-year highs in the first quarter of 2022 and investors grow more optimistic about its continued growth in used motor oil (WMO) collections, as well as oil prices at 13-week high last week, shares of the energy company have jumped 254.3% so far this year and 68.8% in the past month.

    However, the stock is down 2% in the past five days as the US stock market is now in bearish territory amid fears of a potential recession. While the environmental services company could benefit from the optimism surrounding the energy transition market, its losses widened significantly year-over-year in the first quarter. Additionally, VTNR’s negative profit margin could be a concern. While the energy company’s strong operating momentum and growing regional demand may help it improve its margins, its lofty valuation is not keeping pace with its mounting losses.

    Here is what could influence the performance of VTNR in the short term:

    Acquisition of the mobile refinery

    In April, the specialty refiner acquired the Mobile, Alabama refinery and related marine terminal and logistics assets from Equilon Enterprises LL for $75 million in cash, as well as approximately $25 million for capital expenditures. As the acquisition positions the energy transition company to become a leading regional supplier of renewable and conventional products, it could increase spending and weigh heavily on its already fragile balance sheet.

    Energy market volatility

    While the financial market and oil prices see wild swings amid nervousness over a possible recession, inflation and rising interest rates, the energy market is expected to remain volatile. Moreover, with several countries facing challenges in increase their crude production supply, oil prices are expected to remain volatile. Since energy company VTNR is exposed to market risks related to the volatility of crude oil and refined petroleum products and interest rate risks, its stock price could experience a decline in the short term.

    Unstable finances

    For the first quarter ended March 31, 2022, VTNR’s gross profit was $1.54 million, down 27.6% from the prior year period. Its operating loss was $7.27 million from $760.94 thousand. VTNR suffered a net loss of $808.87 thousand and a loss per share of $0.24 over this period. Additionally, the company reported free cash flow of negative $10.81 million.

    VTNR’s trailing 12-month gross profit margin of 3.4% is 91.4% below the industry average of 39.5%. In addition, its net profit margin, EBITDA margin, the ROA and ROE are respectively negative at 18.2%, 14.7%, 8.5% and 74.2%. Additionally, the company’s trailing 12-month operating cash flow came in at negative $30.49 million.

    Extended valuation

    In terms of trailing 12-month EV/sales, VTNR is currently trading at 10.03x, 261.1% higher than the industry average of 4.01x. And its 12-month price-to-sales multiple of 7.48 is 276.7% higher than the industry average of 1.99. Additionally, the company’s 12-month price-to-book ratio of 10.26x is 336.4% higher than the industry average of 2.35x.

    POWR ratings reflect bleak outlook

    VTNR has an overall rating of D, which translates to Selling in our POWR Rankings system. POWR ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.

    Our proprietary scoring system also rates each stock against eight different categories. VTNR has a C rating for quality and an F for stability. The stock’s negative profit margin and higher volatility are reflected in these ratings.

    Also, it has an F rating for value. This is consistent with the price-to-sales ratio above that of the industry.

    Beyond the ratings I highlighted above, we also rated VTNR for Growth, Momentum, and Sentiment. Get all VTNR ratings here.

    VTNR is ranked #88 out of 100 stocks in the B rating Energy – Oil & Gas industry.

    Conclusion

    Although shares of VTNR have risen significantly this year due to its high margins on refined products, soaring oil prices and rapid growth in business operations, the stock appears to be highly volatile given the risks in the field of energy in an uncertain environment. On top of that, the stock’s stretched valuation and skyrocketing losses could send its shares plummeting in the coming months. As such, the stock is best avoided now.

    How does Vertex Energy, Inc. (VTNR) compare to its peers?

    Although VTNR has an overall POWR rating of D, one might consider taking a look at its industry peers, Adams Resources & Energy, Inc. (EA) and Whitecap Resources, Inc. (SPGYF), having an A (Strong Buy) rating.


    VTNR shares were trading at $14.64 per share on Monday afternoon, down $1.41 (-8.79%). Year-to-date, the VTNR has gained 223.18%, compared to a -20.05% rise in the benchmark S&P 500 over the same period.

    About the Author: Imon Ghosh

    Imon is a financial analyst and journalist with a passion for financial research and writing. She started her career at Kantar IMRB, a leading market research and consumer advisory organization. After…

    More resources for actions in this article

    Are you at risk for colon cancer? Look for clues in your food choices

    0

    A diet low in fiber could increase your risk of colon cancer

    Photo: iStock

    New Delhi: Cancer that develops in the colon or rectum is called colon cancer. It usually starts as small clumps of non-cancerous cells called polyps that form inside the colon. Over time, these cells can change after a series of mutations occur in their cellular DNA. When these polyps change their DNA, it can lead to colon cancer.

    Cancer cells develop when a series of abnormal or unhealthy cells begin to grow and divide in large numbers, leading to tumor formation. These cells then invade other healthy cells. No single factor can cause or increase the risk of colon cancer, but here are some factors listed.

    Inflammatory bowel conditions: Inflammatory colon diseases, such as ulcerative colitis, can increase your risk of colon cancer.

    family history colon cancer: People with a family history of colon cancer have a higher risk of developing colon cancer. If more than one family member has colon cancer or rectal cancer, the risks are even higher.

    Smoking: Smoking increases the risk of colon cancer.

    Alcohol: Excessive alcohol consumption increases the risk of colon cancer.

    Diet low in fiber and high in fat: A diet high in fat and calories and low in fiber is likely to cause colon cancer and rectal cancer. Some studies have found an increased risk of colon cancer in people whose diets are high in red meat and processed meat.

    Advanced age : Colon cancer can develop at any age, but the majority of people who develop colon cancer are over 50 years old. Although the number of people with colon cancer under the age of 50 has increased.

    African-American Race: People of African American descent have a higher risk of developing colon cancer than people of other races.

    Disclaimer: The tips and suggestions mentioned in the article are for general information purposes only and should not be construed as professional medical advice. Always consult your doctor or dietitian before starting any fitness program or making any changes to your diet.

    Queen’s birthday honor for pioneering subantarctic scientist – Australian Antarctic Program (News 2022)

    0

    Beautiful Macquarie Island

    From 1979 to 2004, Dr. Selkirk undertook 11 expeditions to Macquarie Island to study the island’s plants, their biology, distribution and environment.

    This was summarized in her seminal book “Subantarctic Macquarie: Environment and Biology” which she co-authored with Bob Selkirk and Rod Seppelt.

    In 1992, she was the first scientist in the world to predict the future impact of climate change on the island’s subantarctic ecosystem and to recognize its importance as a sentinel of climate change.

    The island has a special place in his heart.

    I have seen it in many phases over the years as rabbit and rodent populations grew to a point where the devastation to vegetation and the environment was acute,” said Dr Selkirk .

    Their eradication from the island is a fabulous environmental conservation story in terms of solving a problem that humans caused in the first place.

    “But one of the other questions that arises is how the sub-Antarctic will behave in an ever-changing climate. It’s an ongoing story that’s going to require a lot of careful observation and scientific study.

    During his career, Dr Selkirk has also participated in five expeditions to the Antarctic continent, one to the sub-Antarctic Heard Island and one to the sub-Antarctic Kerguelen Islands as a member of the Australian, New Zealand and French Antarctic Programmes.

    Cagr Status, Industry Growth, Trends, Analysis & Forecast To 2028 | Amcor Limited, Bemis Company, Ampac Holding, Sonoco Products, Constantia Flexibles, etc.

    0
    pouches-cushions-flexible-packaging-market

    Flexible Packaging Pillow Bags Market Report Coverage: Key Growth Drivers and Challenges, Regional Segmentation and Outlook, Key Industry Trends and Opportunities, Competitive Analysis, COVID-19[feminine] Impact analysis and projected recovery, and market sizing and forecasting.

    Latest research launched on Global Pillow Bag Flexible Packaging Market, it provides a detailed analysis with presentable graphs, charts and tables. This report covers an in-depth study of the market size, growth and share, trends, consumption, segments, application and forecast 2028. With qualitative and quantitative analysis, we help you to perform a thorough and comprehensive research on the global pillow. Bags Flexible packaging market. This report has been prepared by experienced and knowledgeable market analysts and researchers. Each section of the research study is specially prepared to explore key aspects of the global Pillow Bag Soft Packaging Market. Buyers of the report will have access to accurate information PESTLE, SWOT and other types of analysis on the global Pillow Bag Soft Packaging Market. In addition, it offers very precise estimates on the CAGR, market share and market size of key regions and countries.

    Major Key Players profiled in the report include: Amcor Limited, Bemis Company, Ampac Holding, Sonoco Products, Constantia Flexibles, Janco Inc, Winpak Limited, Multivac, Dupont, Albea, Essel Propack, Huhtamaki, Sealed Air Corp, Mondi Group, Coveris Holdings, Clondalkin Group Holdings and more…

    Download a free sample PDF including COVID-19[FEMININE Analyse d’impact, table des matières complète, tableaux et [email protected]
    https://www.marketinforeports.com/Market-Reports/Request-Sample/489397

    Don’t miss out on the business opportunities in the Pillow Bag Soft Packaging Market. Talk to our analyst and get key industry insights that will help your business grow when you create sample PDF reports.

    Segmental analysis:
    The report categorized the global pillow bag flexible packaging market into segments including product type and application. Each segment is assessed based on its share and growth rate. Additionally, analysts have studied the potential regions that could prove rewarding for pillow bag flexible packaging manufacturers in the coming years. The regional analysis includes reliable predictions about value and volume, helping market players to gain in-depth insights into the overall Pillow Bag Soft Packaging industry.

    Market is split by Type, can be split into:
    Plastic
    Paper
    Foil
    Others
    The market is split by Application, can be split into:
    Cosmetics and personal care
    food and drinks
    Medications
    Industrial
    Consumer goods
    Others

    Share your budget and get an exclusive discount @
    https://www.marketinforeports.com/Market-Reports/Request_discount/489397

    The report authors have analyzed the developing and developed regions considered for research and analysis of the global Pillow Bag Soft Packaging market. The regional analysis section of the report provides in-depth research study on different regional and country-level Flexible Pillow Bag Packaging industries to help players plan effective expansion strategies.

    Regions Covered in the Global Pillow Bag Flexible Packaging Market:
    The Middle East and Africa (GCC countries and Egypt)
    North America (United States, Mexico and Canada)
    South America (Brazil, etc)
    Europe (Turkey, Germany, Russia UK, Italy, France, etc.)
    Asia Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia and Australia)

    Years considered to estimate the market size:
    Historical year: 2015-2019
    Year of reference : 2019
    Estimated year: 2022
    Forecast year: 2022-2028

    Detailed TOC of Soft Packaging Pillow Bags Market Report 2022-2028:
    Chapter 1: Pillow Bag Soft Packaging Market Overview
    Chapter 2: Economic impact on the industry
    chapter 3: Market Competition by Manufacturers
    Chapter 4: Production, revenue (value) by region
    Chapter 5: Supply (Production), Consumption, Export, Import by Regions
    Chapter 6: Production, revenue (value), price trend by type
    Chapter 7: Market analysis by application
    Chapter 8: Analysis of manufacturing costs
    Chapter 9: Industrial Chain, Sourcing Strategy and Downstream Buyers
    Chapter 10: Marketing Strategy Analysis, Distributors/Traders
    Chapter 11: Analysis of market effect factors
    Chapter 12: Pillow Bag Soft Packaging Market Forecast
    Continued……

    To learn more about the report, visit @ https://www.marketinforeports.com/Market-Reports/489397/pillow-bags-flexible-packaging-market

    What market dynamics does this report cover?
    The report shares key information on:

    • Current market size
    • Market forecasts
    • Market opportunities
    • Main Drivers and Constraints
    • Regulatory scenario
    • Industry trend
    • New product approvals/launch
    • Promotion and marketing initiatives
    • Price analysis
    • Competitive landscape

    It helps companies make strategic decisions.

    Does this report offer customization?
    Personalization helps organizations better understand specific market segments and areas of interest. Therefore, Market Information Reports provides customized reporting information based on business needs for mission-critical calls.

    Get Customization [email protected]:
    https://www.marketinforeports.com/Market-Reports/Request-Customization/489397/pillow-bags-flexible-packaging-market

    Why Choose Market Intelligence Reports? :
    Market Info Reports Research provides strategic market research reports, industry analysis, statistical surveys and forecast data on products and services, markets and companies. Our clientele includes a mix of global business leaders, government organizations, SMEs, individuals and start-ups, leading management consultancies, universities, and more. Our library of over 600,000 reports targets high-growth emerging markets in the United States, Europe Middle East, Africa, Asia-Pacific covering sectors like Computers, telecommunications, chemicals, semiconductors, healthcare, pharmaceuticals, energy and electricity, manufacturing, automotive and transport, food and beverages, etc.. This extensive collection of insightful reports helps clients stay ahead of time and the competition. We assist in business decision making on aspects such as market entry strategies, market size, market share analysis, sales and revenue, technology trends, competitive analysis, product portfolio and application analysis, etc.

    Contact us:
    Market Information Reports
    17224 Rue S. Figueroa,
    Gardena, California (CA) 90248, United States
    Call: +1 915 229 3004 (WE)
    +44 7452 242832 (UK)
    Website: www.marketinforeports.com




    Herd immunity has been sold as the way out of the pandemic. Here’s why we don’t talk about it anymore

    0

    At the start of the pandemic, the term “herd immunity” made headlines, along with a polarized discussion about how to achieve it.

    Some groups were wedded to the now discredited notion of letting a dangerous virus pass through the population to reach the critical level of population immunity needed to reduce transmission.

    But more serious conversation has focused on the prospect of achieving herd immunity through vaccination.

    Buy now | Our best subscription plan now has a special price

    The best of Express Premium
    Prime
    “Hoping for more direct taxes than expected for this fiscal year;  watch her cry...Prime
    Married and without prejudicePrime
    The picture of Rajiv Gandhi getting hit - the story in a framePrime

    It’s the idea that vaccines – when available and used at sufficient levels – could crush the transmission of the virus. This would lead to the possible elimination or eradication of SARS-CoV-2, the virus that causes COVID.

    The promise was that it would herald the return of life to normal.

    It’s understandable why this notion garnered so much attention, as it promised a full return to a COVID-free world. But in reality, it’s probably always been a pipe dream.

    Over time, herd immunity has become even less accessible.

    Here’s why we don’t talk about it anymore, even with the high vaccination rates we see today.

    What is herd immunity?

    If enough people in the community develop immunity to an infectious agent such as a virus, an epidemic cannot develop.

    In fact, just as a bushfire goes out when it runs out of fuel to burn, an epidemic begins to wane when the virus runs out of people to infect.

    The level of vaccination coverage needed in a population to allow you to achieve herd immunity is the “herd immunity threshold”.

    It depends on two main parameters – the infectivity of the virus and the effectiveness of the vaccine.

    In short, the more infectious the virus and the less effective the vaccine, the more people need to be vaccinated to achieve herd immunity.

    More and more out of reach

    As the pandemic progressed, herd immunity via vaccination became increasingly out of reach. In fact, based on what we know of the virus variants currently in circulation, herd immunity via vaccination is mathematically impossible today.

    In early 2020, we were grappling with the original strain of SARS-CoV-2, which was far less infectious than current circulating variants.

    The original strain had an estimated R0 (basic reproduction number) of two to three. That is to say, a person infected with the virus would transmit it on average to two or three other people.

    If we assume that we are working with a vaccine with 80% efficacy, this gives an estimate of the herd immunity threshold of 60-80%. In other words, when the original strain of the virus was circulating, we would have had to vaccinate 60-80% of the entire population to see the epidemic decline. Mathematically at least, it was not out of reach.

    However, as we know, circumstances have changed dramatically during the pandemic, with the original SARS-CoV-2 virus being replaced by much more infectious variants.

    Although estimates of variant infectivity are subject to some uncertainty, it is reasonable to assume that Delta has a reproduction number of around five and that Omicron could be around around 20, which places it among the most infectious diseases known.

    Based on these numbers for Delta and Omicron, herd immunity threshold estimates range up to 100-118%.

    Since you can’t vaccinate more than 100% of the population, you can see how relying on vaccination to achieve herd immunity has become increasingly mathematically impossible as the pandemic has progressed.

    That’s not all.

    During the pandemic, we have learned more about the performance of vaccines in the real world and the nature of our immune response.

    Vaccines do not block all transmission

    Herd immunity via vaccination and the calculations above assume that vaccines stop transmission 100% of the time.

    Although vaccines reduce transmission significantly, they do not completely prevent it. If we take this into account in our calculations, the challenge of obtaining herd immunity becomes more difficult again.

    Immunity declines over time

    Achieving herd immunity also assumes that immunity to COVID is maintained over the long term. But we now know that immunity wanes after vaccination and after natural infection.

    So if immunity is not maintained, even if herd immunity was theoretically possible, it would only be transitory. Its preservation would only require a major effort, requiring the regular delivery of reminders to the entire population.

    New viral variants

    Then we saw the emergence of new variants capable of evading the immune response. Any change in the immunogenicity of new variants moves the targets away, further compromising our ability to achieve herd immunity.

    So why do we bother to vaccinate?

    Although achieving herd immunity through vaccination is no longer a realistic proposition, it needs to be put into perspective.

    Vaccines go hand in hand with other measures Herd immunity is best viewed as a gradient rather than a binary concept. In other words, even if we do not reach the herd immunity threshold, the higher the proportion of the population vaccinated, the more difficult it becomes for the virus to spread.

    Therefore, vaccination can combine with other behavioral and environmental measures (such as physical distancing, wearing masks and improving ventilation), to have a substantial impact on the ability of the virus to move. in the population.

    Vaccines protect people

    Despite the allure of herd immunity, the primary goal of COVID vaccination has always been to protect individuals from serious illness and death, and thus the impact of the disease on the population.

    In this respect, despite the decrease in protection against infection, vaccines seem to offer longer-lasting protection against serious diseases.

    So getting vaccinated remains as important today as it ever has been. Right now, at the start of winter and with few COVID restrictions, it has never been more important to make sure you are fully vaccinated.

    📣 For more lifestyle news, follow us on Instagram | Twitter | Facebook and don’t miss the latest updates!

    Your Guide to a Good Night’s Sleep | Health

    0

    New Delhi: Today, most of us idolize those who work 3-4 hours of sleep. That’s cool but I’m sure you remember the sweet taste of sleep? Oh no, I’m not tempting you to sleep for long hours and forget about all your responsibilities. I know we live in a light-footed world and 24 hours just doesn’t seem like enough.

    When you don’t have enough of something, you should always try to optimize it rather than disrupt everything, especially your sleep. Let me explain with an example: when you go on a trip, you pack your things in a nice and organized way, but when you start packing for your trip home, what happens? You know it very well!

    When your responsibilities seem to overwhelm you, stop, take a deep breath, and make those 24 hours your slave.

    How can you do this?

    First, find out what works for you. People need different number of hours of sleep to boost their energy levels. You have to find your optimal level. After that, start planning your work and leisure schedules accordingly.

    Do you feel sleepy but keep fidgeting even after going to bed at the right time?

    If so, it’s probably because of your environment and poor discipline before sleep. To get the sleep you want, you have to work hard. Create an environment that works best for you.

    Discipline before sleep:

    Put all distractions aside mentally and physically, dim the lights, and start getting ready for bed. This will let your mind know that it’s time to sleep and until the moment you go to bed, your head will be light as a feather.

    Set your room temperature
    Body and bedroom temperature can have a profound impact on sleep quality. Studies show that high or low temperatures in the sleeping area can deteriorate the quality of sleep. Depending on your body preferences, you need to find what suits your body for a pleasant and comfortable sleep. In most cases, the bedroom should be cool (between 60 and 67 degrees) for optimal sleep.

    Take a relaxing shower
    A relaxing hot shower is another popular way to sleep better. According to studies, a hot bath before bed improves sleep quality and helps people sleep better. Otherwise, if you don’t want to take a bath at night, just soak your feet in warm water to relax and sleep better.

    Invest in a comfortable bed, mattress and pillow
    Some people wonder why they always sleep better in hotels. Besides having a relaxed environment, the quality of the bed can also affect your sleep. The best mattress and the best bedding are extremely subjective. If you’re considering upgrading your bedding, base your choice on personal preference.

    Sleep hygiene is important
    Blue light from cell phones, TV screens, and laptops can keep you from falling asleep, so be sure to turn them off at least half an hour before you sleep. Even bright light from a lamp or window can affect your pattern; consider using blackout curtains, eye masks, white noise machines and other accessories for a good night’s sleep.

    The bottom line
    Sleep plays a crucial role when it comes to our health. Common sleep disorders such as sleep apnea can lead to sleep loss. people with sleep apnea emit periodic gasps or sniffles, momentarily interrupting their sleep. These obstructions during sleep can lead to serious complications and should be investigated with a medical professional. Additionally, sleep loss and sleep disturbances are linked to hypertension, diabetes, high cholesterol, depression, anxiety, obesity, mental distress, and harmful behaviors. to health such as smoking, physical inactivity and excessive alcohol consumption.

    Moreover, sleeping pills are not the solution and even lead to addiction. If you’re interested in optimal health and wellness, you need to make sleep your top priority and start incorporating some of the tips above.

    (Dr. Sonia Lal Gupta, MD, MBA, FACP, Senior Consultant Neurologist)

    PNOE seeks to improve health by providing the gold standard for measuring biological age.

    0

    PNOE, an integrative health optimization program, aims to help professionals grow their business and improve the health of their clients through breath analysis.

    Preventive care takes center stage and becomes a central point in anticipating illness. The ability to identify areas of concern about one’s health can open new doors in disease prevention, and a focus on biological age appears to be gaining popularity.

    Many people look to their credit score as a means of their financial health and longevity, and now doctors and medical professionals can do the same when looking at health through “biological age.” By better understanding your biological age through oxygen analysis, you can potentially determine your quality of life as you age and the risk factors you may face.

    PNOĒ provides a solution to the aging paradigm by looking specifically at the oxygen molecule and how the body transports and uses oxygen throughout the system. Oxygen is necessary for every metabolic process, for cellular health, and for life itself. Everything from how oxygen is taken in through the lungs, pumped throughout the body in the blood, to how cells use oxygen, is critical to understanding a holistic picture of overall health.

    All chronic diseases can be attributed to the way the body uses oxygen.

    – Metabolic disease, the precursor to type II diabetes, starts from within your cells and begins to emerge when their ability to absorb oxygen is impaired.

    – Cardiovascular disease, the leading cause of death worldwide, is almost always accompanied by a flattening of oxygen consumption during exercise and a low VO2max.

    – Lung diseases, such as COPD, asthma or pulmonary embolism, are almost always accompanied by a reduction in the transfer of oxygen from the lungs to the bloodstream.

    Those who focus on health need to understand the importance of cardiorespiratory fitness (CRF). According to the American Heart Association (AHA), VO2max and aerobic health are the strongest predictors of longevity and quality of life. Measuring aerobic health and understanding which part of the oxygen chain is problematic is the most critical step in understanding longevity. PNOĒ is leading the way in providing the gold standard for measuring aerobic health.

    The AHA said of their research: “In a growing number of studies, CRF has been shown to be a more powerful predictor of mortality risk than traditional risk factors such as hypertension, smoking , obesity, hyperlipidemia and T2DM.”

    A picture containing person, person Description automatically generated

    PNOĒ enables healthcare professionals to provide nutrition and training as medicine through breath analysis. For over 100 years, breath analysis has been the gold standard for longevity assessment, nutritional prescription, and evaluation of the most critical organs (i.e. heart, lungs , cells).

    Until recently, it was only available in sophisticated clinics and considered the most valuable but underutilized assessment in medicine. PNOĒ changed that with the first mass-use, clinical-grade metabolic analyzer and proprietary software package that analyzes human breath for health issues and helps prescribe personalized programs.

    A person showing something to a person on the tablet Description automatically generated with low confidence

    Through the PNOĒ ecosystem, any doctor, gym, or health-related business can deliver the most advanced biological age monitoring and optimization program possible without any training, hiring, or upfront cost.

    Media Contact
    Company Name: NOEP
    Contact person: Panos Papadiamantis
    E-mail: Send an email
    Country: United States
    Website: http://www.pnoe.com/

    Procaps Group (NASDAQ:PROC) Upgraded to Own Zacks Investment Research

    0

    Procaps Group (NASDAQ:PROC – Get a rating) has been updated by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report released Friday to clients and investors, Zacks.com reports.

    According to Zacks, “Procaps Group is a developer of pharmaceutical and nutraceutical solutions, drugs and hospital supplies. It develops, manufactures and markets over-the-counter and prescription drugs, nutritional supplements and high potency clinical solutions. Procaps Group , formerly known as Union Acquisition Corp. II, is based in BARRANQUILLA, Colombia.”

    NASDAQ:PROC shares opened at $8.85 on Friday. The company has a quick ratio of 1.16, a current ratio of 1.59 and a debt ratio of 3.12. Procaps Group has a 1-year low of $5.86 and a 1-year high of $11.98. The company’s 50-day simple moving average is $8.11 and its two-hundred-day simple moving average is $8.80.

    A number of large investors have recently changed their PROC holdings. Penserra Capital Management LLC purchased a new stake in shares of Procaps Group during the fourth quarter valued at approximately $30,000. Geode Capital Management LLC purchased a new stake in shares of Procaps Group during the fourth quarter valued at approximately $107,000. Credit Suisse AG purchased a new equity stake in Procaps Group during the fourth quarter valued at around $169,000. Citadel Advisors LLC purchased a new stake in shares of Procaps Group during the third quarter valued at approximately $458,000. Finally, Itau Unibanco Holding SA increased its position in Procaps Group shares by 148.3% during the fourth quarter. Itau Unibanco Holding SA now owns 297,974 shares of the company valued at $2,861,000 after purchasing an additional 177,974 shares in the last quarter. 1.72% of the shares are currently held by institutional investors and hedge funds.

    Procaps Group Company Profile (Get a rating)

    Procaps Group SA develops, produces and markets pharmaceutical solutions worldwide. The company formulates, manufactures and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology , vision care, central nervous system and respiratory tract.

    Further reading

    Get a Free Copy of Zacks Research Report on Procaps Group (PROC)

    For more information on Zacks Investment Research’s research offerings, visit Zacks.com

    This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

    Should you invest $1,000 in Groupe Procaps right now?

    Before you consider Procaps Group, you’ll want to hear this.

    MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Procaps Group didn’t make the list.

    Although Procaps Group currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

    See the 5 actions here

    SwissandWellness launches immunity supplements in response to pandemic immunity challenges

    0

    The supplements are formulated to help prevent the onset of disease, support immune function, and improve overall health outcomes.

    Highlighting the importance of a strong immune system in the fight against COVID-19 and other health threats, specific-purpose health brand SwissandWellness has launched supplements specially formulated for immune system support and recovery . The capsules contain vitamins D, C, B12 and zinc, all of which are linked to the development of adaptive immune responses. The supplement also blends natural botanicals such as elderflower, acerola, and black currant to provide multifunctional benefits, both therapeutic and preventative.

    According to company founders Andreea Dumitru, a Swiss health expert, and Dr. Mark Emerson, an American lifestyle medicine specialist, nutrition and a healthy lifestyle are the keys to health and well-being. in general. However, a standard diet often falls short of the necessary supply of nutrients the body needs to function at its best. The SwissandWellness supplement is developed to fill this lack of nutrients.

    Dr. Emerson’s broad-spectrum formulation provides the ideal dosage and combination of nutrients to support healthy immune functions, prevent infections, and fight colds. It is optimized for immunity, strength and recovery. In addition, as the product is produced under strict Swiss manufacturing standards, the safety, quality and effectiveness of the product are guaranteed.

    The SwissandWellness supplement is ideal for continuous daily use. It is vegan, gluten-free, lactose-free and available for purchase without a prescription.

    Find more details here: https://swissandwellness.com.

    Disclaimer: Statements made regarding these products have not been evaluated by the Food and Drug Administration. This press release is not intended to replace professional medical advice, diagnosis or treatment. Please consult your doctor. The information site hosting this press release is not associated with SwissandWellness. It is simply publishing a press release announcement submitted by a company, without any stated or implied endorsement of the product or service.

    Media Contact
    Company Name: SwissandWellness
    Contact person: Andreea Dumitru
    E-mail: Send an email
    Country: Swiss
    Website: https://swissandwellness.com/

    Military Power Solutions Market Worth $10.3 Billion

    0

    New York, U.S., June 09, 2022 (GLOBE NEWSWIRE) — Military Power Solutions Market Overview:

    According to a comprehensive research report by Market Research Future (MRFR),Military Power Solutions Market Information by portable and non-portable type, source, Platform, Powerful, Region – Forecast to 2030“, the market is expected to be worth $10.3 billion at a healthy CAGR of 8.0% between 2022 and 2030.

    Market scope:

    Electronic devices, machinery, remote outposts, and military drones or UAVs are all powered by military power solutions. Generators, batteries, and solar cells are the most widely used military power options around the world. Manufacturers of military power solutions continually focus on producing power solutions while keeping in mind the regulations set by defense authorities. Military power solutions are used to power military machinery and equipment on all platforms, from small electronic devices to the largest military vehicles.

    Get Free Sample PDF Brochure @ https://www.marketresearchfuture.com/sample_request/10310

    Report Scope:

    Report attribute Details
    Market size 2030 10.3 billion
    CAGR 8.0%% (2022-2030)
    base year 2021
    Forecast period 2022-2030
    Historical data 2020
    Forecast units Value (USD billion)
    Report cover Revenue forecasts, competitive landscape, growth factors and trends
    Segments Covered By portable and non-portable type, source, platform, power, region
    Geographical areas covered North America, Europe, Asia-Pacific and Rest of the World (RoW)
    Key Market Drivers
    • Growing demand for portable power solutions
    • Emergence of modern warfare techniques
    • Increased defense electronics budget

    Competitive Landscape:

    Notable market players are:

    • Cummins Inc. (USA)
    • Schaefer, Inc. (USA)
    • Gresham Power Electronics Limited (UK)
    • Raytheon Technologies Corporation (USA)
    • Saft Group SA (France)
    • Enersys Inc. (USA)
    • Arotech Corporation (USA)
    • SFC Energy AG (Germany)
    • Eaglepicher Technologies, LLC (USA)
    • Denchi Power Ltd. (UK)

    Browse the In-Depth Market Research Report (100 Pages) Military Power Solutions @ https://www.marketresearchfuture.com/reports/military-power-solutions-market-10310

    Market USP:

    Market campaigns

    The huge growth in energy use in workplaces around the world has been accompanied by a decline in business supply consumption. Due to increased demand, the environment is now more influenced by less portable power grids at the local level, i.e. close to homes and offices. Moreover, with the growing need for mobile phones, personal computers and other electronic devices, the high demand for electricity is expected to grow exponentially, which will further reduce the demand for traditional office items.

    Due to factors such as increasing development of modern warfare strategies and increased demand for the use of unmanned aerial vehicles (UAVs) in modern warfare, the market for military power solutions is expected to grow significantly over the course of the forecast period. Additionally, the market is expected to grow owing to the growing demand for the use of next-generation generators or systems. Additionally, increasing military spending in developing countries like China and India, due to expanding territorial tensions in Asia-Pacific, is expected to propel the military power solutions market forward.

    Due to increasing geopolitical instability and the changing nature of warfare, there is an increasing demand for various military power solutions or systems. As modern combat has progressed, the military has become more reliant on technological technologies. As a result, there has been an increase in demand for military power solutions. Additionally, as the sophistication of communication, situational awareness, and weapon systems increases, more power-dense systems are required to power these next-generation, power-hungry systems. Military budgets are increasing, driving the market forward. Market Drivers: Several countries have increased their budget spending on military electronics which is expected to propel the military power solutions market forward over the forecast period. Market Constraints: However, issues such as inefficiency in producing high power output and high initial cost of deployment may hinder the growth of the market. The military power solutions industry has been hampered by declining defense spending in wealthy countries and the high cost of thermoelectric materials.

    COVID-19 analysis

    COVID-19 is a global public health disaster that has damaged virtually every industry, with long-term implications that are expected to limit industrial growth over the forecast period. The financial priorities of governments in various countries are changing due to the Covid-19 outbreak, which may limit the chances of purchasing defense equipment in countries with struggling economies, hurting market prospects for internationally relevant energy solutions.

    Buy now: https://www.marketresearchfuture.com/checkout?currency=one_user-USD&report_id=10310

    Market segmentation

    By Type, the market is segmented into wearable and non-wearable.

    By source, the market is segmented into batteries, generators, fuel cells, solar energy and energy harvesters.

    By platform, the market is segmented into Air, Marine and Ground.

    By power, the market is segmented into low power, tactical medium power, and high power.

    Regional outlook:

    Due to the presence of leading companies such as Schaefer, Inc. and Advanced Conversion Technology, Inc., North America dominated the military power solutions market in 2019. One of the major causes of the The region’s revenue development is the deployment of US troops to various parts of the world due to US involvement in various global crises. Various portable military equipment is used in these military camps and command units, requiring compact and transportable power solutions to provide continuous or backup power as needed. Aboard several of the country’s defense platforms, the country is focused on improving current battery technology and power solutions.

    Due to the increasing development of advanced military ships and vessels by countries such as UK, Germany, Russia, and others that demand advanced power solutions, the military power solution market in Europe is expected to grow at a steady CAGR over the study period. . As a result, the regional market is growing.

    For any request @ https://www.marketresearchfuture.com/enquiry/10310

    During the forecast period, the Asia-Pacific market is expected to grow at the fastest rate. The demand for military force solutions in Asia-Pacific is likely to increase as countries like China, Japan and India increase their defense spending.

    Elsewhere in the world, rising domestic conflict, drug smuggling and trafficking in Mexico, Brazil, the Gulf States and Africa are likely to increase demand for military power solutions.

    Discover more research reports on Aerospace and defense industryby Market Research Future:

    Aircraft Micro-turbine Engine Market Research report: information by engine type (micro-turbine turbojets and micro-turbine turboshafts), platform (VTOL, air taxis, cargo aerial vehicles (CAV), light aircraft and military unmanned aerial vehicles), use Final (Military & Defense and Commercial) and Region (North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America) – Forecast to 2027

    Aircraft Mounts Market Report: By Mount Type (Indoor and Outdoor Mounts), End Use (Aftermarket and OEM), Platform (Commercial Aviation and Military Aviation), and Region (North America, Europe, Asia-Pacific, Middle East and Africa) and Latin America) – Forecast to 2027

    Drone Parcel Delivery System Market Research Report: Information by Solution (Platform, Software, Infrastructure, and Service), Duration (Short-Range and Long-Range), Scope (Short-Range and Long-Range), Package Size (5 kilograms), End Use (Retail Goods Delivery, Food Delivery, Postal Delivery, Medical Aids Delivery and Others) and Region (North America, Europe, Asia Pacific and Rest of World) – Forecast to 2030

    About Market Research Future:

    Market Research Future (MRFR) is a global market research company that prides itself on its services, offering comprehensive and accurate analysis with respect to various markets and consumers around the world. Market Research Future has the distinct objective of providing clients with top quality research and granular research. Our market research by products, services, technologies, applications, end users and market players for global, regional and country market segments enables our clients to see more, know more and do more , which helps answer your most important questions. questions.

    Follow us: LinkedIn | Twitter

    
    

    UTSA awards $4 million to Alzheimer’s researchers worldwide

    0

    A UT Health San Antonio professor is among four researchers from around the world who have been awarded $500,000 each – part of the Oskar Fischer Prize at the University of Texas at San Antonio – for their work to advance understanding to society the causes of Alzheimer’s disease.

    UTSA on Wednesday announced the results of its Oskar Fischer Prize, an international competition that awards $4 million in prizes to 10 people. The competition awarded gold, silver and bronze prizes of $500,000, $400,000 and $300,000, respectively.

    San Antonio scientist Bess Frost received one of the $500,000 prizes for her theory on the cause of Alzheimer’s disease.

    Frost is the Bartell Zachry Professor Emeritus for Neurodegenerative Disorders Research at the Barshop Institute for Longevity and Aging Studies, the Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Disorders, and the Department of Cellular Systems and Anatomy at UT Health San Antonio.

    She proposes that neurodegeneration in Alzheimer’s disease and related tauopathies result from the negative consequences of pathogenic forms of tau on three-dimensional DNA packaging. In his submission, Frost wrote that this type of DNA restructuring affects the cellular identity of brain cells and results in cell death.

    Frost’s lab at the University of Texas Health Sciences Center at San Antonio, which studies the basic science underlying Alzheimer’s disease, is currently recruiting patients with an early diagnosis of Alzheimer’s disease to a phase 2 clinical trial. The trial is studying an antiretroviral drug called 3TC, which has been approved to treat HIV.

    Gold awards were also given to Carlo Abbate of IRCCS Fondazione Don Carlo Gnocchi, Istituto Palazzolo, Italy; Estela Area-Gomez of Columbia University in New York and the Centro de Investigaciones Biológicas “Margarita Salas” in Spain; and Ralph Nixon of the Nathan S. Kline Institute for Psychiatric Research just outside New York.

    Silver prizes were awarded to Bernd Moosmann of Johannes Gutenberg University in Germany and Donald Weaver of the University of Toronto. The bronze award recipients are Annelise Barron from Stanford University, Gunnar Gouras from Lund University in Sweden, Varghese John from UCLA and Russell Swerdlow from the University of Kansas Medical Center.

    The Oskar Fischer Prize was launched in late 2019 following a $5 million philanthropic gift to UTSA from Texas businessman James Truchard, who co-founded software company National Instruments.

    UTSA President Taylor Eighmy said in a statement that the competition “allows us to have a significant impact on new discoveries in the field of brain health that will directly help solve the mysteries of brain disease. ‘Alzheimer’s’.

    “Despite a century and tens of billions of dollars spent on research into Alzheimer’s disease, no definitive explanation for a cause has been found,” Truchard said. “The objective of the prize is to generate ideas that can lay the foundations for future research. Although no single entry covers all the major aspects of Alzheimer’s disease, I believe that a combination of these ideas creates a launch pad for future research.

    According to Alzheimer’s Disease International, approximately 55 million people worldwide live with dementia. This population is expected to reach 78 million by 2030.

    [email protected]

    Amaroq Therapeutics Takes First Steps and Makes Key Scientific Advisory Board Appointments

    Promising ‘dark matter’ cancer therapy has clinical trials in sight

    DUNEDIN, New Zealand, June 8, 2022 /PRNewswire/ — Amaroq Therapeutics, a biotech company focused on developing a new class of therapeutics targeting lncRNA in cancer, is advancing towards clinical trials after a promising initial development phase and earning key nominations at within its Scientific Advisory Board (SAB).

    Amaroq Therapeutics is pleased to announce the first milestone achievements and appointment of Teacher David L. Spector (chair), Teacher Sherene Law, Teacher Anna Pyleand Doctor Henrik Orum as members of the SAB.

    “We are truly fortunate to welcome four leading experts to our Board of Directors. With a mix of expertise in cancer research, RNA biology, drug development and clinical trials, Amaroq has never been better supported to advance our therapy to market,” says Dr. Sarah DiermeierScientific Director and Founder, Amaroq Therapeutics.

    These nominations from industry leaders from the scientific community are a great mark of confidence in our development of RNA therapy. This brings us much closer to clinical trials and delivering potentially breakthrough treatments to patients with some of the most common cancers,” says Diermeier.

    Amaroq Therapeutics is one of the first companies in the world to explore long non-coding RNAs (ncRNAs), often referred to as the “dark matter” of the genome, for applications in oncology. Their newly strengthened team of experts is exploring the use of lncRNA molecules as therapeutic targets and diagnostic markers in the treatment of cancer.

    Amaroq Therapeutics research has shown that specific lncRNA molecules are highly expressed in cancer cells, but not in normal healthy cells. Removing these lncRNA molecules from cancer cells can slow down the process of cell division.

    “This gives us very real hope that lncRNA molecules may hold the key to treating many common forms of cancer such as breast, colorectal and liver cancer,” says Diermeier. “The next generation of RNA-based therapies we are developing could be the breakthrough treatment the world has been waiting for to treat cancers – one of the world’s deadliest and most debilitating diseases.”

    Led by Brandon Capital and backed by Otago Innovation Ltd, NZ Innovation Booster and Cure Kids Ventures, a total of $14 million has been invested in Amaroq Therapeutics to date.

    “We are delighted to continue to support Amaroq Therapeutics towards clinical development, and the very high level of experience and expertise among the new board members speaks to the potential we all see in them as pioneers of RNA therapy. We will be watching with keen interest,” says Duncan MackintoshChief Investment Officer at Brandon Capital Partners.

    New appointments to the board of directors of Amaroq SAB:

    Teacher David L. SpectorChair

    David L. Spector, Ph.D., is a professor and research director at Cold Spring Harbor Laboratory. He is co-lead of the Gene Regulation and Inheritance program at the National Cancer Institute designated Cold Spring Harbor Laboratory Cancer Center. In 2014, he was elected to the American Academy of Arts and Sciences and as a foreign associate member of the European Molecular Biology Organization. In 2017, he was elected a Life Member of the American Society of Cell Biology for his distinguished contributions to the advancement of cell biology.

    Teacher Sherene Law

    Sherene Law is a medical oncologist specializing in the treatment of breast cancer and group leader at the Peter MacCallum Cancer Centre, Melbourne, Australia. She is internationally recognized as a leading clinician scientist whose work has led to new insights into the field of breast cancer immunology, including an immune biomarker and the formation of the international TILs working group. Professor Loi’s research is highly cited – she has been ranked in the top 1% of most cited researchers in the world by the Web of Science since 2018. She co-chairs the International Breast Cancer Study Group (IBCSG) based in Bern, Switzerland, which conducts breast cancer clinical trials in more than 16 countries. She is currently the inaugural chair of the National Breast Cancer Foundation (NBCF) of Australia and a researcher at the Breast Cancer Research Foundation (BCRF), New York.

    Teacher Anna Marie Pyle

    Anna Marie Pyle is a Yale Sterling Professor of Molecular, Cellular, and Developmental Biology and Chemistry, and a research fellow at the Howard Hughes Medical Institute. Dr. Pyle formed her own research group in 1992 in the Department of Biochemistry and Molecular Biophysics at Colombia University Medical Center. In 2002, she moved to Yale University, where his group specializes in determining the structure and function of large RNA molecules and associated protein enzymes. Pyle is Past President of the RNA Society, she is Vice Chair of the Brookhaven National Laboratory Science and Technology Steering Committee, and serves on the Scientific Advisory Board of Arrakis Therapeutics and RADD Pharma.

    Dr. Henrik Orum

    Henrik Ørum brings over 25 years of experience in all aspects of starting, building, leading and exiting successful biotechnology companies. dr. Ørum began his career in biotechnology at PNA Diagnostics A/S in 1993, serving as Scientific Director from 1993 to 1999. During his tenure, the company was sold to Boehringer Mannheim in 1994 and then to Hoffman-La Roche in 1997 In 1996, Dr. Ørum co-founded Exiqon A/S, a nucleic acid diagnostics company listed on the Copenhagen Stock Exchange in 2007. In 2000, he co-founded Santaris Pharma A/S, where he served as Chief Scientific Officer and Vice President Business Development ‘upon the acquisition of the company by Roche in 2014. In 2017, Dr. Ørum founded CiVi Biopharma Inc, where he serves as Chief Scientific Officer.

    About Amaroq Therapeutics

    Amaroq Therapeutics is a New Zealandbiotechnology company based on the development of a new class of therapeutic products targeting lncRNAs in cancer.

    Long non-coding RNAs are a relatively recently discovered class of molecules, often referred to as the “dark matter” of the human genome. These natural molecules do not code for proteins but perform important regulatory functions in the cell that could be exploited as a new therapeutic approach for multiple indications. Amaroq’s research team discovered ncRNA molecules that are highly expressed in cancer cells and once removed, cancer cell growth slows. Amaroq Therapeutics develops innovative therapies to target lncRNAs for the treatment of cancer.

    Amaroq Therapeutics is funded by the Medical Research Commercialization Fundmanaged by a life sciences venture capital firm Brandon Capital Partners, Otago Innovation Ltd, University of Otago, Heal the childrenand New Zealand Innovation Booster. The company grew out of research from the University of Otago in Dunedin, New Zealand.

    About Brandon BioCatalyst and Brandon Capital

    Brandon Capital is Australasia’s leading life sciences venture capital firm, with a strong global presence supported by key partnerships and team members in the US and UK. From seed investment to expansion capital, Brandon Capital supports life sciences companies from proof of concept to commercialization.

    Managed by Brandon Capital, Brandon BioCatalyst is a unique collaboration of more than 50 leading medical research institutes, investors and governments united by a single goal: to advance the next generation of medical therapies and technologies that improve health and save lives. lives.

    www.brandoncapital.vc | www.brandonbiocatalyst.com

    SOURCE Amaroq Therapeutic

    Rugged PC Market Research Report 2022 to 2030 – Company Profiles, Regional Share Analysis and Forecast – mbu timeline

    This major report presents a clear view of the current performance of the global Rugged PC market and its likely development in the coming years. The key findings of the Global Rugged PC Market report focus on changing Global Rugged PC Market dynamics, substantial new opportunities, critical forces likely to contribute to the growth of the Global Rugged PC Market, both in advanced economies than in developing economies.

    This report focuses on the key players in the Global Rugged PC Market:
    Getac, Laptop Group, Roda, Panasonic, Xplore Technologies, GE, Dell, Lenovo

    Get a FREE sample PDF copy of the report @ https://marketstrides.com/request-sample/rugged-pc-market

    The report undertakes research and analysis that helps market players understand the global Rugged PC market status in advanced and developing economies, future market scenarios, opportunities and identify solutions on how to organize and operate in the global rugged PC market. The report begins by examining how the global rugged PC market has evolved through the pandemic to this post-pandemic point, key forces at work, implications of the covid-19 pandemic on businesses and policy makers. Most importantly, the report has performed an in-depth analysis of the selected segments and countries.

    A detailed analysis of the capital-intensive market companies, their strategic trends and their impacts on industry production and growth are studied in the report. The objective of the report is to present the forces that would impact different parts of the global rugged PC industry today. The report aims to map the risks faced by different regions, countries, and segments operating in the market, along with offering a range of options and responses. It recommends best practices to improve efficiency, protect against future risks as well as supply chains against possible threats. Finally, the report helps market players to anticipate trends and seize market opportunities with the data and forecast provided in the report.

    Rugged PC Industry: Main Product Form:
    desktop, laptop

    Apps containing:
    Outdoor, Scientific Research, Military, Other

    Global Rugged PC Market Research Report Offers–

    — The report discusses the main mergers and acquisitions, organic investments including R&D.
    — The report presents a study on the response of major manufacturers to understand the elasticity of target markets.
    – The report provides a detailed assessment of the long-term outlook for the global rugged PC market.
    – The report assesses business segments, products, services, and supply channels of the global Rugged PC market.
    – The report highlights the challenges faced by players in the global Rugged PC market in expanding into new industries, trading in certain goods or products during the pandemic, and expanding into new consumer segments.
    – The report highlights both opportunities and threats shaping the global Rugged PC market, especially the consumer segments.
    — The report discusses the Global Rugged PC Market financial structure, business and operating models.
    — The report identifies innovation strategies adopted by well-established companies in the global rugged PC market.

    Key questions answered by the report include:

  • Which new builders are strongly growth oriented and likely to achieve aggressive growth in the coming years?
  • What is the largest geography of the global rugged PC market?
  • How has the pandemic variously impacted the GDP of the global rugged PC market in the selected countries?
  • What is the global economic outlook for the rugged PC industry?
  • What are the performance indicators of the rugged PC industry between 2019 and 2020?
  • How are market players recovering from the covid-19 pandemic?
  • What is the road to recovery from the covid crisis?
  • About Us:

    Market strides is a global aggregator and publisher of market intelligence development reports, stock reports, database directories and economic reports. Our repository is diverse, covering virtually every industry sector and even more so all categories and sub-categories within the industry.

    Our pre-integration strategy for publishers is perhaps what sets us apart in the market. The publishers & their market share, the reports are meticulously validated by our panel of internal consultants, before being posted on our website. These in-house consultants are also responsible for ensuring that our website features only the most recent reports.

    You have a question ? Ask our experts

    Market Strides has a team of professionals who assist you in many advanced industry-specific trends, content and test different strategies and implement the most productive one for the business.

    For more information, Email – [email protected]

    Contact us: +1 856 677 8909 (USA)

    Direct purchase report

    Follow us on social networks:

    Facebook || LinkedIn || Twitter || pinterest || tumblr || instagram || Medium

    Other reports:
    https://marketstrides.com/report/shutoff-valve-market
    https://marketstrides.com/report/rubber-additive-chemical-market
    https://marketstrides.com/report/inflatable-toys-market
    https://marketstrides.com/report/automatic-perfume-dispenser-market

    Immune protein may lead to relapse of alcoholism

    0

    The anxiety that occurs during withdrawal from excessive alcohol consumption and which contributes to relapse may be due in part to the release of an immune protein in the brain, according to a new study by scientists at Scripps Research. .

    The discovery, reported online June 6, 2022, in Molecular Psychiatrysheds light on the molecular details of the brain’s response to alcohol withdrawal and suggests that the immune protein colony-stimulating factor 1 (CSF1) may be a target for future treatments for alcohol use disorder (AUD) .

    “Alcohol withdrawal activates the stress system in the brain, which contributes to relapse, and in this study, we have linked this stress response to CSF1, a neuroimmune mediator, opening new opportunities for therapeutic intervention” , says the study’s lead author, Marisa Roberto, PhD. , Professor and Schimmel Family Chair in the Department of Molecular Medicine at Scripps Research.

    The study’s first author, who performed numerous experiments, is Reesha R. Patel, PhD, a former postdoctoral researcher at the Roberto Lab.

    Alcohol is by far the most abused and abused recreational drug. According to the 2019 National Drug Use and Health Survey, nine million men and more than five million women in the United States have alcohol use disorder (AUD), which is defines as an inability to control alcohol consumption despite its negative impact on the user’s health, social life and/or employment. Drug treatments, talk therapies, and support group-based treatments are available, but relapses are common, primarily due to limited understanding of the brain circuitry dysfunctions underlying AUD.

    Relapse-promoting symptoms of alcohol withdrawal include increasing feelings of anxiety, caused at least in part by the release of stress molecules such as corticotropin-releasing factor (CRF) in the brain, scientists know. CRF stimulates receptors on neurons in the prefrontal cortex and the limbic system, a set of more primitive brain structures that process emotions. If scientists could fully identify and characterize these CRF-responsive neuronal populations, they could better understand how anxiety occurs during withdrawal and potentially design effective treatments to block it.

    To that end, Roberto and his team, in the new study, identified a population of neurons in the medial prefrontal cortex (mPFC) of mice that are sensitive to CRF because they express a CRF receptor called CRF1. Scientists have shown that these neurons are involved in modifying mood and behavior during alcohol exposure and withdrawal.

    The team’s early experiments revealed that suppressing these CRF-responsive neurons makes mice less anxious, suggesting that the neurons normally mediate anxious behaviors.

    The researchers then found that these CRF-responsive mPFC neurons became less excitable — less likely to send signals to other neurons when stimulated — in alcohol-dependent mice in alcohol withdrawal. In contrast, nearby mPFC neurons lacking CRF receptors become more excitable.

    “These CRF-responsive mPFC neurons appear to constitute a unique neuronal population that undergoes profound neuroadaptations with chronic alcohol exposure,” says study co-author Pauravi Gandhi, PhD, postdoctoral research associate in the Roberto lab.

    Curiously, the researchers found that alcohol withdrawal, while reducing the excitability of CRF-sensitive neurons, also induced large increases in CSF1 gene expression in these neurons. CSF1 is an immune protein best known for its role in stimulating the maturation of stem cells into large white blood cells called macrophages. In the brain, CSF1 is thought to play a similar role in maintaining brain-resident immune cells called microglia. Additionally, previous research in mice has suggested that under conditions of chronic stress, CSF1 production increases in the mPFC, leading microglia to prune the connections between neurons, which in turn causes signs of anxiety. and depression.

    Looking more closely at the role of CSF1 in alcohol withdrawal, Roberto and colleagues artificially increased CSF1 production in CRF-responsive mPFC neurons in mice, and observed that the animals exhibited many of the same neural changes and behavioral than those observed during alcohol withdrawal, suggesting that elevated CSF1 mPFC levels may be a key factor in the signs and symptoms of alcohol withdrawal.

    “Targeting CSF1 can therefore be a good strategy for trading AUD, and we are now looking forward to testing this in our preclinical models,” says Patel.

    Sercel sells WiNG land node system for energy transition studies to Smart Seismic Solutions

    0


    06/07/2022

    (WO) – Sercel on Tuesday announced the sale of a 15,000-channel WiNG system to Smart Seismic Solutions (S3), a French seismic and geophysical contractor. This new sale comes after S3 successfully deployed WiNG in Europe on a series of large clean and mineral energy projects (helium, geothermal and salt).


    “This new sales agreement demonstrates once again the performance and versatility of our latest generation WiNG wireless node solution,” said Emmanuelle Dubu, CEO of Sercel. “Sercel is proud to leverage its recognized expertise in seismic data acquisition to support energy transition projects.”

    Convinced of the performance of Sercel’s ground node system, S3 aims to get the best[1]state-of-the-art equipment and provide its customers with state-of-the-art solutions for seismic surveys mainly focused on projects with positive environmental impact.

    Featuring QuietSeis, Sercel’s ultra-sensitive high-speed digital sensor, WiNG nodes deliver the highest data quality for unparalleled subsurface imaging. Additionally, when equipped with Sercel’s proven Pathfinder transmission management technology, WiNG provides operators with real-time visibility into propagation, ensuring the most comprehensive and efficient quality control.

    “With the WiNG featuring QuietSeis and Pathfinder technologies, we can offer our customers reliable equipment to deliver highly accurate imaging,” said Patrick Robert, COO of Smart Seismic Solutions. “Sercel continues to be a trusted solutions provider that anticipates our needs and supports us to meet the most complex challenges, even in difficult-to-reach environments.”



    Joseph Frederick Hoffman, Ph.D.

    0

    Joseph Frederick Hoffman, PhD, Eugene Higgins Emeritus Professor of Cellular and Molecular Physiology, died May 19, 2022 at the age of 97. He was a tireless and dedicated red blood cell researcher who published papers until the age of 93.

    Hoffman was born March 7, 1925, in Oklahoma City, Oklahoma, where, like his two older brothers, he attained the rank of Eagle Scout. He graduated from the University of Oklahoma in 1948 after earning bachelor’s and master’s degrees. He was then admitted to the graduate school of Princeton University where he obtained a second master’s degree (1951) and a doctorate in physiology (1952). After graduating, he joined the faculty of the Department of Biology at Princeton and conducted studies at the Brookhaven National Laboratory.

    He left Princeton in 1956 to pursue research at the University of Cambridge, and in 1957 he was hired by Robert Berliner (future Dean of the Yale School of Medicine) who then held the position of Director of the Renal Metabolism Laboratory. and electrolytics at the National Institutes of Health. Hoffman came to Yale in 1965 to join the faculty of the Department of Physiology, serving as department chairman from 1967 to 1968 and from 1973 to 1979.

    While at Princeton, Hoffman began his studies of the membrane permeability properties of red blood cells, which became his central focus for more than six decades of research. He was intrigued by the roles of ion pumps and ATP-driven ion channels in defining the ion composition of a cell’s cytoplasm and in regulating cell volume. During his time at Brookhaven, Hoffman met and formed a lifelong friendship with Daniel Tosteson (who later served as dean of Harvard Medical School). Hoffman and Tosteson became close scientific collaborators and in 1960 published a landmark article in the Journal of General Physiology who described their “pump-leak” model. This mathematical formulation provided a theoretical framework that explained in predictive detail how flows through ion pumps, channels, and transporters explain ion distributions across a cell’s plasma membrane and the maintenance of A stable cell volume despite osmotic forces that might be expected to produce cell swelling and lysis.

    While at Yale, Hoffman continued to explore membrane transport mechanisms and their role in cell shape determination. Hoffman and his colleagues created very versatile light-activated chemical probes that could be used to label ion transport proteins and to study the kinetic properties of ion transport processes. Although he officially closed his laboratory and became professor emeritus in 2003, he remained passionately involved in the biology of red blood cells. His last two research papers, which explored the mechanisms by which red blood cells retain their intriguing biconcave disc shape, were published in the Proceedings of the National Academy of Sciences in 2016 and 2018, when he was 91 and 93 years old. For his many accomplishments as a scientist and as a leader, Hoffman received numerous accolades, including election to the National Academy of Sciences in 1981 and the American Academy of Arts and Sciences in 1984. He has served as president of the Biophysical Society and the Society of General Physiologists, and has edited numerous books and journals. Hoffman was very active in the intellectual life and community spirit of the Department of Cellular and Molecular Physiology until he fell ill in early April of this year.

    Hoffman’s survivors include his nephew, Richard E. Hoffman, MD (Molly), of Denver, CO; his nieces, Patricia Ann McNichols of Milwaukee, WI, Jill E. Tiernan (Thomas) of Dallas, TX, and Claudia Citkovitz (John Barnard) of Shutesbury, MA; his sister-in-law, Evgenia Citkowitz; and six great-nieces, as well as cousins ​​and in-laws. He was predeceased by Elena Citkowitz, MD (Yale ’83), his wife of 41 years, and his two brothers, Edmund Hoffman and Henry Hoffman Jr.

    University of Vermont: Advancing Healthcare Through Impactful Medicine

    In the serene greenery of the Burlington landscape sits an intimate yet vibrant campus that is the fifth oldest University of New England, after Harvard, Yale, Dartmouth and Brown. It’s the University of Vermont (UVM), a leading research university that champions multidisciplinary learning at all levels of study. Here, ideas and opportunities flow dynamically between students and faculty, enhanced by its stunning natural landscapes that foster some of the country’s brightest minds.

    The Graduate College This is where excellence is taken up a notch to reshape the way ideas are expressed. With its world-class faculty and outstanding research, this small but mighty powerhouse of knowledge offers a world of opportunities for students to initiate meaningful change. Take her College of Nursing and Health Sciences (CNHS), for example, which promotes the highest level of patient-centered care committed to improving their quality of life. Through practical experience and rigorous professional preparation, graduates emerge ready for a career in providing compassionate and informed health care to others.

    Targeted and innovative health care

    Far from simply preparing graduates for their profession, the CNHS relies on evidence-based practice to keep abreast of current developments in health care and well-being. In addition to professional doctoral programs in Feeding with milk, occupational therapy and physical therapyincoming students can choose from one of five master’s programs and a Interprofessional doctorate in health sciences. program. For aspiring nurses, there are two options to enroll in the program – either through the Nursing: Master of Science Clinical Nurse Leader route for those with previous nursing degrees, or the Direct entry road if you hold a bachelor’s or higher degree in fields other than nursing.

    Apart from nursing care, the CNHS offers specializations in Speech therapy, science of physical activity and well-beingand medical laboratory science for students who wish to diversify into other health disciplines. Immerse yourself in hands-on work under the guidance of licensed speech-language pathologists to prepare for a clinical fellowship, engage in preventative health through expert understanding of the mind-body connection, or develop new technologies to stop communicable diseases – the potential to go further is endless in college.

    With UVM’s reputation as 100 Best Public Research Universities in the United States, it is not surprising that the CNHS is engaged in research advance multimodal treatment with an emphasis on prevention and wellness promotion strategies. Researchers at the college have made progress on several fronts in healthcare, ranging from the employment of precision medicine to improving cancer therapies at long term effects of concussion in academic performance. The Interprofessional Health Sciences (IHS) provides the opportunity to engage in interprofessional research in all fields and in biomedical and psychosocial areas relevant to the health sciences. The UVM Dissertation of the Year award in Social Sciences, Humanities and Creative Arts for 2021-22 was won by an IHS student, Dr. Mariana Wingood.

    Medicine of the future

    Taking the reins of innovation, UVM’s Larner College of Medicine has been at the forefront of reinventing a holistic approach to healthcare for generations. Since his foundation in 1822this seventh oldest medical school in the United States is ranked first nationally for acute patient care and primary care physicians per capita, and is home to more than 300 graduate students across several branches of medical studies.

    With the University of Vermont Medical Center On campus, students benefit from an extensive network of first-hand clinical programs and services, with which they will interact repeatedly throughout their studies. Direct student-faculty engagement is key to fostering an immersive and experiential environment to cultivate advanced clinical and research skills.

    For example, the Master of Science in Pharmacology offers a thesis-based degree option where experimentation in areas such as cardiovascular regulation and medicinal chemistry can be conducted in any pharmacology-focused laboratory within the university. The faculty also trains doctoral students in transversal programs such as neuroscience Where cellular, molecular and biomedical sciences.

    Burlington’s academic environment and the university’s close-knit research community encourage greater interactivity among students for a dynamic exchange of ideas. Source: University College, University of Vermont

    The result of this collaborative nature in the dissemination of knowledge speaks for itself: students continue to write award-winning original theseswhile faculty members are inducted into prestigious science academies such as the National Academy of Sciences and the American Association for the Advancement of Science (AAAS).

    Except Doctor of Medicine (MD) qualification, the college is home to other advanced training graduate programs in health sciences. If you want to pursue your passion to the fullest, the doctoral programs in college can prepare you for a bright future in academia, industry, or government work.

    100% online Master in Public Health takes population health beyond pathology to explore broader issues shaping policies and crisis interventions to address current and emerging challenges in health care disparities. There is also the option of taking courses leading to a graduate certificate if you cannot commit to long-term study. Gain a deeper understanding in areas such as epidemiology and professional end-of-life care to progress to the next level of your career within the sector while being surrounded by a close-knit scientific community.

    Actionable science starts here

    Part of the solution to improving patient access to care begins with training competent and compassionate healthcare professionals. UVM has all the tools and expertise in its arsenal to constantly push the boundaries of medicine for the improvement of collective well-being through evidence-based studies.

    The health-oriented programs of the Graduate College are not only in line with the most recent developments in scientific research; they are also human in practice, placing the needs of patients at the forefront in the delivery of effective and quality care. Science may be behind UVM’s pioneering achievements in healthcare, but it’s empathy that makes all the difference in a patient’s healing journey.

    To join a team of exceptional healthcare professionals at the Graduate College, Click here.

    Follow the University of Vermont Graduate College on Facebook and Twitter

    Aerobic exercise can help boost immune system against cancer: Study: The Tribune India

    0

    New York, June 5

    Aerobic exercise, which includes brisk walking, swimming, running or cycling, can help reprogram the immune system to reduce tumor growth and amplify the effects of immunotherapy, a new study has found.

    Published online in Cancer Cell, the study, which focused on pancreatic cancer, provides new insights into how the mammalian immune system, designed to attack foreign invaders like bacteria, can also recognize cancer cells as abnormal.

    According to New York University researchers, exercise-induced increases in adrenaline levels lead to changes in the immune system.

    It includes the activity of cells that respond to the signaling protein interleukin-15 (IL-15).

    The study found that exercise promotes the survival of IL-15-sensitive CD8 T cells and doubles the number of them that go to pancreatic ductal adenocarcinoma (PDAC) tumors in mice.

    Such “effector” T cells have been shown by other studies to be able to kill cancer cells. Further tests revealed that aerobic exercise for 30 minutes five times a week reduced the rate of cancer formation by 50% in a mouse model of PDAC and reduced tumor weight by 25% in another model, in which mice ran on treadmills for three weeks.

    Working with the University of Texas MD Anderson Cancer Center, the study authors then found that human patients who exercised before surgery to remove their pancreatic tumors had more CD8 effector T cells that expressed a protein called granzyme B, which confers the ability to kill tumor cells. .

    Patients who exercised and had more of these cell types had a 50% better five-year overall survival than patients who had fewer.

    “Our results show, for the first time, how aerobic exercise affects the immune microenvironment in pancreatic tumors,” said first author Emma Kurz, graduate student at NYU Grossman School of Medicine.

    “The work revealed that activation of IL-15 signaling in pancreatic cancer could be an important therapeutic approach in the future.” IANS

    Electricity production drops during partial shutdown of gas-fired power station Oben – Federal Government

    0

    The federal government said the latest drop in electricity production in the country was the result of a partial shutdown of the Oben gas plant.

    The shutdown caused power cuts across the country for days.

    The government said the Oben gasworks had been closed to allow repairs to critical gas-processing equipment.

    Isa Sanusi to Energy Minister Abubakar Aliyu said so in a statement yesterday.

    Earlier, the management of Abuja Electricity Distribution Company (AEDC) also attributed the instability of power supply to reduced load distribution in its franchise area.

    AEDC’s Chief Marketing Officer, Mr. Donald Etim, in a statement in Abuja, said the company was aware that the instability in power supply had persisted.

    According to him, AEDC’s current allocation is 228.65 megawatts (MW), which is significantly lower than the average allocation of 650 MW during peak generation.

    “AEDC wishes to assure its clients that the benefit received by the company will be fairly distributed while all stakeholders work tirelessly towards a lasting solution.

    “We sincerely regret the inconvenience and appeal to your usual understanding,” he said.

    Additionally, Eko Electricity Distribution Company notified its customers of the power outage in the early hours of today.

    “Dear valued customers, we regret to inform you of the significant drop in load allocation on our network which has led to massive load shedding,” he said.

    “Please bear with us as we are currently working with our TCN partners for a quick resolution.”

    Mr Sanusi said the incident came at a time when other power plants on other gas sources are undergoing planned maintenance and capacity testing.

    “We wish to inform the public that Seplat Energy Plc has mobilized equipment, materials and personnel to the site with a view to accelerating the restoration of normal gas supply to the plants concerned,” he said.

    “We were assured that the repair work would be completed this weekend and normalcy would be restored. While advocating with electricity consumers on the current state of supply, we wish to assure the general public that efforts are being made for a sustained improvement in supply across the country.

    This is the sixth collapse this year. The government attributed the latest collapse to “vandalism” of a transmission tower on the Odukpani – Ikot Ekpene 330kV dual circuit transmission line, which resulted in a loss of about 400 MW of generation.

    The future of food is not too far away – The New Indian Express

    0

    Express press service

    Nothing emerges from nowhere. Unless it’s meat. Air Protein™ revolutionizes the way meat is eaten by blending elements of air with lab cultures to produce a protein-rich meal that is also 100% carbon negative, in addition to being hormone-free, GMOs and pesticides. Once the flour is processed, it can be transformed into any type of “meat” (or eggs and seafood) with the color, texture and taste of the actual product, in a matter of hours. This is the future of food for you. Scalable, sustainable, sensible and affordable.

    Experts predict that food systems will look very different from what they look like now. “It is an industry that is expected to feed 9.7 billion people by 2050. So the future of food must revolve around planet-friendly processes, community-backed initiatives and solutions. to manage the global food crisis,” said Pawan Bisht, Corporate Chef. , One8 Commune, New Delhi. Some of the things that will matter the most are:

    The transformative power of technology
    Agtech will bring big changes in food production. The market is expected to reach $30-35 billion by 2025, according to a report by Bain & Company. “We use everything from data analytics, the Internet of Things, artificial intelligence and other systems to streamline processes for high efficiency, while reducing greenhouse gas emissions. Another upcoming feature is the use of specialized RNAi-based technologies instead of chemical pesticides to save soil. These biopesticides or pesticides derived from natural materials are easily broken down by microbes in the soil, thus avoiding bioaccumulation,” says Gurjeet Singh Dillon, Agtech entrepreneur based in Ludhiana.

    Cellular farming
    Still in its infancy, the next decade will be definitive for cell culture proteins or proteins grown in the laboratory. Considering that the demand for protein is expected to increase by 40% by 2050, cellular agriculture is on the threshold of a major impact. Also driven by issues of animal welfare, health, environmental stability and sustainability, the demand for animal protein is increasing. In cellular agriculture, there is no need for breeding. “Proteins can germinate using fermentation. In another process, stem cells are placed in bioreactors and pumped with essential nutrients to obtain animal-free proteins. The properties of meat, eggs or seafood are imitated by vegetable alternatives. Even the coloring agents are derived from natural pigments,” says Bisht. This type of protein is easier to produce, store and keep on the shelf, not to mention much cheaper.

    If cultured protein were to take more than 15% of the global dairy market by 2035, the price of traditional dairy products and the number of dairy cows would decline, according to a collaborative research project between PATH, IFPRI, the University Duke and The Nature Conservancy. It will make dairy products more affordable and reduce the prevalence of stunting and wasting. Cultivated proteins have a positive impact on the environment by reducing the area currently allocated to grazing. It also reduces cows’ emissions of methane, a potent greenhouse gas, which will lead to fewer premature deaths from respiratory and cardiovascular disease by 2050, according to the fine.

    Genome-specific customizations
    Nutrigenetics services are gaining ground. It examines the role of bioactive food compounds in the expression of a person’s genes, while offering solutions specific to their biology. Food in the future will be less of a generalization and more of a customizable product. Precision nutrition is catching up. “Doctors will use genetic testing to uncover flaws in DNA and fill those gaps with tailored solutions. Studying the gut microbiome, unique to every human being, will play a huge role in developing diet charts,” says Prapti Sharma, community dietician based in Manipal.

    waste no more
    More than a third of the world’s food production, around 1.3 billion tonnes, is wasted every year. Global waste is expected to increase by 70% by 2050, according to the United Nations Environment Programme. A third of all food is wasted and 25% of greenhouse gas emissions come from the food industry, reveals Deloitte’s The Future of Food: Challenges and Opportunities report. “Since around half of industrialized food waste occurs at the consumer stage, its reduction at the household level will gain ground in the future. Expect home food preservation techniques such as pickling, fermentation, dehydrating, freeze-drying, salting, canning and recycling to gain momentum,” says Aanchal Gupta, a Delhi-based food upcyclist. Small efforts such as saving seeds to allow them to self-pollinate, eating the skins of certain fruits and vegetables, or storing food properly will become common practice.

    Robotic kitchens
    Robotics technology is on fire right now. The restaurants of the future will have robots not only to serve us (which they already do), but also to cook and take orders. Robotic technology takes much less space and time and also reduces labor costs.

    Blumenthalist atmosphere
    Expect to see the unexpected. The kitchen of the future will be inspired by British chef Heston Blumenthal’s inventive cookbook. What does it mean? Edible spray paint could land on your table, as could seaweed protein snacks or beer made from sewage or even lollipops designed to cure hiccups, if Dr. Stuart Farrimond, food scientist at BBC Inside the Factory.

    We hope you have the appetite for it.

    Baldwin alum graduates from medical school | News, Sports, Jobs




    Wailuku’s Dr. Kellen Bean smiles after graduating from John A. Burns School of Medicine earlier this month. — Photo courtesy of the Bean family

    A 2014 Baldwin High School graduated from John A. Burns Medical School at the University of Hawaii earlier this month, his family announced.

    Dr. Kellen Bean has received several awards, including:

    • ACP Bernard Yim, MD, Award for the student who exemplified excellence in his third-year internal medicine externship.

    • Merck Award for Academic Excellence, awarded to two graduating students who excelled at the highest level in their third year externship.

    • The Terry CY Wong, MD Memorial Award, given to the student who demonstrates patient advocacy and academic excellence in internal medicine.

    • The Po’okela No’eau Prize, which recognizes the student whose characteristics best illustrate the qualities of the ideal physician. The recipient is chosen by class vote.

    Born and raised in Wailuku, Bean attended Waihee Elementary and Iao Intermediate before graduating summa cum laude as Baldwin’s valedictorian in 2014. He then attended Yale University, where he was president of Saybrook College and earned his bachelor of science degree. in Molecular, Cellular and Developmental Biology in 2018.

    While at JABSOM, he served as President of the Alpha Omega Alpha Honor Medical Society and earned the Dean’s Certificate of Distinction.

    Bean plans to work in internal medicine in the Kaiser Permanente Hawaii residency program from 2022 to 2025.

    He is the son of Charles and Traci Bean and the brother of Kendra Bean.


    Today’s breaking news and more to your inbox



    Westwood Holdings Group (NYSE: WHG) research coverage has begun on StockNews.com


    StockNews.com initiated a hedge on the shares of Westwood Holdings Group (NYSE: WHGGet a rating) in a note released Saturday to investors. The firm has set a “buy” rating on the asset manager’s shares.

    WHG Stock opened at $16.51 on Friday. The company’s 50-day moving average price is $15.67 and its 200-day moving average price is $16.57. The company has a market capitalization of $141.62 million, a price-earnings ratio of 22.62 and a beta of 1.23. Westwood Holdings Group has a fifty-two week low of $13.93 and a fifty-two week high of $27.01.

    Westwood Holdings Group (NYSE: WHGGet a rating) last released its quarterly results on Wednesday, April 27. The asset manager reported EPS of $0.07 for the quarter. Westwood Holdings Group achieved a net margin of 7.94% and a return on equity of 6.24%. The company had revenue of $17.22 million in the quarter.

    Institutional investors and hedge funds have recently changed their positions in the stock. Morgan Stanley increased its holdings of Westwood Holdings Group shares by 8.2% in the first quarter. Morgan Stanley now owns 28,686 shares of the asset manager worth $415,000 after buying 2,172 more shares in the last quarter. Geode Capital Management LLC increased its stake in Westwood Holdings Group by 3.0% during the 3rd quarter. Geode Capital Management LLC now owns 66,177 shares of the asset manager worth $1,257,000 after purchasing an additional 1,941 shares in the last quarter. Royal Bank of Canada increased its position in Westwood Holdings Group by 21.5% during the third quarter. Royal Bank of Canada now owns 7,572 shares of the asset manager worth $145,000 after purchasing an additional 1,341 shares during the period. Ancora Advisors LLC increased its stake in Westwood Holdings Group by 36.8% in the third quarter. Ancora Advisors LLC now owns 190,153 shares of the asset manager valued at $3,613,000 after buying an additional 51,177 shares in the last quarter. Finally, Centiva Capital LP acquired a new stake in shares of Westwood Holdings Group in the third quarter valued at approximately $190,000. 61.73% of the shares are held by hedge funds and other institutional investors.

    Westwood Holdings Group Company Profile (Get a rating)

    Westwood Holdings Group, Inc, through its subsidiaries, manages investment assets and provides services to its clients. The Company operates in two segments, Advisory and Trust. The Advisory segment provides investment advisory services to corporate pension plans, public pension plans, endowments, foundations, individuals and Westwood funds; and investment sub-advisory services for mutual funds, pooled investment vehicles and its trusts business.

    See also



    Receive daily news and reviews for Westwood Holdings Group – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Westwood Holdings Group and related companies with MarketBeat.com’s free daily email newsletter.

    Immune Therapeutics, Inc. Announces Expansion of Board of Directors

    0

    ORLANDO, Fla., June 03, 2022 (GLOBE NEWSWIRE) — Immune Therapeutics, Inc. (OTC: BB IMUN), a specialty pharmaceutical company involved in the development, commercialization, distribution and marketing of novel, patented therapies to combat chronic-threatening diseases through activation and modulation of the body’s immune system, announced today that it will expand its board of directors from two to five members.

    Join the Board of Directors as of May 31st2022, will be Dr Stephen Wilson, Dr Clifford Selsky and Mr Robert Wilson who have been appointed for interim terms until an annual meeting of shareholders can be called to provide a formal vote on the nominees.

    Dr. Stephen Wilson. Dr. Wilson is a qualified immunologist with over 25 years of experience in biomedical research and executive management. He is Chief Innovation Officer of Statera Biopharma, Inc. and Associate Clinical Professor at the University of California, San Diego. Previously, he was chief operating officer at the La Jolla Institute of Immunology; during his tenure, the Institute grew from $14 million in annual R&D to become a global leader in immunology research with nearly $1 billion in total operations as well as the world’s leading workplace by The Scientist magazine. His original research has been published in high-impact journals, and he has been principal investigator or co-principal investigator on over $75 million in grants and competitive awards, most recently developing the award-winning CoVID-19 rapid diagnostic test. X-Prize 2021. Dr. Wilson has served as an advisor to elite medical research organizations, served on national boards, and is a founding scientist and board member of Invivoscribe Technologies, Inc. , a leading company in the field of molecular diagnostics and oncology therapeutics. Dr. Wilson received his doctorate from the University of Arizona College of Medicine in Immunology and was a member of the National Multiple Sclerosis Society and the National Institutes of Health.

    Dr Selsky has been a practicing pediatrician in central Florida for twenty years. He is the founder of the Children’s Center for Cancer and Blood Disease at Florida Hospital Cancer Institute, which he established after training in pediatrics at Yale New Haven Hospital and a fellowship in hematology and of Pediatric Oncology at Yale University School of Medicine. Dr. Selsky is board certified in pediatrics, pediatric hematology and oncology, and palliative medicine. Currently, he is a pediatrician at Family First Pediatrics which he established in 2013.

    Also, an accomplished scientist, Dr. Selsky earned his Ph.D. in Microbiology and Molecular Genetics at the University of Miami School of Medicine. He then did DNA repair research studies at the Harvard School of Public Health Radiobiology Laboratory and the Stanford University Biophysics Laboratory.

    Mr Wilson has spent over 25 years building and launching businesses. As a business strategist, retail marketer and content developer, Robert is experienced in assessing business situations, conducting research, creating strategic plans, recommending solutions to management, monitoring competitors and measuring the results of marketing strategies. Robert has been involved in securing over $150 million in seed and angel funding, developing launch and pivot strategies, and identifying growth opportunities for over two dozen public companies ranging from the energy sector and electric vehicles to healthcare and lifestyle brands.

    Note: Dr. Stephen Wilson and Mr. Robert Wilson are unrelated.

    Kevin Phelps, CEO commented; “We are pleased to welcome our new members to the Board of Directors. The Company is at an inflection point in the development of its strategy and the experience and skills of these individuals will be invaluable moving forward. We are fortunate to be able to attract such talent.

    Compensation terms for board members have not been finalized, but new board members have requested that their compensation be deferred until the company has met its strategic funding and operating goals.

    
    

    Questions to ask yourself after a bad ride – Cycling West

    0

    By Sarah Kaufman — A bad run or a bad run can really cut our hearts. If you’ve been working hard, preparing, and training consistently, it can be quite demoralizing to feel that the energy and time you’ve invested aren’t paying off. Sometimes it feels like a bad run or run is a deeper reflection of who you are as a person or an athlete. Try to separate these feelings of inadequacy and see it as a single result and an opportunity to gain experience. (If you want to learn more about changing your psychology on this, check out Breneì Brown’s work on guilt versus shame).

    Photo courtesy Sarah Kaufmann

    There are days that are hard to explain and we don’t have a clear way to identify what went wrong. But usually there is one or more reasons why things did not go as we would like or expected and here are some questions to help identify what might be the cause. I write these considerations to be relevant to both a key workout and a race/event. When an athlete I coach writes in their notes that the practice or event didn’t go well, here are the things we usually address in order;

    If they are training with power and we have a clear idea of ​​their physical condition, we must first assess their expectations. Was it as bad as they think? If it is a race result, do their expectations match their current physical condition? Are they just too hard on themselves?

    If it was a race and below the athlete’s current ability, we dig and find what specifically caused the result. In a gravel, MTB or CX race, was the athlete wasting time in the pedaling sections or the technical sections? In the above or a road race, were there any tactical errors made?

    If there is both heart rate and power data, I look at both and compare whether the heart rate is abnormally high or low for the power output. Abnormally high heart rate, especially with poor recovery, can be related to heat, dehydration, dysregulation of the central nervous system (a kind of outside stress), lack of sleep, suboptimal reduction , at altitude, the athlete may be about to get sick, there may have been a refueling problem, or many other things, and this indicates that something is wrong. A path to follow. An abnormally low heart rate for power output could indicate general fatigue or overtraining, also a refueling problem, cold temperatures and, again, many other things, but, again, a sign that something is wrong. thing is wrong. If there is no power but we have heart rate data, we can still get an idea of ​​whether HR was high or low compared to how that person’s HR typically behaves at these intensities. If this is the case for you, assess whether you felt like you were pushing as hard as you could and at your physical maximum, but not going as fast as you could reasonably expect OR if you had the felt like you couldn’t access deeper intensities and you felt ruled.

    What did you eat and drink during the event? If you’re confident that your endurance fitness is solid, but you passed out late in the race, chances are you haven’t refueled or haven’t hydrated yourself properly. appropriate. If your race fueling and hydration seems adequate and appropriate, review what you ate and drank in the 24-36 hours before the race, taking into account the 4-6 hours before the race. Was it balanced and adequate? Have those foods and drinks you’ve consumed before been successful?

    Did you sleep enough before the event? We worry less about the night just before but pay more attention to the overall trend over the previous several nights.

    If the rider is female, is she about to start her menstrual cycle? Women experience ups and downs with training depending on when in their cycle. We typically see a decrease at certain training intensities (largely peak and neuromuscular energy output) in the week or so before menstruation and/or around ovulation. Although this is often mitigated in a running situation, a bad run could be attributed to the timing of its cycle. A bad workout could more likely be attributed to this. Tracking your cycle is a great tool for this purpose and can help determine the likelihood. The Notes app on your phone or a dedicated app can be very helpful. Although sprinting and neuromuscular energy production are the intensities most likely to be affected, PMS can affect overall energy levels and increase exogenous carbohydrate requirements. So the need to stay on top of supply becomes a higher priority and what you might normally think is enough could leave you underpowered. Likewise, core temperature is elevated in the days leading up to menstruation, so the likelihood of being underhydrated also increases.

    Finally, were there any outside factors that could have contributed to a poor outcome? Was it excessively hot or cold and/or were you not acclimatized to these conditions or were your clothes not suitable for the temperatures? Was the departure time earlier or later than your normal travel time and could this have disrupted your pace? Were you at high altitudes from where you normally live/train? Each of these different factors could be its own column and each of them can be mitigated with some planning and different protocols.

    A “bad” ride or race is an opportunity to learn. A victory or a good race is good, but it doesn’t give us the same opportunities. Try to change your perspective so that the disappointment is not a reflection of yourself but an opportunity for growth. Ask yourself these questions and see if you can avoid the same mistakes in the future.

    Sarah Kaufmann is the owner of K Cycling Coaching. She is an elite level XC and CX racer for DNA Pro Cycling Team. She is based in Salt Lake City, UT and can be reached at [email protected] or 413.522.3180.

    (Visited 10 times, 10 visits today)

    The findings could explain why drugs designed to remove amyloid deposits failed to stop the disease

    A disruption in the way brain cells get rid of waste precedes the buildup of debris-filled plaques known to occur in Alzheimer’s disease, according to a new study in mice.

    The field has argued for decades that such plaques, containing the beta-amyloid protein, accumulated outside cells as a crucial first step toward the brain damage seen in Alzheimer’s disease. Led by researchers from NYU Grossman School of Medicine and the Nathan Kline Institute, the new study challenges this idea, known as the amyloid cascade hypothesis.

    Instead, the study’s latest findings support that the neuronal damage characteristic of Alzheimer’s disease takes root inside cells and long before those thread-like amyloid plaques fully form and clump together in the brain.

    Publication as a cover article in the journal Natural neuroscience online June 2, the study traced the root dysfunction seen in mice bred to develop Alzheimer’s disease to the lysosomes of brain cells. They are little sacs inside every cell, filled with acidic enzymes involved in the routine breakdown, elimination, and recycling of metabolic waste products from daily cellular reactions, as well as disease. Lysosomes are also essential, the researchers note, for breaking down and eliminating a cell’s own parts when the cell dies naturally.

    As part of the study, the researchers tracked the decrease in acid activity inside the intact lysosomes of mouse cells as the cells were injured by the disease. Imaging tests developed at NYU Langone Health and Nathan Kline (to follow the removal of cellular waste) showed that some brain cell lysosomes enlarged by merging with so-called autophagic vacuoles filled with waste that had not been broken down. These autophagic vacuoles also contained earlier forms of beta-amyloid.

    In the most severely damaged neurons destined for premature death, the vacuoles clustered in “flower-like” patterns, bulging from the outer membranes of the cells and massing around the center or nucleus of each cell. Accumulations of beta-amyloid have formed filaments inside the cell, another hallmark of Alzheimer’s disease. Indeed, the researchers observed almost completely formed plaques inside some damaged neurons.

    “Our first-time results link the neuronal damage seen in Alzheimer’s disease to problems inside the lysosomes of brain cells where beta-amyloid first appears,” says the study’s lead researcher. , Ju-Hyun Lee, PhD.

    “Previously, the working hypothesis attributed the damage seen in Alzheimer’s disease primarily to what happened after amyloid builds up outside of brain cells, not before and inside neurons.” , says Lee, research assistant professor in the Department of Psychiatry and NYU Langone Health and research scientist at Nathan Kline.

    “This new evidence changes our fundamental understanding of the progression of Alzheimer’s disease; it also explains why so many experimental therapies designed to remove amyloid plaques have failed to arrest disease progression, as brain cells are already paralyzed before the plaques form completely outside the cell,” says study lead researcher Ralph Nixon, MD, PhD.

    “Our research suggests that future treatments should focus on reversing lysosomal dysfunction and rebalancing acid levels inside brain neurons,” says Nixon, a professor in the Department of Psychiatry and Department of Cell Biology. of NYU Langone, as well as director of the Dementia Research Center at Nathan Kline.

    The researchers say they are already working on experimental therapies to address the lysosomal problems observed in their studies.

    A recent study (published in April in Scientists progress) by the NYU Langone team attributed one of the causes of the cell’s waste disposal problems to a gene called PSEN1. The gene has long been known to cause Alzheimer’s disease, but its additional role in causing the disease (through lysosomal dysfunction) is only beginning to become clear.

    Their recent work also showed that neuronal damage in a PSEN1 mouse model of Alzheimer’s disease could be reversed by restoring proper acid levels in lysosomes.

    This work is covered by US Patent 9,265,735 which relates to methods of treating Alzheimer’s disease based on reversing lysosomal deacidification, the underlying cause of waste accumulation. Patent terms and conditions are managed in accordance with health system policies.

    According to the National Institute on Aging, more than 6 million Americans, most aged 65 or older, suffer from dementia, a progressive loss of thinking, memory and reasoning due to Alzheimer’s disease.

    Funding for these studies was provided by National Institute of Health grants P01AG017617, P50AG025688, and R01AG062376.

    Besides Lee and Nixon, other NYU Langone and Nathan Kline study researchers involved in this research include Dun-Sheng Yang, Chris Goulbourne, Eunju Im, Philip Stavrides, Ann Pensalfini, Cynthia Bleiwas, Martin Berg, Chunfeng Huo, James Peddy, Monika Pawlik, Efrat Lévy and Mala Rao. Other co-investigators are Han Chan and Cédric Bouchet-Marquis of Thermo-Fisher Scientific in Hillsboro, Oregon; and Mathias Staufenbiel, from the University of Tubingen in Germany.

    Veganz Group AG: Veganz and epap collaborate for market research innovation

    Veganz and epap Collaborate for Market Research Innovation

    Berlin, 24.05.2022 Veganz and epap are joining forces to jointly develop innovative market research for customer-oriented product development in the fast-moving consumer goods (FMCG) market. The exclusive two-year project aims to gain valuable shopper insights for further development of the vegan product portfolio via digitized receipts.

    Veganz and epap collaborate

    Veganz, a Berlin-based company, is known for its innovative variety of vegan products ranging from snacks to alternatives to meat, fish and cheese. From now on, the further development of the range should be even more customer-friendly with more emphasis on new and creative market research approaches.

    To this end, Veganz is cooperating with the Hannover-based startup epap, which uses the app of the same name to enable paperless receipt and scanning of receipts. With receipts from over 90,000 stores in the app, epap creates an engaging foundation for innovative shopper research in line with the “Ask Your Customer” business philosophy.

    “We are very happy to have a strong partner like Veganz on our side? Germany’s most innovative food brand? with whom we innovate in market research on the FMCG market. We help Veganz gain valuable new consumer insights through our software and infrastructure to drive cultural change in nutrition. At the same time, we benefit from many years of experience in the FMCG market, ? says Fabian Gruß, CEO of epap.

    Moritz Möller, CMO of Veganz, says: “Our partnership with epap is an important part of our digitization strategy to better understand our customer segments. With epap, we have gained an innovative and agile partner to continue to meet all consumer needs for climate-friendly products in the future.

    More information about Veganz and its products is available here.

    More information on epap and market research with receipts is available here.

    About Veganz Group AG

    Vegan? Good for you, better for everyone? brand of foods of plant origin. Founded in 2011 in Berlin, Veganz has established itself as a European chain of vegan supermarkets. With a colorful and inspiring business philosophy, Veganz has succeeded in entering the vegan niche and setting the trend of plant-based nutrition in the market. The current product portfolio includes around 120 products in 17 categories and is available in more than half of European countries and over 22,000 points of sale (POS) worldwide. Additionally, the Veganz product portfolio is continually expanded to include innovative, high-quality items, and the sustainable value chain is constantly improved. For this commitment, Veganz was voted Germany’s most innovative food brand in an exclusive Handelsblatt 2021 ranking.

    Media contact: Moritz Möller | [email protected] | +49 30 2936378 172

    About epap GmbH
    epap enables hyper-targeted market research and insights for product manufacturers based on daily evidence collected by consumers. The Hannover-based startup creates a direct feedback channel to its target group, especially for the FMCG and OTC brands: surveys are sent to specific audiences based on evidence and socio-demographic characteristics via the epap app. Respondents reply on the go in the epap app, with which they digitally manage their receipts and benefit from the automatic budget book. For its innovative approach, epap won first place at the 4th Startup Pitch organized by Markforschung.de and Consulting.de.

    With epap, more than 650,000 receipts have already been received digitally at the checkout or subsequently scanned.

    Media contact: Ruth Rottwitt | [email protected] | +49 152 275 383 81

    02.06.2022 Dissemination of a press release, transmitted by the DGAP – a service of EQS Group AG.
    The issuer is solely responsible for the content of this announcement.

    DGAP distribution services include regulatory announcements, financial/corporate news and press releases.
    Archive at www.dgap.de

    Study suggests potential target for future therapies to prevent or treat inflammatory diseases

    0

    Cedars-Sinai researchers have identified a gene that plays a critical role in the innate human immune system. The gene, NLRP11helps activate the inflammatory response that commands the body’s white blood cells to attack a foreign presence.

    The findings, published in Natural immunologybring medical science closer to understanding a biological process that can both help and harm the body.

    “Chronic inflammation is an underlying cause of countless human diseases,” said Christian Stehlik, PhD, study co-lead author and director of pathology research at Cedars-Sinai. “If you study the molecular mechanisms involved in how inflammation occurs and how it is regulated, you find something that can be applied very broadly.”

    When the immune system detects a bacteria, virus, toxin, or other foreign presence in the body, it sends white blood cells to surround the unwanted substance and release chemicals to attack it. This response leads to inflammation, which causes redness, pain, warmth, and swelling in the affected area as the body heals. Sometimes this defensive response lasts longer than it should, leading to chronic inflammation. Or, the immune system may mistakenly attack healthy cells, leading to autoimmune disease.

    “Acute inflammation is necessary and beneficial to eradicate infection and initiate wound healing,” said Andrea Dorfleutner, PhD, study co-lead author and associate professor in the Cedars Departments of Academic Pathology and Biomedical Sciences. -Sinai. “Chronic, long-term, uncontrolled inflammation, however, is detrimental and can damage organs and tissues in the body.”

    The key to controlling the inflammatory response and preventing chronic inflammation may lie in the ability to influence the expression of the NLRP11 embarrassed.

    The researchers used a gene-editing system called CRISPR/Cas9 to delete genes or introduce genetic mutations into human white blood cells called macrophages. They observed that when they removed NLRP11it prevented an immune system sensor called the NLRP3 inflammasome from being activated and triggering the inflammatory response.

    When investigators restored the NLRP11 gene, the NLRP3 inflammasome sent its attack signals, which triggered the typical inflammatory process. The researchers chose to focus on this particular gene because it is not expressed in mice, which led them to hypothesize that it was an integral part of the complex immune system that exists in humans. man.

    “Now that we have a better picture of the mechanisms driving inflammation, we can come up with completely new strategies to target it that wasn’t possible before,” Dorfleutner said.

    The study’s first authors are Anu Gangopadhyay, Savita Devi, PhD, and Shivendra Tenguria, PhD, all researchers from the Stehlik and Dorfleutner lab.

    Funding: The study was funded by the National Institutes of Health (award numbers AI099009, AR064349, AI134030, AI140702, AI165797, and AI120625) and the American Heart Association (award number 834502).

    Source of the story:

    Material provided by Cedars-Sinai Medical Center. Note: Content may be edited for style and length.

    Mouse Study Links Air Pollution Exposure to Harmful Pregnancy Effects

    0

    Credit: Pixabay/CC0 Public domain

    A new mouse study by UCLA scientists reveals how exposure to traffic-related air pollutants causes cellular changes in the placenta that can lead to pregnancy complications and affect the health of both mother and child. offspring.

    The researchers found that cellular changes caused by chronic exposure to air pollutants were linked to immune activation by foreign substances entering the bloodstream from the lungs. This immune response attacks some of the placental cells necessary for the structural maintenance of the placenta and, more importantly, blood flow from the mother to the developing baby.

    Although previous research has analyzed the effect of air pollution on pregnancy, these studies did not use cell-specific methods or focus on the molecular signatures of the placenta. This study is the first to assess how such exposure can negatively affect the placenta, leading to adverse outcomes during pregnancy.

    A group of female mice were exposed to environmental air pollutants through the nose starting two months before conception and during pregnancy, while the control group of mice were exposed to saline solution. At the end of the study, tissue samples indicated that inhaled air pollutants had compromised placental cell composition and molecular signatures. Researchers have also identified inflammation of the lining of the uterus triggered by pollution.

    The placenta is essential for a successful pregnancy and for maintaining the health of mother and baby. These study results suggest that maternal immune cells may be responsible for the destruction of vital vascular cells in the placenta. This self-destruction of placental structures can disrupt the maintenance of a healthy pregnancy or at least affect the supply of nutrients from the mother to the baby, with the potential for adverse pregnancy consequences or outcomes such as premature labor or uteroplacental insufficiency encountered in pre-eclampsia. .

    “The cellular changes we observed could provide the missing link between exposure to air pollutants and adverse pregnancy outcomes, helping to focus the development of preventive strategies for at-risk pregnancies,” said Dr Sherin Devaskar. , lead study author and physician. -Chief of UCLA Mattel Children’s Hospital and Emeritus Professor of Pediatrics at UCLA’s David Geffen School of Medicine.

    The research also underscores the need to examine the timing of exposure and whether acute and chronic exposures have different effects. The authors also plan to study dietary interventions to alleviate distress on placental molecular signatures, nutrient intake, and development.

    The study is published in Scientific reports.

    The collaborative study also involved Dr. Suhas G. Kallapur, Chief of Neonatology and Developmental Biology; Amit Ganguly, personal research associate; Shubhamoy Ghosh, Ph.D., project scientific assistant; Monica Cappelletti, Ph.D., adjunct assistant professor of pathology and laboratory medicine, all four in the UCLA Department of Pediatrics-Neonatology; Matteo Pellegrini, professor of molecular, cellular and developmental biology at UCLA and Anela Tosevska, Ph.D., bioinformatics scientist in the division of rheumatology, internal medicine at the Medical University of Vienna, Austria.


    Blood tests could be developed to help predict pregnancy complications, new study finds


    More information:
    Anela Tosevska et al, Integrated analysis of an in vivo model of intranasal exposure to instilled air pollutants reveals cell-type specific responses in the placenta, Scientific reports (2022). DOI: 10.1038/s41598-022-12340-z

    Provided by University of California, Los Angeles

    Quote: Mouse Study Links Air Pollution Exposure to Adverse Effects of Pregnancy (June 1, 2022) Retrieved June 1, 2022 from https://medicalxpress.com/news/2022- 06-mouse-links-air-pollution-exposure.html

    This document is subject to copyright. Except for fair use for purposes of private study or research, no part may be reproduced without written permission. The content is provided for information only.

    Air pollution linked to adverse effects of pregnancy — ScienceDaily

    A new mouse study by UCLA scientists reveals how exposure to traffic-related air pollutants causes cellular changes in the placenta that can lead to pregnancy complications and affect the health of both mother and child. offspring.

    The researchers found that cellular changes caused by chronic exposure to air pollutants were linked to immune activation by foreign substances entering the bloodstream from the lungs. This immune response attacks some of the placental cells necessary for the structural maintenance of the placenta and, more importantly, blood flow from the mother to the developing baby.

    Although previous research has analyzed the effect of air pollution on pregnancy, these studies did not use cell-specific methods or focus on the molecular signatures of the placenta. This study is the first to assess how such exposure can negatively affect the placenta, leading to adverse outcomes during pregnancy.

    A group of female mice were exposed to environmental air pollutants through the nose starting two months before conception and during pregnancy, while the control group of mice were exposed to saline solution. At the end of the study, tissue samples indicated that inhaled air pollutants had compromised placental cell composition and molecular signatures. Researchers have also identified inflammation of the lining of the uterus triggered by pollution.

    The placenta is essential for a successful pregnancy and for maintaining the health of mother and baby. These study results suggest that maternal immune cells may be responsible for the destruction of vital vascular cells in the placenta. This self-destruction of placental structures can disrupt the maintenance of a healthy pregnancy or at least affect the supply of nutrients from the mother to the baby, with the potential for adverse pregnancy consequences or outcomes such as premature labor or uteroplacental insufficiency encountered in pre-eclampsia. .

    “The cellular changes we observed could provide the missing link between exposure to air pollutants and adverse pregnancy outcomes, helping to focus the development of preventive strategies for at-risk pregnancies,” said Dr Sherin Devaskar. , lead study author and physician. -Chief of UCLA Mattel Children’s Hospital and Emeritus Professor of Pediatrics at UCLA’s David Geffen School of Medicine.

    The research also underscores the need to examine the timing of exposure and whether acute and chronic exposures have different effects. The authors also plan to study dietary interventions to alleviate distress on placental molecular signatures, nutrient intake, and development.

    The collaborative study also involved Dr. Suhas G. Kallapur, Chief of Neonatology and Developmental Biology; Amit Ganguly, personal research associate; Shubhamoy Ghosh, PhD, project scientific assistant; Monica Cappelletti, PhD, adjunct assistant professor of pathology and laboratory medicine, all four in the UCLA Department of Pediatrics-Neonatology; Matteo Pellegrini, professor of molecular, cellular and developmental biology at UCLA and Anela Tosevska, PhD, bioinformatics scientist in the division of rheumatology, internal medicine at the Medical University of Vienna, Austria.

    Source of the story:

    Materials provided by University of California – Los Angeles Health Sciences. Note: Content may be edited for style and length.

    Lecturer/Senior Lecturer (Research & Teaching) – Co-design work on health care interventions with KINGS COLLEGE LONDON

    This role

    This is an exceptional development opportunity for a talented individual who wants to advance excellent and innovative research and education related to the co-design of healthcare interventions.

    This is one of many new positions offered under a research and teaching contract, with 60% research and 40% teaching. The incumbent will be expected to contribute to and develop a sustainable, high quality applied health care research program in areas critical to one or more divisions or research institutes of the Faculty and relevant to the educational focus of this position. You will have the opportunity to work with relevant research partners in health, charity and industry/business.

    You will join the team led by Professor Glenn Robert. This successful research group focuses on the development, adaptation and application of co-design and other participatory design approaches in the context of health care services and interventions. It includes a senior lecturer, two post-docs and several PhD students, with funding from UKRI, NIHR and the EU. You will strengthen the links between research and clinical partners and develop sustainable research in a range of conditions. You supervise doctoral students within the Faculty.

    From an educational perspective, you will apply the co-design methodological approach to many health care conditions and settings. You will extend and further develop the modules taught at undergraduate and graduate level within King’s related to co-design of healthcare interventions and other topics relevant to your expertise and faculty needs.

    Why choose us

    King’s College London is a leading university with nine faculties. As a member of King’s Health Partners, we have an excellent environment for healthcare interaction and a strong focus on mentorship and career development.

    The 2021 Research Excellence Framework (REF2021) ranked King’s Allied and Applied Research first for: overall proportion of research rated 4* (highest global rating, highest possible rating), research papers rated 4* , impact rated 4*, environment rated 4*(joint), cumulative grade point average and power. REF2021 ranked world leader: 100% of our environment, 86% of our impact and 70% of our global research. More than 95% of our global research has been ranked among the best in the world or internationally excellent.

    For three years, King’s has been number 2 in the world and number 1 in Europe for nursing care (QS world ranking). King’s produces more highly cited research results (top 1% citations) on palliative care than any other international center (SciVal).

    It is based in the heart of central and south London. It includes the Cicely Saunders Institute for Palliative Care, Policy and Rehabilitation, the premier palliative care institute, bringing together clinical, research and education teams.

    Our award-winning NMPC training programs cover pre-registration nursing and midwifery and multidisciplinary postgraduate teaching and research programs. King’s is Europe’s largest healthcare education provider. Our health and applied clinical research transforms therapies, the healthcare experience and outcomes for patients and those who matter to them, wherever they are cared for.

    You must apply if

    We are looking for an enthusiastic and dedicated individual who can make a distinctive contribution, bridge theory and practice, and advance sustainable high quality and impactful collaborative research. You must have excellent teaching and communication skills, be able to inspire and inform students, and a demonstrable ability to deliver high-quality, impactful sustainable research.

    This position will be offered on an indefinite term contract pending successful completion of probation (3 years) The post holder is required to actively participate in the Academic Performance Development (PDR) review each year.

    This is a full-time position – 100% full-time equivalent. However, we offer flexibility for part-time work.

    AstraZeneca + Pfizer vaccines = better immunity Omicron

    0
    Placeholder while loading article actions

    Could the UK have inadvertently given part of its population the best possible immunity against SARS-CoV-2?

    After reports of side effects in certain populations with the AstraZeneca vaccine, the UK and much of Europe decided to use Pfizer injections as a second injection in certain age groups, creating an experience of mixed natural dosage. New data from the UK suggests that this particular mix offered additional immunity against the omicron variant compared to those with other platforms.

    In many ways, this is not surprising. Researchers have known for years that mixing and matching vaccines can produce stronger or longer lasting immunity and also provide better defense against variants. What they didn’t know was how mixing the different vaccine platforms would affect immunity to SARS-CoV-2 and serious illnesses.

    Given the latest scientific data, we should devote much more effort to studying these effects. Below, Therese speaks with Bloomberg Intelligence Senior Pharmaceutical Analyst Sam Fazeli about the new mixed-dosing data.

    Therese Raphael: How has the particular combination prevalent in the UK potentially given people an immune advantage when it comes to the omicron BA.1 variant that first emerged in South Africa last November and has started to spread.

    Sam Fazeli: A new study of vaccinated people in the UK, by Zijun Wang and colleagues, showed that an injection of Pfizer-BioNTech’s Comirnaty vaccine after a first dose of AstraZeneca’s Vaxzevria induced an immune response that not only beat two shots of the Astra vaccine, but looked even better than two doses of Pfizer. This was particularly the case when the authors examined neutralizing antibody (NAb) levels against BA.1, the original omicron variant of concern.

    TR: What difference are we talking about? And does that mean stronger immunity or immunity that lasts longer, or both?

    SF: Levels of neutralizing antibodies in the mixed vaccinated group one month after the second injection were 10 times higher than for two injections of the Pfizer vaccine (mRNA), one third of the individuals in this latter group having no neutralization. This means that those who received a mixed vaccine would probably not only be better protected against an infection, but also, given the higher level of antibodies, this protection could last longer.

    TR: The study also explained why having two injections of Pfizer might be disadvantageous when it comes to omicron. Can you explain?

    SF: The study showed that six months after being vaccinated with two injections of the same mRNA vaccine (Pfizer), people had higher levels of memory B cells (cells that turn into antibody-producing cells when new infection occurs) specific to the receptor binding domain (RBD) of the virus spike protein than those who received a mixed vaccination.

    The spike protein’s RBD is the part that first engages with a human cell and “binds” to its receptor, the human ACE-2 molecule. Without this binding, no infection would occur. Antibodies that interfere with this binding “neutralize” the virus. It is therefore in this region that most of the mutations of the virus occur to circumvent our protective antibodies.

    So if most of your memory B cells target this region, an infection may take longer to resolve or be more likely to lead to more severe disease because the virus mutates the RBD and evades antibodies. In the mix-and-match group, there were more non-RBD antibodies.

    TR: What about the T-cell response, since these are immune cells that limit the severity of disease and contribute to longer-lasting immunity. How does a mixed vaccination regimen compare on this front?

    SF: Here we have two studies that support the notion of using mixed vaccines. Zoltan Banki and colleagues showed that levels of inflammatory markers (cytokines) that mediate the T-cell immune response were higher in those who received a mixed vaccination compared to mRNA-only injections. The authors also showed that there were more multifunctional T cells after mixed vaccination. Higher multifunctionality and higher cytokine levels suggest that protection after mixed vaccination may be better than after two injections of the same vaccine.

    TR: In order to deliver more first vaccines quickly despite supply limitations, the UK has opted for a 12-week gap between the first and second vaccines, much longer than other countries. Could this have had an impact on the results?

    SF: Yes, the difference between a mixed vaccination and two injections of Pfizer could be due to the use of two different vaccines and/or this longer gap between the first and the second injection in people vaccinated with AstraZeneca followed by Pfizer , as opposed to just one month apart for two Pfizer injections.

    TR: We are now seeing a fifth wave of the virus in South Africa, which has mixed the Johnson & Johnson vaccine (similar to that of AstraZeneca) with that of Pfizer. However, the vaccination rate in South Africa is still very low (only 32% fully vaccinated and only 5.4% vaccinated). Can we learn anything from this experience?

    SF: In fact, there was a study (also by Zhang et al.) that looked at the immune response to mRNA vaccines and injections from J&J and Novavax, showing that only those who received an injection of the J&J vaccine, which is similar to the Astra shot in that it uses an adenoviral vector, produced a specific type of memory B cell that is found to be important for mucosal immunity (immunity in the nasal passages and surfaces of the lungs by opposition to “humoral” immunity which is blood based) in two animal models. Mucosal immunity was not demonstrated after mRNA vaccines, suggesting potentially higher protection against reinfection in those who received the J&J vaccine before or after an mRNA vaccine.

    But it’s clear that for any of these vaccines to be effective, people need to take them and get their booster shots. What we do know about the last South African wave is that it was short lived and had even lower infection morbidity/mortality than the omicron BA.1 wave.

    TR: There’s no guarantee that we won’t get a new variant with different properties at some point. Can we learn broader lessons about vaccinations from the new data?

    SF: Continued injections with the same vaccine only provide short-term protection and may not be necessary given the very robust protection against severe disease in most people with the third vaccine, even during the omicron wave . In fact, one of our recent analyzes showed that ICU admission rates per case in the United States, which has the BA.2.12.1 subvariant, are the lowest on record.

    What we really need to do is see if using a different vaccine platform would give us longer and better immunity than repeatedly going for mRNA injections.

    TR: Does the mix of vaccine platforms matter when it comes to severe illness and hospitalizations or is the difference only in terms of the likelihood of infection? And isn’t the problem of side effects with Astra and J&J shots always a problem?

    SF: The answer to the first part of the question is that we just don’t know. More studies are needed to determine whether or not those who received mixed doses have better protection against serious diseases. For this you need a very large cohort since the difference, if any, may be small.

    The side effect issues with the two adenoviral vaccines are much better understood and there are even proposed modifications that can reduce them significantly. But for this to be investigated, government-funded institutions may need to get involved, as manufacturers have essentially stopped investing in them.

    This column does not necessarily reflect the opinion of the Editorial Board or of Bloomberg LP and its owners.

    Therese Raphael is a columnist for Bloomberg Opinion covering health care and British politics. Previously, she was the editorial page editor of The Wall Street Journal Europe.

    Sam Fazeli is senior pharmaceutical analyst for Bloomberg Intelligence and director of research for EMEA.

    More stories like this are available at bloomberg.com/opinion